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Foodborne illnesses are a significant public health challenge in the United States, with an 
estimated 9.4 million illnesses annually attributed to the consumption of contaminated food, of 
which 59% are estimated to be caused by viruses, 39% by bacteria and 2% by parasites.  Timely 
detection and identification of the pathogens causing foodborne outbreaks is vital for the 
implementation of outbreak control strategies, allowing public health officials to prevent 
additional illnesses and maintain confidence in the food supply.  Public health laboratories 
employ a variety of traditional and molecular testing techniques to identify foodborne outbreak 
etiologic agents.  One technology is the Luminex XMap® microsphere system, which is also 
marketed as the Bio-Plex™ 200.  This platform has a multiplexing capability with the potential 
to simultaneously detect up to 100 targets in one reaction.  The studies described here show that 
 the combination of two Bio-Plex assays with real-time virus assays and one extraction method 
provides a flexible foodborne outbreak screening algorithm that potentially identifies an 
outbreak-associated pathogen on the first day of specimen submission and aids in focusing 
confirmatory laboratory testing.  In these studies, two microsphere-based assays were designed 
for use on the Bio-Plex 200 system as screening assays for the detection of four enteric protozoa 
(Giardia intestinalis, Cyclospora cayetanensis, Cryptosporidium parvum, Entamoeba 
histolytica) and six virulence determinants of shiga toxin-producing Escherichia coli (STEC), 
enterotoxigenic Escherichia coli (ETEC), enteroinvasive Escherichia coli (EIEC) and Shigella 
spp.  Precision and limits of detections were established for both assays.  The sensitivity and 
specificity of the protozoan assay as compared to reference methods ranged from 81.25% to 
100% for most targets, while sensitivity for the E. histolytica target was 42.86%.  Sensitivity and 
specificity for the bacterial assay was 100% as compared to reference methods.  However, cross-
reactivity of the protozoan assay E. histolytica target with E. dispar and of the bacterial assay 
uidA target with enteropathogenic E. coli strains was noted.  Additionally, real-time detection of 
norovirus and rotavirus nucleic acids extracted with the QIAamp DNA Stool Mini Kit was 
statistically comparable to detection when extracted with the Ambion® MagMAX™-96 Viral 
RNA Isolation Kit combined with the KingFisher® Magnetic Particle Processor.   
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CHAPTER ONE INTRODUCTION 
 
 
 
Overview of Infectious Gastroenteritis in the United States.  It is estimated by scientists at the 
Centers for Disease Control and Prevention (CDC) that annually in the United States (U.S.), 
there are 36.4 million domestically-acquired cases of gastrointestinal illness caused by 31 
pathogens, with 9.4 million of these cases resulting directly from contaminated food ingestion 
(100).  In addition, over 55,000 hospitalizations and 1,300 deaths are thought to occur due to 
contamination of food by enteric pathogens (100).  The enteric pathogens that cause 
gastroenteritis include bacteria, viruses, and protozoa, and of the 9.4 million annual foodborne 
illness cases in the U.S., 59% are estimated to be caused by viruses, 39% by bacteria and 2% by 
parasites (100).  Transmission routes are not limited to contaminated food, as pathogens may 
also be transferred via waterborne routes or person-to-person via contaminated feces.   
 Understanding the incidence of foodborne disease, trends associated with foodborne 
infection and physical characteristics of acute gastroenteritis-causing pathogens, as well as the 
clinical symptoms of infections caused by these organisms, is vital to the management of 
outbreak investigations and long-term programs to prevent future foodborne outbreaks.  To 
acquire this type of epidemiologic data, the U.S. utilizes a variety of surveillance systems to 
detect and prevent foodborne disease.  Examples of surveillance systems include, but are not 
limited to, the national requirement to report ―notifiable diseases‖, an active sentinel laboratory 
system called FoodNet, a molecular subtyping network called PulseNet, the National 
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Antimicrobial Resistance Monitoring System (NARMS), and the electronic Foodborne Outbreak 
Reporting System (eFORS) (32).  Epidemiologic data from these surveillance systems are used 
by public health laboratories for a variety of purposes.  For example, prevalence and trend 
information may lead laboratories to implement new testing assays to detect and/or conduct 
surveillance for emerging infectious disease strains, or conversely suspend testing due to the low 
incidence of a particular pathogen.  In outbreak investigations, information such as symptoms, 
incubation periods, geographic locations, and potential modes of transmission are immediately 
useful in determining what assays or types of testing must be completed first, to facilitate as 
rapid an identification of the etiologic agent as possible.  Discussed below are characteristics, 
prevalence and trends of enteric pathogens commonly associated with foodborne illnesses and 
outbreaks, with emphasis on the etiologic agents targeted by the detection assays that are the 
focus of the project described in this dissertation. 
Epidemiology of food- and waterborne intestinal protozoan gastroenteritis.  Intestinal protozoa 
are more commonly associated with prolonged symptoms, particularly in travelers, as opposed to 
the acute gastroenteritis symptoms seen in bacterial and viral cases (84).  Nonetheless, parasites 
also cause significant acute disease worldwide, especially Giardia intestinalis, Cryptosporidium 
spp., and Entamoeba histolytica (91).  Although only 2% of domestic foodborne illnesses are 
estimated to be caused by parasites, the prevalence of Cryptosporidium spp., G. intestinalis, and 
Cyclospora cayetanensis are significant enough for their inclusion on the CDC’s Nationally 
Notifiable Infectious Conditions list (100). 
Infection by enteric protozoa occurs due to the ingestion of oocysts or cysts contaminating 
food or water sources, and in the cases of Cryptosporidium spp. and Giardia, as few as 10 
oocysts or cysts are required to cause disease (17, 19, 50).  Transmission of Entamoeba, 
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Cryptosporidium, and Giardia also occurs readily person-to-person, as the organisms are 
infectious immediately upon excretion.  In contrast, Cyclospora oocysts must mature in the 
environment before becoming infectious and therefore person-to-person transmission typically 
does not occur (24).  In the U.S., Giardia and Cryptosporidium are associated with both 
waterborne and foodborne outbreaks.  These two pathogens alone were linked to over 29,000 
cases of illness in 2008, and recently published models estimate that they are responsible for 
approximately 134,000 cases of foodborne illness in the U.S. annually (17, 19, 100).   
The sources of Cyclospora spp. infections are variable, ranging from international travel, to 
foodborne outbreaks, to sporadic cases with no confirmed source (21).  Prominent foodborne 
outbreaks have occurred involving imported foods such as raspberries, basil and snow peas (86).  
One data source that is used to follow food-related infection trends is the CDC’s Foodborne 
Diseases Active Surveillance Network, or FoodNet, a network that tracks laboratory-confirmed 
foodborne illness cases across ten states.  According to 2009 FoodNet data, the incidence of 
infection with Cyclospora is low in the U.S., with an incidence of 0.07 cases/100,000 population 
(20).  Although only 1,110 laboratory cases were reported during 1997-2008, more recent 
estimates by the CDC suggest that there is on average over 11,000 domestically-acquired 
foodborne Cyclospora infections annually (21, 100).  The low reported numbers versus estimates 
is most probably attributed to the fact that many laboratories do not test for Cyclospora without a 
specific testing order, and the organism is not readily detected in a routine ova and parasite 
microscopic examination (21). 
Reports of U.S. food- and waterborne infections or outbreaks due to E. histolytica are not as 
abundant in the literature as for other protozoa.  However, E. histolytica has been implicated in a 
number of waterborne outbreaks in the U.S. since the 1950s (62).  Although infections by E. 
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histolytica are not nationally notifiable, surveillance for E. histolytica cases is conducted in the 
Commonwealth of Virginia, and as of 2009, the five-year average for Virginia cases was 41.4 
per year (115).  These cases typically represented infections acquired outside the U.S., rather 
than outbreak-related infections. 
Epidemiology of food- and waterborne bacterial gastroenteritis.  Based on estimates recently 
published by the CDC, bacteria are the second-leading cause of foodborne illnesses (39% of 
annual episodes), with 20 disease-causing strains predominating (100).  According to published 
estimates, the top five bacterial agents implicated in domestically-acquired foodborne illnesses in 
the U.S. are nontyphoidal Salmonella spp., Clostridium perfringens, Campylobacter spp., 
Staphylococcus aureus, and Shigella spp. (100).  In addition, nontyphoidal Salmonella spp., 
Campylobacter spp. and L. monocytogenes are significant causes of foodborne hospitalizations 
and/or deaths (100).  
 The most recent FoodNet report indicates that there were 17,468 laboratory-confirmed 
cases of foodborne illness due to strains of Salmonella, Campylobacter, Shiga toxin-producing 
Escherichia coli (STEC) of both O157 and non-O157 serotypes, Yersinia, Listeria, and Vibrio 
reported in 2009 (20).  On a positive note, continued declines in cases are occurring for 
Campylobacter, Listeria, Salmonella, and Yersinia.  Significant declines as compared to 2006-
2008 levels were exhibited for Shigella and shiga toxin-producing E. coli (STEC) O157.  
Unfortunately, cases of illness caused by Vibrio spp continue to increase (20). 
 In addition to food, contaminated recreational and drinking water are also sources of 
bacterial pathogens that cause acute gastroenteritis, although the case numbers are not as high.  
According to data from the CDC’s Waterborne Disease and Outbreak Surveillance System, 41 
gastroenteritis illnesses caused by Shigella sonnei, 10 cases of E. coli O157:H7 illness and 6 
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cases of Campylobacter jejuni illness resulting from activity in recreational waters were reported 
in 2005-2006.  Lakes and kiddie pools were the sources primarily implicated (14).  In 2005, 
water ingested from a river was the source for an outbreak involving at least 60 individuals and 
yielded a mix of E. coli O157:H7, C. jejuni, and E. coli O145 (13).  Campylobacter was 
additionally implicated in 38 illnesses in 2006 due to contaminated well water (13). 
 Although not estimated to be one of the top five bacterial agents associated with 
foodborne illness, E. coli strains are of significant public health interest, and are the focus of the 
Bio-Plex bacterial assay described and evaluated in this paper.  E. coli organisms have acquired 
many virulence factors that allow them to expand beyond being commensal intestinal organisms 
and ultimately lead to infection and disease.  These ―diarrheagenic‖ E. coli can be characterized 
based on virulence and pathogenesis into the categories of enterohemorrhagic E. coli (EHEC), 
enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), 
enteroaggregative E. coli (EAEC), and diffusely adherent E. coli (DAEC) (61).  Shiga toxin-
producing E. coli (STEC) that also contain the invasion gene, intimin, are members of the EHEC 
grouping.  
While STEC O157:H7 is a prominent cause of foodborne infections in the US, several 
other diarrheagenic E. coli strains have been implicated as etiologic agents in outbreaks 
occurring in the U.S.  In a retrospective study of 159 outbreaks occurring from 1971 to 1995, 
Dalton et al. (33) described an increasing incidence of enterotoxigenic (ETEC) strains causing 
foodborne outbreaks.  During 1975-1989, ETEC was the causative agent of 6% of outbreaks, and 
between 1990 and1995, the incidence rose to 39%.  A similar increase was observed for cruise 
ship outbreaks, increasing from 6% during 1975-1989 to 36% during 1990-1995.  For most 
outbreak cases, a food item was the implicated source of illness, with seafood being the most 
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commonly implicated vehicle (33).  Based on this study, Dalton recommended that ETEC should 
be considered as a potential cause of acute gastroenteritis outbreaks exhibiting a 24-48 hour 
incubation period with a diarrhea to vomiting ratio of greater than or equal to 2.5 and duration of 
symptoms lasting longer than 60 hours (33).  Further investigation into ETEC outbreaks during 
1996-2003 revealed that the ETEC serotype O169:H41 had become increasingly prominent (4). 
 Although reports of foodborne outbreaks due to EIEC and EPEC are not as frequent in 
the literature, both are considered to be potential causes of foodborne disease (38).  In the past 
several decades, EIEC strains have been attributed to outbreaks due to contaminated French 
cheese and potato salad (38).  EPEC strains are more commonly seen in developing countries, 
particularly in children.  Domestically, food and water may be contaminated by both pathogens 
and cause illness, although there is a paucity of outbreak reports in the scientific literature, most 
likely due to the fact that identification of these strains is not routinely included as part of 
standard foodborne outbreak investigations.  The low incidence of EPEC infections was 
illustrated in a prospective study of diarrheal illnesses in Maryland and Connecticut in which 823 
specimens tested with molecular techniques yielded only two EPEC strains (80). 
Epidemiology of food- and waterborne viral gastroenteritis.  As mentioned previously, viral 
pathogens are the leading cause of foodborne illness in the U.S, with noroviruses being the most 
prevalent viral infectious agent (100).  Noroviruses are estimated to cause 58% of domestically-
acquired gastrointestinal illnesses, equating to an estimated 5.5 million illnesses annually.  Of 
those, 26% are estimated to be due to contaminated food sources (100).  Rotaviruses, 
astroviruses and sapoviruses are estimated to collectively cause slightly over 15,000 illnesses 
annually, with 1% of those being foodborne (100).  In the Commonwealth of Virginia, 
surveillance is conducted for both noroviruses and rotaviruses, resulting in the detection of 
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norovirus in over 2,000 specimens and rotavirus in 38 specimens between 2001 and 2009 (45).  
The initial viral assay design discussed in this paper was intended to detect both noroviruses and 
rotaviruses.   
 In addition to the recent CDC estimates, historical data further support the prevalence of 
norovirus in the U.S.  In one study, norovirus was attributed to 93% of non-bacterial outbreaks 
investigated by the CDC during 1997-2000 (41).  In 2006, a significant increase in norovirus 
cases, including those in foodborne outbreaks, was reported by the CDC (12).  The increase was 
attributed to the emergence of two new co-circulating strains.  The rising trend of norovirus cases 
was experienced across the nation, with food-related venues being the second-most prevalent 
source of infection in Virginia (45).  
 Rotavirus has been implicated in 32% of pediatric acute gasteroenteritis (AGE) cases and 
is the primary pathogen causing AGE in children <5 years old (37, 88).  Though mostly 
associated with infections in children and adults in long-term care facilities, rotavirus has also 
been linked to consumption of contaminated food and water sources.  In 2000, an outbreak 
among college students was attributed to rotavirus, with deli sandwiches being implicated as the 
source (11). This outbreak was reported as being unusual since the population was assumed to be 
naturally immune, and because the suspected source was food.  In 1981, rotavirus was the 
etiologic agent causing a Colorado outbreak due a contaminated community water source (54). 
The Role of Pathogen Identification in Outbreak Investigations.  Timely detection and 
identification of the enteric pathogens causing gastrointestinal outbreaks is vital for public health 
officials to implement strategies for outbreak control and case management, particularly in 
outbreaks that involve food service workers.  Prompt, informed outbreak management allows 
public health officials in the short-term to stop the outbreak and prevent additional illnesses, thus 
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maintaining the public’s confidence in the food supply (32).  For example, rapid identification of 
the environmentally-hardy norovirus in institutional settings allows swift infection control 
measures to be instituted, such as staff restrictions, patient isolation, and use of bleach versus 
quaternary ammonium compounds (22, 65).  In addition, the use of pulsed-field gel 
electrophoresis (PFGE) molecular subtyping by the CDC's PulseNet laboratories has facilitated 
prompt Listeria spp., Salmonella spp. and STEC outbreak identifications and food product 
recalls (118).  To illustrate, PFGE was central to alerting public health officials about a unique 
cluster of Salmonella serotype Typhimurium in 2008, linked to peanut butter products 
manufactured in a single facility.  Control measures culminated in the recall of over 400 
commercially-distributed products and the subsequent closure of the manufacturing facility (15). 
 Pathogen identification also enables the long-term development of prevention strategies 
and infection control guidelines.  For example, establishing the epidemiology of rotavirus 
infections assisted in the development and subsequent FDA clearance of two rotavirus oral 
vaccines in the U.S.  Continued characterization of this virus is necessary to detect shifts in 
antigenicity that may compromise or reduce vaccine efficacy (25).  Characterizing outbreaks also 
allows public health officials to identify new pathogens, food vectors, and/or gaps in the food 
safety system (32).  FoodNet surveillance provides a strategic benefit by facilitating an 
understanding of the foodborne illness burden and an understanding of food practices that may 
potentially be outbreak-associated (118).  For example, a Listeria monocytogenes outbreak 
attributed to turkey deli meat resulted in 54 identified illnesses and the recall of over 30 million 
pounds of meat products.  This outbreak led to intensified USDA regulations for L. 
monocytogenes control, resulting in a 25% reduction in the number of specimens testing positive 
within one year (48). 
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Established Methods of Pathogen Identification.  Public health laboratories employ a variety 
of traditional and molecular-based testing techniques to identify etiologic agents responsible for 
gastroenteritis outbreaks. 
Identification of foodborne enteric protozoa.  Traditional ―gold standard‖ ova and parasite 
(O&P) microscopic examinations are typically used to identify the presence of enteric protozoa 
in clinical stool specimens.  However, a known limitation of microscopy is the inability to 
morphologically distinguish certain strains such as pathogenic E. histolytica from non-
pathogenic E. dispar.  Cryptosporidium may also be identified using O&P examination, although 
this organism is usually missed unless a specific request for identification is submitted (55).  
Identification of Cryptosporidium may be facilitated using a modified acid-fast stain for 
microscopic examination.  Cyclospora oocysts can also be identified during O&P examination, 
however, they are quite small. Hot safranin stain may facilitate identification, and presence can 
also be confirmed by looking for autofluorescence with the use of an excitation filter (86).  
Several commercial kits are also available for identification of G. intestinalis and C. parvum, 
including a lateral-flow immunoassay, a direct fluorescent-antibody (DFA) assay, and microplate 
enzyme immunoassays.  One study compared several of these methods and determined that the 
DFA method was most effective in detecting both Giardia and Cryptopsoridium (58).  In 
addition to these techniques, a growing number of singleplex and multiplex molecular assays 
have been described in the literature for detection and speciation of intestinal parasites, including 
assays differentiating E. histolytica from E. dispar.  However, these have not yet been widely 
implemented in public health laboratories for surveillance or outbreak detection purposes.  
Identification of foodborne bacterial pathogens.   Traditional ―gold standard‖ microbiological 
methods used for the identification of enteric bacterial pathogens include staining, culture using 
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selective and differential media, and biochemical testing using manual methods such as the API 
20 E® strip (bioMérieux SA, l’Etoile, France) or automated biochemical systems such as the 
bioMérieux Vitek® and the Seimens MicroScan® instruments.  Commercial immunoassay kits 
have been developed for the detection of shiga toxins produced by E. coli in stool and/or culture, 
although some do not differentiate between Shiga toxin types 1 and 2.  In addition, E. coli strains 
may be further characterized using latex agglutination to confirm the O157:H7 serotype.  
Serological testing of Salmonella spp. using antisera specific for somatic and flagellar antigens is 
conducted in many public health laboratories in order to support national surveillance programs.  
Due to the increasing availability of genome sequences and simplicity of molecular techniques, 
information on enteric bacterial virulence factors and their corresponding gene targets is widely 
available in the scientific literature.  This has facilitated an ever-increasing number of singleplex 
and multiplex PCR assays in the scientific literature for epidemiological use.   
Identification of foodborne viruses.  Culture methods for enteric viruses are of limited use in 
public health laboratories.  Noroviruses are currently unculturable, and although methods are 
described in the literature, rotaviruses and astroviruses are not easily cultured (69, 83, 93, 101).  
Electron microscopy has been considered as the gold standard for virus identification, but this 
capability is not readily available in most clinical or public health laboratories due to its cost and 
training requirements.  To facilitate rapid identification, commercial enzyme immunoassay (EIA) 
and latex particle agglutination kits have been developed for norovirus and rotavirus detection, 
although norovirus diagnostic kits are of limited availability in the U.S.  Recently an FDA-
cleared norovirus EIA kit became available in the U.S.; however, its use is intended for 
preliminary screening purposes only with all negative results requiring further confirmation with 
molecular-based methods (22).  According to the World Health Organization and the CDC, the 
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sensitivity and specificity of several EIA assays for the detection of rotavirus are adequate for 
surveillance, and these are used in some public health laboratories (16, 117). 
 As is the case for protozoa and bacteria, many molecular assays for the detection and 
classification of enteric viruses are described in the literature.  Molecular methods are the 
primary method of detection of noroviruses by laboratories in support of outbreak investigations 
(22).  Use of molecular methods for the detection of rotavirus occurs mainly in research settings 
and is particularly useful in genotyping virus strains (16). 
Investigation of Gastroenteritis Outbreak Cases at DCLS.   A primary interest of the 
Division of Consolidated Laboratory Services (DCLS) and other state public health laboratories 
is the detection and characterization of common enteric pathogens typically associated with 
infectious disease outbreaks.  DCLS receives clinical specimens for the detection and 
characterization of enteric pathogens for two main reasons:  1) to confirm and report pathogens 
on the Virginia Reportable Disease List, as required by law, and 2) to investigate AGE outbreaks 
within the Commonwealth of Virginia.  During 2008-2010, DCLS confirmed over 1,000 
bacterial, viral and protozoan pathogens in association with outbreak investigations.   
 The venues of outbreaks are numerous, ranging from social functions to long-term care 
facilities to schools and day care centers, and specimen submission to DCLS is triggered by 
reports of clusters of similar illnesses to the Department of Health.  Disease clusters are assigned 
a formal outbreak number, and a representative number of specimens are submitted for testing to 
identify an etiologic agent.  The initial goal for identifying a pathogen in a cluster investigation is 
to determine if the cases represent an outbreak, which is defined as two or more cases of a 
similar illness in unrelated individuals with a common link or exposure (32).  Results 
communicated to epidemiologists can be further used to aid in making decisions regarding future 
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investigation, additional specimen sampling, food recalls and traceback investigations, isolation 
and restrictions of ill persons, and infection control.  Results are typically not used for diagnostic 
purposes or for decisions related to patient treatment.  In addition to directly supporting outbreak 
investigations, DCLS also submits representative specimens for selected pathogens to the CDC 
for further characterization.  These results are used to populate data for surveillance programs 
such as CaliciNet, a national norovirus surveillance program, and a variety of other enteric 
bacterial surveillance systems for Salmonella, STEC, Shigella and Vibrio. 
Current DCLS Enteric Pathogen Detection and Characterization Capabilities.  At DCLS, 
laboratory analyses in response to infectious gastroenteritis outbreaks encompass a variety of 
methods, including microscopy, culture, EIA and molecular protocols. These methods are 
performed in separate sections of the laboratory using multiple sample types and a variety of 
different procedures.  Pathogen identification can take as long as six days depending on the 
pathogen type and the initial testing performed.  Figure 1 provides a general overview of the 
testing capabilities at DCLS, which is reflective of most public health laboratories.  The figure 
also includes a listing of the primary specimen types received, and the testing typically initiated 
in outbreak situations.  The decision regarding which tests to perform is determined by the 
epidemiological information provided to the laboratory upon submission.  In some cases, only 
minimal information is known (symptoms, time of onset), so the ability to target testing to a 
specific etiologic agent matching the clinical presentation is not always possible.  In other cases, 
an organism is known due to the fact that the patient was tested elsewhere, and the 
epidemiologists require additional testing to pinpoint sources and/or follow-up food service 
employees.     
Intestinal protozoan testing at DCLS.  Protozoan pathogens have historically been identified at  
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Figure 1.  Overview of typical foodborne outbreak specimen testing algorithm.  General 
overview of the outbreak testing approach at DCLS, the typical specimen types received, and 
examples of testing typically undertaken in outbreak investigations.  The decision regarding 
which laboratory tests to perform on outbreak-related specimens is determined based on the 
epidemiological information provided to the laboratory upon specimen submission.  
Abbreviations :  LV-PVA, polyvinyl alcohol; NoV, norovirus; EIA, enzyme immunoassay; RV, 
rotavirus; RT-PCR, reverse transcriptase polymerase chain reaction; STEC, shiga toxin-
producing E. coli. 
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DCLS using fecal concentration and staining techniques.  A molecular assay to differentiate E. 
histolytica from E. dispar is available, but has been rarely used.  Testing for the identification of 
parasites in clinical specimens has been suspended at DCLS and many other state public health 
laboratories, resulting in a gap in the ability of laboratories such as DCLS to screen outbreak 
specimens for protozoan pathogens.  Therefore, specimens submitted in association with 
outbreaks investigations for which an enteric parasite might be implicated must be sent to a 
private or reference laboratory for testing, greatly delaying the receipt of laboratory results. 
Enteric virus testing at DCLS.  Enteric virus testing is conducted at DCLS and encompasses 
real-time and conventional RT-PCR protocols developed by scientists at the CDC for norovirus 
and rotavirus.  In a typical outbreak in which parasites are not suspected, the first testing initiated 
is typically norovirus real-time RT-PCR, as results are available within just a few hours.  
Rotavirus real-time RT-PCR testing may also be initiated on the first day, depending on the 
symptoms of the cases in an outbreak.  If symptoms do not prompt the immediate inclusion of 
rotavirus testing, then testing could be delayed until the next day if all outbreak specimens are 
negative for norovirus.  If the norovirus assay results are positive, rotavirus testing is not 
typically initiated.  If the results are all negative, testing to identify enteric bacteria begins.  
DCLS also has the capability to further characterize norovirus-positive specimens using 
sequencing protocols developed by scientists at the CDC.  In addition to the genogroup identified 
by real-time RT-PCR, sequencing provides further genotype information.  This information is 
then entered and tracked using the CaliciNet surveillance program.  The typical turnaround time 
for outbreak results is 3 hours to 2 days, depending on the timing of rotavirus testing. 
Enteric bacterial testing at DCLS.  Bacterial pathogens are identified by DCLS using 
microscopy, biochemical testing, and EIA techniques.  On the first day of outbreak specimen 
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submission, plates and broths are prepared and incubated to begin the process of pathogen 
isolation.  On the second day, bacterial identification begins with enzyme immunoassay testing 
for toxins if the specimens are submitted for reference confirmation.  Reference specimens 
negative for toxins are reflexed for molecular toxin testing.  Toxin-positive outbreak specimens 
continue to be processed using microbiological techniques for organism identification.  On day 3 
and beyond, final biochemical and confirmatory testing takes place as appropriate for the 
suspected organism.  The approximate time to results is 2-6 days. 
 Additional STEC characterization is typically performed using real-time PCR molecular 
methods; however, this testing is mainly used to characterize isolates, and is not performed for 
outbreak testing purposes.  Specific identification of diarrheagenic E. coli  strains other than 
STEC O157 is currently not available at DCLS using classical microbiological techniques.  A 
real-time PCR protocol is maintained for ETEC strain detection, although it is typically reserved 
for outbreaks in which primary testing has not yielded an alternate pathogen identification.   
Use of Microsphere-Based Multiplex Screening Assays for Pathogen Identification and 
Detection.  The rapid turn-around time of molecular techniques, combined with increased 
sensitivity as compared to classical testing methods, has resulted in an explosion of PCR-based 
testing protocols in the literature.  Classical methods such as EIA and microscopy are traditional 
identification techniques, but are of limited value due to their high detection limits and the 
inability to differentiate between closely-related pathogens (e.g., E. histolytica versus E. dispar) 
(110, 118).  For viruses like norovirus and astrovirus, electron microscopy has been a gold 
standard method.  However, sensitivity is hampered due to viral morphology and the 
accessibility and complexity of this technology (25).   
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 Because molecular techniques can be designed to detect distinct genomic regions, and 
due to their ability to detect small numbers of a microorganism, they may provide greater 
sensitivity and specificity versus traditional methods.  Another advantage of molecular 
techniques is that they lend themselves readily to multiplex applications, allowing a number of 
pathogens to be targeted within one reaction tube.  Multiplexing has proven useful in identifying 
pathogens in clinical specimens, with a variety of protocols described for enteric bacteria, 
viruses, and parasites (50, 53, 97, 97).  However, multiplex assay design is extremely 
challenging due to the potential for primers to interfere with each other.  Careful research and 
use of design software can facilitate the identification of optimal primer pair combinations.  
Detection of PCR-amplified products may be accomplished in a variety of ways, including 
conventional gel electrophoresis and staining or real-time fluorescence detection.  Visualization 
with agarose gel is the most flexible method, as the number of targets that can be visualized at 
one time is not limited.  Real-time detection platforms, however, are limited in the number of 
fluorophores that may be used for detection at one time.   
 The Luminex XMap® microsphere technology is an open platform that has the capability 
for  simultaneous detection of up to 100 targets within one reaction.  This technology is also 
marketed by BioRad as the Bio-Plex™ 200 (BioRad Laboratories, Hercules, CA), and its use is 
the focus of this project.  The Bio-Plex 200 system consists of a 96-well microtiter plate reader, a 
"flow-based" detection system that employs two lasers for detection, and a high throughput 
fluids module (7).  Integral to the system are the 100 different microspheres (sets), each color-
coded with a unique mix of two fluorophores.  Each microsphere is made specific for a genomic 
target by chemically oligomerizing amplicon-specific probes to the microspheres, the process of 
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which is illustrated in Figure 2.  This system can detect up to 100 targets in 96 specimens per 
run, thus providing rapid detection without the real-time fluorophore and batch-size restrictions.   
 Prior to detection with the Bio-Plex, nucleic acids are extracted from clinical specimens 
and amplified in multiplex using conventional PCR (Figure 3).  One primer of each primer set in 
the multiplex reaction mix is biotinylated at the 5’ end.  The amplified specimens are then mixed 
with a multiplex microsphere ―mix‖ which contains the microsphere sets corresponding to the 
targets of the assay, and incubated to allow hybridization of biotinylated amplicon corresponding 
with the target microspheres.  After incubation, streptavidin-R-phycoerythrin (SAPE) is added to 
the sample wells to facilitate detection.  The R-phycoerythrin serves as a fluorescent reporter dye 
and streptavidin binds the dye to the biotinylated amplicon, if present.  The plate is then placed 
on the Bio-Plex reader platform and processed for target detection.  Using flow-based fluidics, 
the Bio-Plex instrument analyzes the microspheres in each sample well individually using lasers 
to detect specific bead color for identification purposes and the SAPE:biotin-tagged amplicon 
hybridization.  Results are provided by the Bio-Plex 200 platform as a value designated the 
median fluorescent intensity ( ―FI‖ for the Bio-Plex system), which represents the average 
fluorescence of 100 target-specific beads per specimen well. 
 Utilization of this technology for the multiplex detection of pathogens has been 
increasingly described for all pathogen types, in both research and commercial settings, with 
pathogen detection assays employing the microsphere-based technology of Luminex and/or the 
Bio-Plex 200 detection platform being described for bacteria, fungi, viruses, and parasites (40, 
71, 77, 116).  A microsphere-based assay for the detection of intestinal protozoa and parasites 
was recently described by Taniuchi et al., from which selected pathogen targets are being 
evaluated in this project (107)  To date, only one Luminex-designed nucleic acid assay is  
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Figure 2.  Protocol for coupling pathogen-specific DNA probes to microspheres.  This figure 
provides an overview of the steps required to couple a pathogen-specific probe and a uniquely-
numbered microspheres for each target in a Bio-Plex multiplex assay.  An image of the 
purchased microspheres is shown to the top left.  The microspheres initially only possess 
carboxyl groups on their surface.  DNA probes are synthesized to contain an amino modifier C12 
link at the 5’ end.  The number of microspheres used to make a batch can vary, but in the studies 
described herein, five million beads were typically used.  Microspheres are pelleted and the 
storage buffer is removed.  A pH 4.5 buffer is added to establish the reaction conditions.  Next, 
the target-specific probe is added followed by addition of  EDC {1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride} to react with the carboxyl groups on the 
microspheres and create a chemical intermediate at each carboxyl site.  The intermediate has an 
affinity for the amines attached to the probes, thus linking the probes to the microspheres.  After 
two washes with buffers, the microspheres are counted using a hemacytometer for accurate 
addition to the detection plate specimen wells.  This process is completed for each target-specific 
microsphere to be used in the multiplex assay.  Prior to a detection reaction on the Bio-Plex, a 
multiplexed bead mixture is made 
  
 20 
 
 
 
  
 21 
 
Figure 3.  Overview of nucleic acid hybridization and detection methodologies using the 
Bio-Plex 200.  This figure overviews the Bio-Plex 200 detection plate setup and hybridization 
steps as described in Materials and Methods.  Nucleic acids are extracted from clinical 
specimens and amplified with organism-specific primer sets in which one primer is biotinylated.  
After amplification, the Bio-Plex plate is prepared.  First, organism-specific microspheres are 
added to the wells of a 96-well plate (1), followed by addition of the biotinylated amplicon (2). 
This mix is heated to eliminate secondary structures, then incubated to allow hybridization of 
amplification products to complementary probes.  Next, a streptavidin-linked fluorescent reporter 
is bound to the biotinylated amplicon (3).  If the target DNA is present, the amplified DNA will 
hybridize to the probes on the microspheres, creating a microsphere-amplicon-reporter 
―sandwich‖ (middle right).  The plate is placed on the Bio-Plex analyzer for fluorescence 
detection.  The Bio-Plex uses two lasers:  one to read the spectral address of each bead, thus 
identifying the organism target, and the second to measure the presence of the reporter dye, thus 
indicating that a target has hybridized.  Histograms in the Bio-Plex software are used to measure 
bead detection, and final fluorescent intensity results are exported for analysis as qualitative 
results. 
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available as an FDA-cleared in vitro diagnostic kit -- the xTAG™ RVP (Respiratory Viral Panel) 
kit, which targets 12 respiratory virus targets.  Two other bead-based assays are available for 
research use only:  the ResPlex1® assay, which tests for seven respiratory pathogen targets, and 
the StaphPlex® which tests for 18 targets to allow Staphylococcus aureus identification and drug 
resistance determinations.  Luminex Corporation is currently marketing a new xTAG kit 
targeting 15 intestinal pathogens.  However, it is not yet currently available in the U.S. 
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CHAPTER 2 OVERVIEW OF RESEARCH PROJECT 
 
 
 
 Introduction to the Research Project.   Locally and nationally, there is an urgent need for 
simple, rapid and cost-effective testing methods for public health laboratories to detect and/or 
identify pathogens of national health concern (81).  Rapid detection is vital in identifying 
foodborne pathogens, allowing public health officials to quickly become aware of problems with 
the food supply that otherwise may have gone unnoticed.  Once an outbreak is identified, public 
health officials can control the occurrence of further infections (32).  A wide variety of parasites, 
bacteria and viruses may cause foodborne gastrointestinal infections (100).  Therefore, to support 
the urgency of obtaining outbreak investigation results, simple and rapid testing methods are 
desired in order to concurrently screen for as many typical foodborne pathogens as possible.  As 
discussed in Chapter 1, there are a wide variety of testing methods available for the detection of 
foodborne pathogens, ranging from traditional microbiological techniques to multiplex molecular 
assays.  However, each technique is limited in providing a rapid comprehensive foodborne 
pathogen screening capability, either by the number of pathogens that can be detected 
concurrently or the time required to obtain a result.   
Perhaps the most promising technology to enable comprehensive screening in one testing 
format for foodborne pathogens is that of multiplex molecular-based assays, many of which are 
described in the literature.  However, many of the assays are developed for real-time (RT)-PCR 
platforms that may accommodate only a small number of fluorophores, limiting the size of 
 25 
 
multiplex reactions and thus the number of pathogens that may be concurrently detected.  The 
potential of the Luminex XMap® microsphere technology incorporated into the Bio-Plex 200 to 
detect up to 100 molecular targets in one reaction makes the platform an attractive candidate for 
the development of multiplex assays capable of detecting more targets than currently allowed on 
real-time multiplex platforms, enabling comprehensive screening of foodborne outbreak clinical 
specimens on one instrument. 
The national emphasis regarding the development of diagnostic techniques for use in 
public health laboratories, combined with the availability of the advanced multiplex detection 
capability of the Bio-Plex 200, led to the hypothesis that the integration of multiplex Bio-Plex 
microsphere protocols with a common extraction method for the simultaneous detection of 
protozoan, bacterial, and viral organisms would enable prioritization of public health laboratory 
testing efforts and assist in reducing the timeline for identifying the causative agent of a 
suspected outbreak.   
To address this hypothesis, three specific aims were developed for this research project.  
The first specific aim was to assess the performance of a Bio-Plex microsphere assay for the 
detection of four different protozoan pathogens in clinical stool specimens.  The second specific 
aim was to develop and assess the performance of a Bio-Plex microsphere assay for the detection 
of enteric bacterial pathogens in clinical stool specimens, with an emphasis on diarrheagenic E. 
coli virulence determinants.  Finally, the third specific aim was to incorporate a common nucleic 
acid extraction method to be used in conjunction with the Bio-Plex assays and two standardized 
real-time RT-PCR viral assays utilized for the detection of norovirus and rotavirus agents.   
Rationale for Evaluating a Microsphere-Based Multiplex Testing Platform.  The detection 
of infectious agents associated with enteric outbreaks can be hampered by lack of information, 
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improper specimen collection, and non-specific symptoms.  Outbreak investigations occurring in 
immigrant populations and at institutions such as schools, day care centers, and long-term care 
facilities also make information-gathering difficult.  In all these cases, the gathering of critical 
epidemiological data may be hindered by challenges such as language barriers, age and mental 
status, and may ultimately result in misguided testing decisions and delayed pathogen 
identification.  
   Another challenge with respect to outbreak testing is the specimen requirements for 
individual testing methods.  For example, specimens transported in Cary-Blair medium are 
preferred for traditional bacteriological testing, while formalin and low-viscosity polyvinyl 
alcohol (LV-PVA) preservation are optimal for traditional parasite microscopy.  Depending on 
the molecular protocols employed by laboratories, some assays may not be validated for certain 
specimen types.  For example, specimens preserved in formalin are typically not acceptable 
molecular analysis as the formalin may inhibit PCR (94).  Should unacceptable specimen types 
be submitted, the collection of additional specimens may be required, resulting in testing delays.  
If additional specimens cannot be collected, no further testing can be performed.  Additionally, 
concurrent pathogen testing with multiple methods may require large sample volumes.  If sample 
volume is low, laboratorians must decide which testing can and should be performed first, 
potentially at the expense of testing for a complete panel of pathogens. 
 Finally, the characteristics of the pathogens also present obstacles.  Most public health 
laboratories typically characterize outbreaks based on disease onset times and reported 
symptoms of ill persons.  However, many organisms have similar or overlapping symptoms or 
sources.  Listed in Table 1 are a number of pathogens associated with significant numbers of 
foodborne and waterborne illnesses annually, along with representative incubation times and 
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typical symptoms (118).  The list is arranged in order of incubation period, from shortest to 
longest.  These incubation periods are often used by public health authorities to guide laboratory 
testing.  Of significant note is the overlap in incubation periods and symptoms between many of 
the pathogens, which can be misleading in trying to initially determine an outbreak etiologic 
agent and may render diagnostic testing decisions difficult.  For example, patients may exhibit 
similar incubation periods and symptoms when infected with either Salmonella spp. or norovirus, 
particularly early in the illness (118).  In another example, misinterpretation of non-specific 
symptoms was described in one Florida outbreak leading to an initial assessment as norovirus, 
but further testing revealed the cause to be Cryptosporidium (68).   
 Challenges such as those described above potentially cause a delay in identifying the 
outbreak pathogen. Using typical laboratory testing protocols, even the preliminary identification 
of a causative agent may take up to six days post-submission, as previously shown in Figure 1.  
Designing and employing an integrated screening algorithm that incorporates a common 
extraction method and multiplex Bio-Plex screening assays to detect enteric pathogens 
implicated in AGE outbreaks has the potential to allow laboratorians locally, nationally and 
internationally to test specimens and provide preliminary results for multiple pathogen types on 
the first day of submission.  Therefore, a practical goal for this project was to design a qualitative 
screening algorithm in which a variety of specimen types are prepared with a single extraction 
method and tested concurrently using the Bio-Plex platform targeting ten protozoan pathogens 
and bacterial gene targets in order to decrease the time to preliminary results and to better focus 
confirmatory testing.  Should this initial screening protocol exhibit acceptable performance and 
meet practical goals, it may serve as a testing backbone to which additional molecular targets 
may be added to meet future epidemiological testing needs.  
 28 
 
Table 1.  Symptoms characteristic of infection by common foodborne pathogens.  Outbreaks 
involving infectious agents are typically based on time to disease onset and symptoms.  The 
occurrence of similar or overlapping symptoms or sources have the potential to hinder public 
health investigation and laboratory testing decisions. 
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Agent
a
 Incubation Period Symptoms
b
 
Chemical toxins 1 min-3 hrs Varied 
S. aureus enterotoxins  30 min-6hrs V, D, N, Cr 
B. cereus enterotoxins  1-6 hrs or 6-15 hours V or D, Cr, V 
Salmonella spp., nontyphoidal 6 - 72 hours N, V, D, Cr 
C. perfringens enterotoxins  8-24 hours N, D, Cr 
Noroviruses 10-51 hours V, D, Cr, Hd, N 
Shigella spp. 12 – 50 hours  D (bloody), Cr, F, V 
Rotaviruses 24-72 hours V, D (copious) 
E. coli O157:H7  3-9 days Cr, D (bloody), F (low) 
Cryptosporidium spp. 2-28 days V, D, N, F 
Giardia intestinalis 7 - 14 days D, Cr, N, F, Gas 
Salmonella typhi 14 – 40 days F, N, Cr,  
Hepatitis A Virus 15-50 days Jaundice, N 
a  
Data from reference 118. 
b
 V=vomiting, D=diarrhea, N=nausea, F=fever, Cr=cramps, Hd=headache 
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Overview of Assays in this Study.  Assays targeting enteric protozoa and enteric bacteria were 
designed and evaluated in this study.  In addition, use of the Bio-Plex extraction method was 
evaluated for use with two standardized real-time RT-PCR assays for virus detection.  A general 
overview of each of the assays that are part of the Bio-Plex screening algorithm is outlined 
below, with details of the molecular targets provided in specific assay chapters. 
Intestinal protozoan assay.  A multiplex assay to detect select intestinal protozoa was designed 
by scientists at the University of Virginia (UVA).  An initial design employed two multiplex 
tests (a two-plex and seven-plex) targeting G. intestinalis, Enterocytozoon bieneusi, Isospora 
belli, C. cayetanensis, C. parvum/hominis, Encephalitozoon intestinalis, and E. histolytica.  
Preliminary testing showed that the assay had potential for successful screening of specimens 
preserved in LV-PVA (data not shown).  However, several pathogens targeted by the assay had 
no foodborne public health significance in the U.S.  Therefore, E. bieneusi, I. belli, and E. 
intestinalis were removed from the multiplex, and the primers and probes targeting the remaining 
four pathogens were combined into one multiplex PCR detection assay.  Details of the primer 
and probe sets are provided in Chapter 4.  Final assay evaluations were conducted using 
unpreserved and LV-PVA specimens.   
Enteric bacterial assay.  An initial six-plex bacterial assay to detect diarrheagenic E. coli strains 
was developed by collaborators at UVA, and included primers and probes specific for EHEC, 
ETEC and EPEC genome targets.  Preliminary testing using stool-inoculated broth specimens 
(hereafter referred to as ―stool broth specimens‖) submitted for STEC reference confirmation 
demonstrated the potential of this assay or specimen screening (data not shown).  Several 
changes were made to the multiplex prior to conducting a formal evaluation.  Because the 
incidence of EPEC in foodborne outbreaks is very low in the U.S., primers and probes for two 
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EPEC molecular targets were removed from the multiplex.  Instead, two additions were made, 
enabling detection of an E. coli O157-specific gene target (DCLS addition) and a shared target in 
enteroinvasive E. coli (EIEC) strains and Shigella spp. (UVA design).  Details of the genomic 
regions targeted by the primer and probe sets are provided in Chapter 5.  Preliminary evaluation 
of the revised six-plex assay was conducted with stool broth specimens.  Because stool broth 
specimens are not typically submitted for outbreak investigations, final validation of this 
specimen type was not conducted.  Final evaluation of the assay was conducted using stool 
specimens diluted in Cary-Blair transport medium.   
Enteric viral assay.  A Bio-Plex viral assay design targeting  norovirus genogroups I and II, and 
Group A rotaviruses was initiated at DCLS.  Following preliminary testing, the benefit of adding 
this assay to complement the other two Bio-Plex assays as part of a multi-pathogen screening 
algorithm was re-evaluated.  The decision to forego a formal evaluation of this assay was made 
for the following reasons:  1) the norovirus genome targets were identical to standardized real-
time RT-PCR protocols currently in use at DCLS, 2) the rotavirus Bio-Plex assay did not provide 
any additional information than that obtained with standardized real-time RT-PCR protocols 
currently in use, and 3) the Bio-Plex protocol required twice as much time to complete as the 
real-time RT-PCR protocols, therefore providing no turnaround time benefit.    
 The use of real-time RT-PCR assays to test viral agents provides a time advantage over 
the proposed Bio-Plex assay.  However, if outbreak specimens require both Bio-Plex and real-
time RT-PCR testing, the existing protocols as designed require two nucleic acid extractions.  
Therefore, to make the screening algorithm more efficient, use of a common extraction method is 
optimal.  To meet this goal, a study was completed in which nucleic acids were extracted from 
unpreserved and Cary-Blair specimens using both the Bio-Plex extraction method and the 
 32 
 
extraction method currently in use at DCLS for the standardized viral assay.  Nucleic acids were 
then tested using real-time RT-PCR assays to detect norovirus or rotavirus, and results were 
compared.  Achieving comparable results between the two extraction methods would enable 
laboratories to utilize the Bio-Plex extraction method simultaneously with the real-time RT-PCR 
assays, thus reducing the need for a second extraction when both Bio-Plex testing and viral 
testing is required.  
Overview of Validation Studies.  In order to implement Bio-Plex assays for outbreak specimen 
screening, specific performance characteristics must be established for each of the assays.  
Regulations governing validation are provided in the Clinical Laboratory Improvement 
Amendments (CLIA), section 493.1253, which state that performance characteristics must be 
established for both qualitative and quantitative assays that are not FDA-cleared or subject to 
clearance, a category within which the described Bio-Plex assays fall (31).  The performance 
standards to be evaluated include accuracy, precision, analytical sensitivity/specificity, reportable 
range of results, and reference intervals, as appropriate for the assay (31).  To facilitate these 
studies, the Clinical and Laboratory Standards Institute (CLSI) offers guidance on assessing 
molecular assay performance characteristics, and a comprehensive review article consolidating 
validating recommendations is available in the literature (8, 27, 29).  Review of these guidelines 
and publications allowed for the selection of several Bio-Plex assay performance characteristics 
to be evaluated as part of this project. 
 Qualitative tests have one of two possible results: detected or not detected (28).  The 
multiplex assays evaluated for this project have three steps: nucleic acid extraction, nucleic acid 
(template) amplification, and analyte (amplicon) detection.  The Bio-Plex instrument is used for 
the detection step and yields a numerical ―median fluorescent intensity‖ (FI) value that is 
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translated into a qualitative result of ―detected‖ or ―not detected‖ by the operator.  Specific 
guidance for the validation of qualitative multiplex molecular assays is provided in CLSI 
documents MM17-A and MM3-A2 and determinations of accuracy, precision, and analytical 
specificity are required for qualitative molecular assays (27, 29).  Because a numerical value is 
used to generate a qualitative result, assessments of analytical sensitivity, or limits of detection 
(LoD), are also important as these values potentially impact the positive cutoff point of the assay 
(30).  Therefore, the validation studies performed as part of this project included the performance 
characteristics of analytical sensitivity (limit of detection, LoD), analytical specificity (cross-
reactivity, interference), precision (repeatability, reproducibility), and accuracy (comparison-of-
methods).   
Reference/Testing materials.  The primary specimens used for the validation studies were 
archived stool specimens, including unpreserved stools and stool specimens diluted in LV-PVA 
or Cary-Blair transport medium.  Bacterial isolates and commercially-purchased protozoan 
cysts/oocysts were used for both analytical specificity and sensitivity testing studies.  Cloned 
PCR amplification products inserted into vector plasmids were used for selected analytical 
sensitivity testing.  All clinical specimens were anonymized prior to use in the validation testing 
studies. 
Determination of positive cutoff value.  All analytical test methods required the establishment of 
a cutoff value for determining positivity of results.  The CLSI guidelines suggest determining the 
highest FI value that is likely to be observed for a blank or negative sample and using this value 
to help determine the cutoff (27, 29).  However, for the purposes of this project, the FI value for 
the blank samples was not used as the cutoff for the following reasons:  1) assay cutoff values for 
selected assays had previously been established by collaborators developing the initial testing 
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protocols, and 2) preliminary testing in our laboratory showed that negative specimens yielded 
fluorescent readings lower than the minimum FI regarded to be relevant (<50 FI) by the Luminex 
Corporation (J. Eveleigh, personal communication).  Alternative guidelines suggest that 
choosing a signal-to-noise ratio between 2:1 and 5:1 allows the nucleic acid targets to be 
distinguished from background (27).  Therefore, the working cutoff for designating positive 
results was established at two times greater than the background value when background value 
was subtracted.  Precedence for using this cutoff is also provided in the scientific literature (39, 
40, 116). 
 Additionally, a final cutoff value for the Bio-Plex assays under evaluation must be chosen 
to indicate positivity based on the data gathered during the study.  Standardized guidance is not 
available in the literature; rather, various approaches to assigning a positive value have been 
described.  Typical approaches compare sample and negative background well FI values and 
calculate cutoffs at either two times background fluorescence, two times background 
fluorescence with the background fluorescence subtracted, or fluorescent values up to nine times 
background (39, 40, 71, 116).  An alternative approach to establishing cutoff values employs the 
use of receiver operating characteristic (ROC) plots (71, 107).  Data generated for the screening 
assays described for this project were calculated using a value of two-times background. 
Analytical sensitivity or limit of detection (LoD).  The LoD, or analytical sensitivity, of an assay 
describes the lowest amount of analyte that can be detected consistently at a specified level of 
confidence (8, 27).  The LoD can be established using two approaches.  First, the LoD can be 
calculated using the FI data generated with negative specimens (statistical testing) or second, 
established by testing specimens with known amounts or concentrations of target (empirical 
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testing) (8).  Empirical testing should take place over a series of days to account for procedural 
variations and the LoD determined for each target in a multiplex and for each matrix type (8, 29).   
 For this project, empirical testing was used to determine the assay’s LoD.  Each matrix 
was spiked with serial dilutions of known concentrations of organism or cloned nucleic acid.  It 
is recommended that 60 data points be collected in LoD studies (8, 30).  However, guidelines 
also acknowledge that availability of resources and cost may impact study design (8, 29).  Due to 
the relatively high cost-per-test, and the intent of these assays to serve as screening assays, not 
confirmation assays, it was determined that performing a minimum of three replicate 
experiments per organism or nucleic acid was acceptable.  In most cases, five dilutions were 
tested in each experiment, representing dilutions above, at, and below the anticipated LoD for the 
target(s) being tested, yielding an average of 15 data points for each assay target per matrix type.  
The limits of detection were established as a range in which the lower limit represented the 
lowest dilution yielding one positive result and the upper limit represented the lowest dilution 
yielding three positive results.  
 Once the LoD is established for each assay target, it is recommended that data 
verification be conducted by incorporating additional targets or reaction components that could 
potentially interfere with the detection of low-concentration targets (29).  For example, for the 
detection of infectious disease agents, it may be useful to add a high-concentration target to a 
low-concentration target (i.e., pathogen), as this could mimic a true clinical specimen and a high-
concentration target could potentially interfere with detection of the low-concentration target.  
For the purposes of this study, this type of parameter was automatically evaluated in the study 
since numerous high-concentration nucleic acid targets  in combination with low-concentration 
pathogen assay targets was inherent in the stool specimens,  as a wide variety of normal flora 
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were present in the stool specimens.  The question as to whether these assays can detect targeted 
pathogens in the presence of other organisms is additionally supported by the fact that in most 
public health outbreak investigations, a single etiologic agent is identified and is often recovered 
from multiple specimens submitted as part of the outbreak investigation. 
Analytical specificity (cross-reactivity/interference).  Analytical specificity describes the ability 
of an assay to detect only the agent that is targeted (29).  Assessing analytical specificity may be 
accomplished in multiple ways: 1) using multiplex data to rule out cross-reactivity or 
interference of primer and probe sets with non-target nucleic acids, 2) challenging reactions with 
organisms not specifically targeted by the assay but that may be considered normal flora or 
causative agents of similar symptoms, 3) spiking specimens with substances that might interfere 
with the analytical procedure, and/or 4) evaluating sequences for potential cross-reactivity using 
internet databases and comparison programs (8, 29).  
 Most of the primer and probe sequences were adapted from published studies for which 
specificity experiments had been previously described.  Therefore, data detailing the non-target 
organisms against which the primers and probes were tested for cross-reactivity was available.  
The analytical specificites of the Bio-Plex assays described in this study were further assessed in 
multiple ways.  Novel primer and probe sequences designed for use in this study were tested for 
potential cross-reactivity by collaborators using the Basic Local Alignment Search Tool 
(BLAST) maintained by NIH (data not shown).  In addition, each target in the multiplex assay 
was assessed for cross-reactivity to non-complementary nucleic acid templates, mainly using 
qualitative results obtained during the comparison-of-methods study.  Specifically, results for 
assay targets that were expected to be negative based on reference testing were quantified and 
compared.  If no cross-reactivity exists between non-target primers and probes or with known 
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non-target organism in the specimen, a negative result should be expected.  For example, a 
Giardia-positive specimen is expected to yield negative results when tested using the other three 
non-Giardia primer and probe sets in the protozoan assay multiplex.  If all negative results are 
observed, the data suggests no cross-reactivity.  If positive results are detected for any of the 
targets other than Giardia, the data indicates there is potential cross-reactivity between the non-
target primers and probes and the nucleic acid template.  Finally, additional pathogens were 
included in order to assess for cross-reactivity to assay primers and probes.  For the protozoan 
assay, the majority of the LV-PVA validation specimens were determined by reference method 
to contain other intestinal parasites not targeted by the current Bio-Plex assay (e.g., Blastocytis 
hominis, Chilomastix mesnili, etc.).   Therefore, the absence of positive results in the presence of 
non-complementary target can be used to rule out cross-reactivity to these organisms.  For the 
bacterial assay, several sources of non-target pathogens were used to challenge the Bio-Plex 
assay, including bacterial isolates representing non-targeted E. coli strains and serotypes and 
other enteric bacterial pathogens. 
It has been well documented that stool samples contain multiple inhibitors of nucleic acid 
amplification reactions, including medications and/or their breakdown products, food 
components, bile salts and normal bacterial flora (111).  Directly assessing all the potential 
interfering substances, known and unknown, in a stool specimen by spiking studies is not 
practical and was not part of the current validation studies.
 
  However, assay interference was 
indirectly assessed since the specimens tested in the current validation studies were 
representative of stool specimens typically submitted to DCLS and, therefore, included a range 
of different consistencies, normal bacterial flora, storage conditions, and preservation methods, 
and presumably contained a variety of medications and other components reflective of patient 
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diets, as specimens are submitted from a variety of different patients throughout the 
Commonwealth of Virginia.  To assess interference by these variables, comparison-of-method 
study data was evaluated for negative results obtained for targets expected to positive when 
tested with the Bio-Plex system.  Specimens yielding false negative results were diluted and 
tested to determine potential presence of inhibitors. 
Precision (repeatability and reproducibility).  Precision describes how well replicates of a given 
measurement agree when tested under defined conditions (8, 29).  Precision studies typically 
incorporate two types of evaluations: repeatability and reproducibility.  In repeatability studies 
(―within-run‖ studies), specimens of varying concentrations are tested in replicate using the exact 
same conditions.  For the protozoan and bacterial assays, amplicons from specimens representing 
various concentrations of organism, matrices, and assay targets were tested in ten replicates on a 
single Bio-Plex run by a single operator.   
In reproducibility studies (―between-day studies‖), specimens of varying concentrations are 
tested under a variety of conditions.  Ideally, variation should include multiple lots of reagents, 
multiple operators, various testing times, etc. (29).  However, reproducibility studies often 
employ single lots of reagents and single operators, as was conducted in the current study (8).  
Reproducibility for the protozoan and bacterial assays was determined by amplifying extracted 
nucleic acid templates from select specimens and performing the detection step in single wells on 
the Bio-Plex system, one time per day over five days.  Testing occurred only once per day, as 
opposed to multiple runs, to reflect how the assay would actually be used during an outbreak 
investigation (8).  The reproducibility studies included both replicate detection of the same 
amplicon over multiple days and replicate amplification combined with Bio-Plex detection over 
multiple days.  Thus, statistics describe both the precision of the detection step and overall 
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precision of the amplification and detections steps together, taking into account the single 
variable of time. 
 Guidelines recommend that precision studies be conducted with specimens of typical 
clinical analyte concentrations and that represent all specimen matrices to be tested (29).  
Evaluations of quantitative assays should include specimens not only at the assay cutoff point, 
but also at other points in the assay measuring range.  Evaluations of qualitative assays should 
emphasize specimens at or near the limit of the assay (8, 29).  Because this multiplex assay is a 
semi-quantitative assay (quantitative results are used to generate a qualitative result), the 
precision evaluation is based on both recommendations and employs specimens yielding 
fluorescence results both near the assay cutoff of two times background, and results higher in the 
measurement range.  As recommended, the specimen panels evaluated included the typical 
specimen matrix type for each assay (29)  For both repeatability and reproducibility studies, 
mean and standard deviation (SD) of the FI minus background results were calculated for both 
positive and negative multiplex targets.  In addition, the coefficient of variation [CV, 
(SD/mean)x100] was calculated for positive targets.  CV was not calculated for negative targets 
as the resulting percentages are statistically impractical.   
 Guidance publications also provide varying recommendations for precision study sample 
size, ranging from 40 replicates for qualitative tests to 120 data points for quantitative tests (8).  
However, it is acknowledged that achieving these numbers of replicates may not be feasible due 
to limited specimens and resources (28). Minimizing the panel size, number of replicates, and the 
scope of the precision study decreases the confidence level of the results and may underestimate 
the overall assay imprecision.  However, because the assay is intended to be used as a screening 
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assay to rule in suspected pathogens, the precision data was adequately descriptive for this 
intended use. 
 The literature contains limited data with respect to the precision of Bio-Plex 200 nucleic 
acid assays and there are no standards established to determine the acceptability of precision data 
for molecular assays (8).  Therefore, the repeatability and reproducibility data generated by this 
evaluation were compared to data available in two commercial and scientific studies (75, 77).  In 
order to assess the precision of organism-positive assay targets, the CV data generated in this 
study were compared to positive target CV data published for the only commercially-available, 
FDA-cleared, infectious disease microsphere multiplex assay, the xTAG® RVP (Respiratory 
Viral Panel) (Luminex Molecular Diagnostics, Inc., Toronto).
  
The RVP data differed from the 
current study data in that the RVP study represented a multiple-laboratory evaluation and 
measured precision for extraction, amplification and detection steps (75).  However, to the 
author’s knowledge it is the only commercial document available in the U.S. describing 
precision for Luminex-based nucleic acid assays, and therefore was used for comparison 
purposes.   
 Fluorescent intensity values less than 50 are below the detection threshold of the 
Luminex technology, and variation is considered difficult to assess (J. Eveleigh, personal 
communication).  Prior experience with the BioPlex assay has suggested that CV values of 
negative specimens are often impractically high and potentially misleading; therefore SD values 
were used to describe the variation for target-negative specimens.  To assess statistical 
acceptability for negative targets, the calculated SD values were compared to those described for 
an alternate microsphere-based assay described in the literature (77). 
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 Because there are no established standards of precision acceptability for Bio-Plex nucleic 
acid assays, it is incumbent upon the testing laboratory to determine criteria for acceptability.  
Standards of precision for chemistry assays provide some basis for analysis, although even these 
assays demonstrate a 15% to 30% variance (8).  Because this technology is relatively new, and 
well-established precision data is not available, comparisons to that described for the RVP assay 
and by McNamara et al. (75, 77) were considered acceptable. 
Analytical accuracy (comparison-of-methods).  Accuracy describes how closely a result agrees 
with an established reference, or for validation studies, how closely a new method correlates with 
the reference method (8, 29).  Therefore, a comparison-of-methods study may be conducted to 
evaluate the accuracy of a new method.   
Comparison-of-methods studies were conducted to assess the performance of the Bio-
Plex protozoan and bacterial assays and to determine their potential for use in outbreak 
investigations.   Previously characterized specimens -- as determined using the reference 
methods of microscopy, molecular methods, or enzyme immunoassay -- were tested using the 
appropriate Bio-Plex assay and the results compared to establish the level of agreement between 
the two methods.  Bio-Plex results were designated as either true positive (TP), true negative 
(TN), false positive (FP), or false negative (FN) (Figure 4).  Additionally, the sensitivity (Se) and 
specificity (Sp) for each assay target were calculated as described in Figure 4.  Bio-Plex results 
that did not correlate with the reference method results were investigated using re-extraction and 
re-testing, repeating the reference method testing, and/or using alternative molecular assays, as 
available.   
The number of specimens recommended for a comparison-of-methods study varies 
greatly, ranging from a minimum of 20 specimens to 100 specimens, although typically 40-50    
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Figure 4.  General algorithm to determine correlation between a new test method and the 
corresponding reference method.  To determine correlation (sensitivity and specificity) 
between a new test method and a reference method, specimens were tested with both methods 
and the results compared.  A grid is generated for each target in the assay. A specimen that is 
positive when tested with both a reference method and a new method is considered to be a true 
positive (TP).  Similarly, a specimen that tests negative with both methods is considered a true 
negative (TN).  A specimen giving positive results with the reference method and negative 
results with the new method is a false negative (FN), and likewise, a negative reference method 
result and a positive result with a new method indicates a false positive (FP).  Upon completion 
of the study, the sensitivity and specificity are then calculated for each target using the equations 
to the right of the grid. 
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specimens are tested (8).  CLSI guidelines for qualitative test comparison studies recommend 
that 50 positive and 50 negative specimens be tested, although smaller sample sizes may be used 
with resulting larger confidence intervals (8, 28).  The goal for the protozoan and bacterial assays 
was to test a minimum of 40 specimens.  However, for certain targeted pathogens, the number of 
available specimens was limited; in these cases, all available specimens were tested and the 
small sample size noted.   
The parameters of Se and Sp are important in assessing the appropriateness of assay use 
and guides result interpretation.  The higher the sensitivity, the more confident a user can be that 
a negative result is truly negative, since there will be few false negatives.  Conversely, the higher 
the specificity, the more confident a user can be that a positive result is truly positive, since there 
will be few false positives.  As discussed previously, the intended use of these Bio-Plex 
multiplex assays is to screen specimens submitted as part of foodborne or waterborne outbreak 
investigations.  Any positive results would allow for preliminary notification of epidemiologists 
and a prioritization of confirmatory testing used to characterize the detected pathogen.  In most 
outbreak investigations, up to six specimens are typically accepted for testing.  At least two 
specimens from different patients must be positive with a confirmatory method to assign a 
causative agent to an outbreak.  If all specimens are negative, testing will continue regardless of 
the screening results as illustrated in Figure 1.  Therefore, high specificity is the desired outcome 
since the decision to continue with testing is based on positive results.  A lower sensitivity 
(higher number of false negatives) is acceptable for the following reasons:  1) all specimens will 
be confirmed regardless of whether positive or negative, 2) no action decisions will be made 
based on negative screening results, and 3) multiple outbreak specimens will typically be tested, 
inherently increasing the overall screening sensitivity for the outbreak.  Based on these factors, 
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the minimum acceptable standards were established to be 80% sensitivity and 95% specificity 
for the Bio-Plex assays.  
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CHAPTER 3 MATERIALS AND METHODS 
 
 
 
Materials and Methods – Protozoan Assay. 
 
Specimens.  Specimens tested in this study were anonymized to fulfill the requirements of the 
University of Virginia IRB for Health Sciences Research exemption (IRB-HSR #14597).  Forty 
stool specimens preserved with low-viscosity polyvinyl alcohol (LV-PVA) and 30 unpreserved 
stool specimens were examined.  The 40 LV-PVA specimens included specimens positive for the 
assay targets of  G. intestinalis (n=8),  E. histolytica/dispar (n=3), and both G. intestinalis and E. 
histolytica/dispar (n=4), as determined by microscopy. The 30 unpreserved stools included 
specimens positive for C. cayetanensis (n=6),  C. parvum (n=2), C. hominis (n=1)  and G. 
intestinalis (n=3), as determined by PCR.  LV-PVA specimens were stored at room temperature 
or washed and stored at -80ºC prior to testing.  Unpreserved specimens were stored at 4ºC or       
-80ºC prior to testing.  Nucleic acids extracted from the specimens were stored at -80ºC prior to 
comparative testing.  Specimens containing C. cayetanensis, C. parvum, and C. hominis were 
generously provided by Dr. Alexandre J. da Silva of the Centers for Disease Control and 
Prevention, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Division of 
Parasitic Diseases, Atlanta, GA. 
Cyst and oocsyt standards.  G. intestinalis cysts and C. parvum oocysts were purchased as 
1x10
6
/4mL concentrations from Waterborne, Inc.  (New Orleans, LA).  Following vortexing 
and/or sonication, cysts were ten-fold serially diluted in 1X phosphate-buffered saline.  To 
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establish assay limits of detection, dilutions of 10
4
-10
0 
 cysts (40 μL) were spiked into 200 mg of 
parasite-negative LV-PVA or unpreserved stool to yield 10
4
-10
0
 cysts per 200 mg of stool.  
Spiked stool specimens were vortexed to evenly distribute organisms and stored at 4°C for a 
minimum of 30 minutes prior to extraction, amplification and detection as described below.  
Dilution series were tested in triplicate and total numbers of positive and negative qualitative 
results for each dilution were summarized.  The limits of detection were established as a range in 
which the lower limit represented the lowest dilution yielding one positive result and the upper 
limit represented the lowest dilution yielding three positive results. 
Cloned DNA standards.  C. cayetanensis and E. histolytica DNA was PCR amplified and cloned 
into the pCR®2.1 TA vector (Invitrogen, Carlsbad, CA) per manufacturer’s TOPO TA cloning 
kit instructions.  Screen-positive cells were grown overnight and plasmid DNA isolated using the 
PureLink™ Quick Plasmid Miniprep Kit per manufacturer’s instructions (Invitrogen).  The 
concentration of cloned DNA was determined using a NanoDrop 2000 (Thermo Scientific, 
Wilmington DE).  The cloned nucleic acid stock concentration was used to calculate 
approximate genome copies/μL for this study as described by Staroscik (106).  To establish assay 
limits of detection, ten-fold serial dilutions were prepared in nuclease-free water and spiked in 10 
μL volumes into 200 mg of parasite-negative LV-PVA or unpreserved stool aliquots.  LV-PVA 
specimens were washed twice with 1X PBS prior to spiking with clone.  Spiked stool specimens 
were vortexed to evenly distribute plasmid DNA and stored at 4°C for a minimum of 30 minutes 
prior to extraction, amplification and detection as described below.  Dilution series were tested in 
triplicate and total numbers of positive and negative qualitative results for each dilution were 
summarized.  The limits of detection were established as a range in which the lower limit 
represented the lowest dilution yielding one positive result and the upper limit represented the 
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lowest dilution yielding three positive results.  Concentrations expressed as genome copies/μL 
were converted to reflect approximate organisms/200 mg stool using the following formula:  
(genome copies/200mg stool) / (genome copies/organism).  Copy numbers of the assay gene 
targets for Cyclospora spp. and E. histolytica are estimated to be 2-20 copies/oocyst and 200 
copies/trophozoite, respectively (5, 112). 
Extraction of nucleic acids.  Nucleic acid was extracted from stool specimens (200 mg) using 
the QIAamp DNA Stool Mini Kit (QIAGEN, Hilden, Germany) per manufacturer’s instructions, 
with modification.  PVA-preserved stools were washed twice using 1 mL of 1X phosphate-
buffered saline per wash and centrifuging at 10,000 rpm for 2 minutes.  QIAamp Buffer ASL 
was added to all specimens, followed by the addition of beads from one UltraClean® Fecal DNA 
Isolation Kit Dry Bead Tube (Mo Bio Laboratories, Inc., Carlsbad, CA).  Beads were not 
included in the extraction of spiked clone standards in order to preserve the integrity of the 
cloned DNA.  The extraction continued per manufacturer’s instructions to the final elution of 
DNA in 200 μL of AE buffer.  Extracted DNA was further purified using a Zymo-Spin™ IV-
HRC filtration column (Zymo Research, Orange, CA) per manufacturer’s instructions. 
Primers and probes.  Primers and probes were previously described or designed by collaborators 
at the University of Virginia (Table 2).  Reverse primers were modified at the 5’ end with biotin-
TEG and probes with the amino modifier C12.  Expected amplification products were as follows:  
G. intestinalis (62 bp), C. cayetanensis (280 bp), C. parvum/hominis (138 bp), and E. histolytica 
(134 bp).  Primers and probes were purchased from Integrated DNA Technologies (Coralville, 
IA) or Eurofins MWG Operon (Huntsville, AL).  
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Table 2.  Oligonucleotide primers and probes for a microsphere suspension array assay for 
the simultaneous detection of G. intestinalis, C. cayetanensis, C. parvum/hominis and E. 
histolytica.  Modifications at the 5’ end are biotin-TEG (reverse primers) and amino modifier 
C12 (probes).  
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Target Sequence (5’-3’) Ref. 
G. intestinalis  
     G62F 
     G62btn 
     G62P  
 
GACGGCTCAGGACAACGGTT 
TTGCCAGCGGTGTCCG 
CCCGCGGCGGTCCCTGCTAG 
(107, 113) 
C. cayetanensis  
     Cc280F 
     Cc280Rbtn 
     Cc280P  
 
GTAGCCTTCCGCGCTTCG 
CGTCTTCAAACCCCCTACTGTCG 
GCATTTGCCAAGGATGTTTT 
(24, 85)
 
 
 
This study
 a
 
C. parvum/hominis  
     C138F 
     C138Rbtn 
     C138p  
 
CGCTTCTCTAGCCTTTCATGA 
CTTCACGTGTGTTTGCCAAT 
CCAATCACAGAATCATCAGAATCGACTGGTATC 
(44)  
E. histolytica  
     Eh134F 
     Eh134Rbtn 
     Eh134P  
 
AACAGTAATAGTTTCTTTGGTTAGTAAAA 
CTTAGAATGTCATTTCTCAATTCAT 
ATTAGTACAAAATGGCCAATTCATTCA 
(98, 107) 
a
  Designed by Dr. Mami Taniuchi, Division of Infectious Diseases and International Health, 
University of Virginia, Charlottesville, VA (unpublished data) 
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Coupling of oligonucleotide probes to microspheres.  Oligonucleotide probes were coupled to 
microspheres (Bio-Rad Laboratories, Hercules, CA) using the recommended coupling protocol 
provided by Luminex Corporation (Austin, TX), with the addition of a 1400 rpm rotation step  
during the first incubation (74).  Coupled microspheres were enumerated using a hemacytometer 
per the Luminex protocol. 
Protozoan assay multiplex PCR.  Amplification of extracted nucleic acid was performed in 50 
μL reaction volumes using Bio-Rad iQ™ Multiplex Powermix (Bio-Rad).  Each reaction 
contained 25 μL of 2X iQ Multiplex Powermix and 0.3 mmol/L of each primer.  Amplification 
was performed using the 96-well GeneAmp® PCR System 9700 (Applied Biosystems, Carlsbad, 
CA), and cycling conditions consisted of 3 minutes at 95°C followed by 40 cycles of 15 seconds 
at 95°C and 60 seconds at 58°C.  
Detection of nucleic acid targets using Bio-Plex microsphere assay.  Hybridization of 
amplicons to coupled microspheres was conducted using the recommended hybridization 
protocol provided by Luminex Corporation, with modifications (73).  Briefly, detection reactions 
were performed in 50 μL volumes in 96-well plates, and consisted of approximately 5000 
coupled microspheres for each of the four targets (G. intestinalis, C. cayetanensis, C. 
parvum/hominis, E. histolytica), 33 μL of 1.5X TMAC solution, 12 μL of 1X TE buffer, and 5 
μL of amplified DNA.  Reaction plates were incubated at 95°C for 3 minutes to denature 
oligonucleotide secondary structure, then underwent 15 minutes of shaking incubation at 50°C 
and 800 rpm.  After addition of 25 µL of 10 μg/mL streptavidin-R-phycoerythrin reporter dye, 
plates underwent a second shaking incubation at 50°C and 800 rpm for 10 minutes.  Detection of 
hybridized amplicons was performed using the Bio-Plex® 200 Suspension Array System using a 
low RP1 target setting.  Specimens were tested in single wells, with negative non-template 
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amplification controls placed at the beginning, middle and end of each detection run.  The 
negative well placed at the end of the run was used as the background well for result calculation.  
Data output of the Bio-Plex 200 is median fluorescent intensity (FI).  In order to determine 
positivity or negativity, the FI of the background well was subtracted from the FI of the 
specimen and compared to background.  Results greater than or equal to two times the 
background were considered to be ―screen positive‖. 
Trichrome stain.  Trichrome staining was performed using Remel Wheatley Trichrome Stain 
(Remel, Lenexa, KS). Slides were placed into Coplin jars containing 70% alcohol plus iodine for 
20 minutes, followed by two washes with 70% alcohol for five minutes each.  Slides were then 
placed into trichrome stain for eight minutes, followed by a rinse with 95% alcohol.  Slides were 
placed into a second jar of 95% alcohol for five minutes, then carbol-xylene for 10 minutes, and 
xylene for 10 minutes.  Slides were mounted with coverslips using Permount  and were 
examined by oil immersion microscopy at 100X.  
Singleplex PCR assay for the detection E. histolytica and E. dispar (alternate molecular 
method).  Amplification of nucleic acid was performed using PSP3 and PSP5 primers specific 
for E. histolytica and NSP3 and NPSP5 primers specific for E. dispar (26).  Singleplex reactions 
were mixed in 50 μL volumes using ABI AmpliTaq Gold® Master Mix (Applied Biosystems, 
Carlsbad, CA).  Each reaction contained 25 μL of master mix and 0.24 mmol/L of each primer.  
Template DNA was diluted 1:10 and 10 µL of template added to the reaction volume.  
Amplification was performed using the 96-well GeneAmp® PCR System 9700 (Applied 
Biosystems, Carlsbad, CA), and cycling conditions consisted of 5 minutes at 95°C followed by 
40 cycles of 15 seconds at 94°C, 15 seconds at 50°C and 90 seconds at 72°C.  Amplification was 
completed with a final extension step at 72°C for 10 minutes.  Amplification products were 
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visualized using 2% agarose gel electrophoresis or Agilent DNA1000 Kit and the Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA).  Nucleic acid extracted from E. dispar 
trophozoite cultures was thoughtfully provided by Dr. Ibne Karim Ali, Division of Infectious 
Diseases and International Health, University of Virginia, Charlottesville, VA.  
Precision studies.   Precision characteristics of the Bio-Plex 200 assay were determined by 
testing DNA extracted and amplified from a panel of five specimens that included two LV-PVA 
stool specimens positive for G. intestinalis and E. histolytica, respectively, and three unpreserved 
stool specimens positive for G. intestinalis, C. cayetanensis, and C. hominis, respectively.  The 
specimens chosen for this panel demonstrated fluorescence results both near the assay cutoff of 
two times background or results higher in the Bio-Plex measuring range.  Repeatability (within-
run precision) was determined for select specimens by testing amplicon from a single specimen 
in ten separate wells of a Bio-Plex detection plate.  Results were calculated by subtracting the 
mean of ten background wells from the Bio-Plex FI output for individual sample wells.  The 
mean and standard deviation (SD) of the FI minus background results for ten individual wells 
were calculated for both positive and negative multiplex targets. In addition, the coefficient of 
variation [CV; (SD/mean)x100] was calculated for positive targets.  CV was not calculated for 
negative targets as the resulting percentages are statistically impractical.  Reproducibility 
(between-day precision) was determined for select specimens by amplifying extracted nucleic 
acids from each specimen and detecting in single wells on the Bio-Plex system one time per day 
over five days.  In order to determine variability in the detection step only, amplicon from the 
first day of the study was detected in single wells on the Bio-Plex system one time per day for 
four days.  The FI minus background values of each target in the multiplex were calculated for 
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each specimen by subtracting the FI value of the negative background well at the end of the run 
from the FI value of each sample well.  
Materials and Methods – Bacterial Assay. 
 
Specimens.  Specimens tested in this study were anonymized to fulfill the requirements of the 
University of Virginia IRB for Health Sciences Research exemption (IRB-HSR #14597).  
Testing of the bacterial Bio-Plex assay was performed using 50 stool broth specimens, which 
were primarily MacConkey’s enrichment broths inoculated with a sterile swab dipped into a 
small quantity of stool then placed into the broth (―stool broth specimens‖).  Specimens were 
stored at -80°C prior to testing.  The 50 stool broth specimens included positives for the assay 
targets of stx1 (n = 31), stx2 (n = 21), and uidA (n = 4).  Specimens were previously 
characterized by PCR to be positive for one or multiple assay targets.  Eight stool broth 
specimens evaluated were negative for all targets.  Validation studies were completed using 
specimens place into Cary-Blair medium (n = 16), and included stools positive for E. coli 
O157:H7 (n = 2), E. coli non-O157 (n = 1), E. coli of unknown serotype (n = 3), Shigella spp. (n 
= 4), and Salmonella spp. (n = 5).  Specimens were stored at -80°C prior to testing.  Specimens 
were previously characterized to be positive for one or multiple assay targets by PCR.  One stool 
specimen in Cary-Blair medium included in the study was determined to contain no pathogenic 
enteric bacteria by reference methods. 
Additional bacterial strains.  Additional bacterial isolates used in this study for establishing 
performance characteristics included ETEC strains (serotypes O153:H45, Ound:H16, Ound:NM, 
O6:H16, O148:NM) and EPEC strains (serotypes O119:H6, O55:NM, Ound:NM, O115:NM, 
Orough:H8) graciously provided by Victoria Lappi, Molecular Epidemiology Unit, Public Health 
Laboratory - Clinical Labs, Minnesota Department of Health, St. Paul, MN.  Two EIEC strains 
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(serotypes O124:NM, O29:NM) were obtained from DCLS archives.  Additional EPEC strains 
(serotypes O111:NM, O55:H6, O111:H2, O128:H1, O86:H34) were thoughtfully provided by 
Dr. Nancy Strockbine, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, 
Centers for Disease Control and Prevention, Atlanta, GA. 
Bacterial standards.  Reference strains for establishing analytical sensitivity included ETEC 
(ATCC 35401), E. coli O157:H7 (EDL 9333), and Shigella flexneri (ATCC 12022).  Several 
colonies grown on blood agar plates were inoculated into 0.85% sterile saline to yield a turbidity 
reading of 0.1, approximating a bacterial count of 10
8
 CFU/mL.  Ten-fold serial dilutions were 
performed in 1 mL volumes and 100 μL of the 104-100 dilutions transferred to blood agar plates.  
Dilutions were spiked in 10 μL volumes into 200 mg (µL) of Cary-Blair stool negative for 
enteric bacteria as follows:  ETEC (10
8
-10
3
), O157:H7 (10
8
-10
4
) and S. flexneri (10
6
-10
2
).  
Spiked specimens were then extracted, amplified and detected, as described.  Inoculated blood 
plates were incubated overnight, and colonies counted at approximately 24 hours.  Dilution 
series were tested in triplicate and total numbers of positive and negative qualitative results for 
each dilution were summarized.  The limits of detection were established as a range in which the 
lower limit represented the lowest dilution yielding one positive result and the upper limit 
represented the lowest dilution yielding three positive results. 
Extraction of nucleic acids, isolates and stool broth specimens.  Nucleic acid was extracted 
from isolates or stool broth specimens using a boil preparation method.  For isolates, a 1 µL 
calibrated loop was used to remove bacterial growth from blood agar plates.  The bacteria were 
suspended into 300 µL of nuclease-free water.  The sample was vortexed and heated at 100°C for 
10 minutes.  Following centrifugation at 4,500 rpm for two minutes, the supernatant was 
removed and used for amplification.  For stool broth specimens, 300 µL of specimen was 
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vortexed, heated and centrifuged, as described.  Supernatant was removed and used for 
amplification.   
Extraction of nucleic acids, Cary-Blair specimens.  Nucleic acids were extracted from 200 mg 
of stool diluted in Cary-Blair medium using a QIAamp DNA Stool Mini Kit (QIAGEN, Hilden, 
Germany) per manufacturer’s instructions.   
Primers and probes.  Primers and probes were previously described or designed by collaborators 
at the University of Virginia (Table 3).  Reverse primers were modified at the 5’ end with biotin-
TEG, and probes with amino modifier C12.  Expected amplification product sizes are as follows:  
stx1 (132 bp), stx2 (255 bp), uidA (143 bp), eltA (62 bp), estA (172 bp) and ipaH (64 bp).  
Primers and probes were purchased from Eurofins MWG Operon (Huntsville, AL). 
Coupling of oligonucleotide probes to microspheres.  Oligonucleotide probes were coupled to 
BioPlex microspheres (Bio-Rad Laboratories, Hercules, CA) using a standard coupling protocol 
provided by Luminex Corporation (Austin, TX), with the addition of rotating step at 1400 rpm 
during the first incubation (74).  Coupled microspheres were enumerated using a hemacytometer 
per the Luminex protocol.   
Bacterial assay multiplex PCR.  Amplification of extracted nucleic acids was performed in 50 
μL reaction volumes using the QIAGEN® Multiplex PCR Kit (QIAGEN, Hilden, Germany).  
Each reaction contained 25 μL of 2X Multiplex PCR Master Mix, 5 μL of Q-Solution, and 0.2 
mmol/L of each primer.  Amplification was performed using the 96-well GeneAmp® PCR 
System 9700 (Applied Biosystems, Carlsbad, CA).  Cycling conditions consisted of 15 minutes 
at 95°C followed by 40 cycles of 30 seconds at 94°C, 30 seconds at 58°C and 60 seconds at 
72°C.  A final extension step was performed for 10 minutes at 72°C.  
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Table 3.  Oligonucleotide primers and probes for a microsphere suspension array assay for 
the simultaneous detection of stx1, stx2, uidA, eltA, estA and ipaH.  Modifications at the 5’ 
end are biotin-TEG (reverse primers) and amino modifier C12 (probes). 
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Target Sequence (5’-3’) Ref. 
stx1  
     EH132F 
     EH132Rbtn 
     EH132P3  
 
ACTTCTCGACTGCAAAGACGTATG 
ACAAATTATCCCCTGAGCCACTATC 
CTCTGCAATAGGTACTCCA 
(53) 
 
 
stx2  
     EH255F 
     EH255Rbtn 
     EH255P2  
 
GGCACTGTCTGAAACTGCTCC 
TCGCCAGTTATCTGACATTCTG 
GGGGAGAATATCCTTTAATA 
(90) 
 
 
This study
a
 
uidA  
     uidAF241 
     uidAR383btn 
     uidAP266
a
 
 
CAGTCTGGATCGCGAAAACTG 
ACCAGACGTTGCCCACATAATT 
ATTGAGCAGCGTTGG 
(119) 
eltA (LT)  
     ET62F 
     ET62Rbtn 
     ET62P  
 
TTCCCACCGGATCACCAA 
CAACCTTGTGGTGCATGATGA 
CTTGGAGAGAAGAACCCT 
(53) 
estA (ST) 
     ET172F 
     ET172Rbtn 
     ET172P 
 
TTCACCTTTCGCTCAGGATG 
AGCACCCGGTACAAGCAG 
ATTACTGCTGTGAATTGTG 
This study
a
 
ipaH 
     EI64F 
     EI64Rbtn 
     EI64P 
 
CCTTTTCCGCGTTCCTTGA 
CGGAATCCGGAGGTATTGC 
CGCCTTTCCGATACCGTCTCTGCA 
 
This study
a
 
a
  Designed by Dr. Mami Taniuchi, Division of Infectious Diseases and International Health, 
University of Virginia, Charlottesville, VA (unpublished data) 
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Detection of nucleic acid targets using Bio-Plex microsphere assay..  Hybridization of 
amplification products to coupled microspheres was conducted using a standard hybridization 
protocol by Luminex Corporation, with modifications (73).  Briefly, detection reactions were 
performed in 50 μL volumes in 96-well plates, and consisted of approximately 5000 coupled 
microspheres for each of the six targets (stx1, stx2, uidA, LT, ST, ipaH), 33 μL of 1.5X TMAC 
solution, 12 μL of 1X TE buffer, and 5 μL of amplified DNA.  Reaction plates were incubated at 
95°C for 3 minutes to denature oligonucleotide secondary structure, then underwent 15 minutes 
of shaking incubation at 50°C and 800 rpm.  After addition of 25 µL of 10μg/mL streptavidin-R-
phycoerythrin reporter dye, plates underwent a second shaking incubation at 50°C and 800 rpm 
for 10 minutes.  Detection of hybridized amplification products was performed using the Bio-
Plex® 200 Suspension Array System using a low RP1 target setting.  Specimens were tested in 
single wells, with negative non-template amplification controls placed at the beginning, middle 
and end of each detection run.  The negative well placed at the end was used as the background 
well for result calculation.  Data output of the Bio-Plex 200 is median fluorescent intensity (FI).  
In order to determine positivity or negativity, the FI of the background well was subtracted from 
the FI of the specimen and compared to background.  Results greater than or equal to two times 
the background were considered to be ―screen positive‖.    
Real-time PCR for the detection of stx1 and stx2.  Amplification of stx1 and stx2 targets was 
performed using a multiplex shiga toxin real-time PCR reaction containing the previously 
described primers and probes STEC-1, STEC-2, STEC I-HP-1, STEC I-HP-2, STEC II-HP-1, 
and STEC II-HP-2 (56, 95).  Each reaction was prepared as follows using the LightCycler® 
DNA Master HybProbe kit (Roche Applied Science, Indianapolis, IN), for a total of 19 µL:  2 
mM MgCl2, 2 µL of 10X LightCycler DNA Master HybProbe, 0.5 mmol/L of each primer and 
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0.2 mmol/L of each probe.  Each reaction capillary contained 18 µL of the shiga toxin PCR 
reaction mixture and 2 µL of nucleic acid template.  Amplification and detection was performed 
on the LightCycler® 2.0 Instrument (Roche Diagnostics Corporation, Indianapolis, IN).  Cycling 
conditions consisted of 30 seconds at 95°C followed by 50 cycles of 0 seconds at 95°C, 20 
seconds at 50°C and 30 seconds at 72°C.  Melting conditions consisted of 0 seconds at 95°C, 10 
seconds at 40°C and continuous detection from 40°C to 95°C.  The reactions were cooled at 
40°C for 2 minutes. 
Real-time PCR for the detection of uidA.  Amplification of the uidA target was performed in 
singleplex utilizing the previously described primers and probes O157-PT-2, O157-PT-2, O157-
HP-1, and O157-HP-2 (10, 53).  Each reaction was prepared as follows using the LightCycler® 
DNA Master HybProbe kit, for a total of 19 µL:  2 mM MgCl2, 2 µL of 10X LightCycler DNA 
Master HybProbe, 0.5 mmol/L of each primer and 0.2 mmol/L of each probe.  Each reaction 
capillary contained 18 µL of the shiga toxin reaction mixture and 2 µL of nucleic acid template.  
Amplification and detection was performed on the LightCycler® 2.0 Instrument.  Cycling 
conditions consisted of 30 seconds at 95°C followed by 40 cycles of 0 seconds at 95°C, 10 
seconds at 65°C and 20 seconds at 72°C.  Melting conditions consisted of 0 seconds at 95°C, 10 
seconds at 55°C and continuous detection from 55°C to 95°C.  The reactions were cooled at 
40°C for 2 minutes. 
Real-time PCR for the detection of LT and ST.  Amplification of LT and ST gene targets of 
ETEC was performed utilizing previously described primers and probes (96).  To amplify the LT 
target, each singleplex reaction was prepared as follows using the LightCycler® DNA Master 
HybProbe kit, for a total of 19 µL:  2 mM MgCl2, 2 µL of 10X LightCycler DNA Master 
HybProbe, 0.5 mmol/L of each primer and 0.2 mmol/L of each probe.  Each reaction capillary 
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contained 18 µL of the LT reaction mix and 2 µL of nucleic acid template.  To amplify ST 
targets, each multiplex reaction was prepared as follows using the LightCycler® DNA Master 
HybProbe kit, for a total of 19 µL:  2 mM MgCl2, 2 µL of 10X LightCycler DNA Master 
HybProbe, 0.5 mmol/L of each primer and 0.2 mmol/L of each probe.  Each reaction capillary 
contained 18 µL of the LT reaction mix and 2 µL of nucleic acid template.  Amplification and 
detection was performed on the LightCycler® 2.0 Instrument.  Cycling conditions consisted of 
30 seconds at 95°C followed by 50 cycles of 0 seconds at 95°C, 20 seconds at 50°C, and 30 
seconds at 72°C.  Melting conditions consisted of one cycle of 0 seconds at 95°C, 10 seconds at 
40°C, and continuous detection from 40°C to 95°C.  The reactions were cooled at 40°C for 2 
minutes. 
Precision studies.   Precision characteristics of the Bio-Plex 200 were determined by testing 
template DNA extracted and amplified from a panel of four specimens that included Cary-Blair 
clinical specimens positive for O157:H7 (stx1, stx2, uidA) and S. flexneri (ipaH).  A Cary-Blair 
stool specimen spiked with ETEC (ATCC 35401) was also included (eltA, estA).  The fourth 
panel specimen was a Cary-Blair specimen characterized to be negative for pathogenic enteric 
bacteria. The specimens chosen for this panel represented fluorescence results both near the 
assay cutoff of two times background (stx2, uidA, estA) and higher in the Bio-Plex measuring 
range (stx1, eltA, ipaH).  Amplicon for determining repeatability (within-run precision) was 
obtained by amplifying two 50 µL reactions per specimen and combining the products.  Ten 
separate wells of amplicon from each specimen were then tested on a single Bio-Plex detection 
plate.   Results were calculated by subtracting the mean of ten background wells from the Bio-
Plex FI output of individual sample wells.  Mean and standard deviation (SD) of the FI-
background results for ten individual wells were calculated for both positive and negative 
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multiplex targets. In addition, the coefficient of variation [CV, (SD/mean)x100] was calculated 
for positive targets; CV was not calculated for negative targets as the resulting percentages are 
statistically impractical.  Reproducibility (between-day precision) was determined for select 
specimens by amplifying extracted nucleic acid template from each specimen in single reactions 
and detecting in single wells on the Bio-Plex system one time per day over five days.  In order to 
determine variability of the detection step only, amplicon from the first day of the study was 
detected in single wells on the Bio-Plex system one time per day for four days.  The FI-
background values of each target in the multiplex were calculated for each specimen by 
subtracting the FI value of the negative background well at the end of the run from the FI value 
of each sample well. 
Materials and Methods – Viral Assay. 
 
Specimens.  Specimens were anonymized to fulfill the requirements of the University of Virginia 
IRB for Health Sciences Research exemption (IRB-HSR #14597).  Comparison of extraction 
methods was performed using unpreserved and Cary-Blair stool specimens.  Unpreserved 
norovirus specimens were stored at 4°C and unpreserved rotavirus specimens were stored at -
80°C prior to testing.  Cary-Blair specimens were stored at room temperature prior to testing. 
Automated extraction of nucleic acids.  Nucleic acid was extracted from unpreserved stool 
specimens and stool specimens diluted in Cary-Blair transport medium (300 mg) using the 
Ambion® MagMAX™-96 Viral RNA Isolation Kit (Ambion, Inc., Austin, TX) automated on 
the KingFisher® Magnetic Particle Processor (Thermo Fisher Scientific, Inc., Vantaa, Finland).  
Extractions were performed according to manufacturers’ instructions.  
Manual extraction of nucleic acids.  Nucleic acids were manually extracted from unpreserved 
stool specimens and stool specimens diluted in Cary-Blair transport medium (200 mg) using the 
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QIAamp DNA Stool Mini Kit (QIAGEN, Hilden, Germany) per manufacturer’s instructions.   
Real-time RT-PCR for the detection of norovirus GI and GII.  Amplification of norovirus GI 
and GII targets was performed using two singleplex reactions containing previously described 
primers and probes (60).  Each NoV GI reaction was prepared as follows using the LightCycler® 
RNA Amplification Kit HybProbe kit (Roche Applied Science, Indianapolis, IN), for a total of 
19.8 µL:  3.0 mM MgCl2, 4.0 µL of LightCycler
®
 RT-PCR Reaction Mix HybProbe, 0.4 µL of 
LightCycler
®
 RT-PCR Enzyme Mix, 0.4 mmol/L of each NoV GI primer and 0.2 mmol/L of 
each NoV GI probe.  NoV GII reactions were prepared as follows, for a total of 19.0 µL per 
reaction:  2.0 mM MgCl2, 4.0 µL of LightCycler
®
 RT-PCR Reaction Mix HybProbe, 0.4 µL of 
LightCycler
®
 RT-PCR Enzyme Mix, 0.4 mmol/L of each NoV GII primer and 0.4 mmol/L of 
NoV GII probe.  Reaction capillaries for both GI and GII contained 19 µL of the respective 
reaction mixture and 1 µL of nucleic acid template.  Amplification and detection was performed 
on the LightCycler® 2.0 Instrument (Roche Diagnostics Corporation, Indianapolis, IN).  Cycling 
conditions began with a 30-minute reverse transcription step at 55°C followed by initial 
denaturation for 30 seconds at 95°C and 45 cycles of 0 seconds at 95°C, 60 seconds at 58°C and 
13 seconds at 72°C.  The reactions were cooled at 40°C for 30 seconds. 
Real-time RT-PCR for the detection of rotavirus.  Amplification of the rotavirus genome target 
was performed in singleplex utilizing previously described primers and probe (59).  Each 
reaction was prepared as follows using the QuantiTect Probe RT-PCR Kit (QIAGEN, Hilden 
Germany) for a total of 24 µL: 12.5 µL of 2x QuantiTect Probe RT-PCR Master Mix, 0.25 µL of 
QuantiTect RT Mix, 0.25 mmol/L of each primer and 0.1 mmol/L of the probe.  Sample wells 
contained 24 µL of reaction mix and 1 µL of RNA template.  Prior to addition to the sample 
well, RNA template was pre-heated to 95°C for 5 minutes, followed by 5 minutes of cooling on 
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wet ice.  Amplification and detection was performed on the ABI 7500 FAST Real-Time PCR 
System (Applied Biosystems, Foster City, CA).  Cycling conditions began with a 30-minute 
reverse transcription step at 50°C followed by initial denaturation for 15 minutes at 95°C and 45 
cycles of 10 seconds at 94°C, 30 seconds at 55°C and 20 seconds at 72°C.   
Statistical Methods.  Shapiro-Wilk test for normal distribution and Spearman’s rho test for 
correlation were both performed using PASW 18.0 (SPSS Inc., Chicago, IL).  Fisher r-to-z 
transformation to determine correlation coefficient confidence intervals was performed using a 
VassarStats web-based calculator (72).   
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CHAPTER 4 EVALUATION OF A PCR-BASED PROTOZOAN BIO-PLEX ASSAY 
 
 
 
Overview of Enteric Protozoa and Assay MolecularTargets.  Primers and probes targeting 
select protozoan pathogens were developed for utilization with the Bio-Plex system by 
collaborators at the University of Virginia.  Targeting four enteric protozoa of public health 
concern in the U.S., the primers and microsphere-coupled probes were combined into one 
multiplex assay for this project, enabling detection of Giardia intestinalis, Cryptosporidium 
parvum, Cyclospora cayetanensis and Entamoeba histolytica. 
Giardia intestinalis.  G. intestinalis (previously called G. lamblia or G. duodenales) is a 
flagellate organism and is the most prevalent protozoan in the U.S. (91).  Its pathogenesis is 
attributed to the damage it inflicts on the intestinal mucosa and the resulting immune response 
(55).  Clinical presentation may be asymptomatic, acute and self-limiting after 7-10 days, or 
chronic (>14 days) (55).  Chronic diarrhea due to Giardia presents with the distinguishing 
symptoms of greasy and foul smelling stools that may alternate with constipation or normal 
stools.  Chronic disease presentation may also result in malabsorption and/or lactase deficiency 
(55). 
 The genetic target of the primers and probe in this assay is a 62 base-pair region of the 
small subunit ribosomal RNA gene (SSU rRNA) (113).  This region is attractive as a molecular 
target for two reasons.  First, rRNA sequences are typically conserved, accompanied by regions 
of variability that provide pathogen specificity for molecular assays (102).  Second, the rRNA 
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genes are organized as a cistron that has been reported to be present in repeats numbering from 
60 – 132 copies per organism, increasing the potential for detection and overall assay sensitivity 
(46, 102).  The primers and probe were originally designed to be used in a singleplex real-time 
PCR assay and subsequently were adapted for use in the current BioPlex assay (107, 113).  
Cryptosporidium spp.  Cryptosporidium spp. are intracellular parasites of the phylum 
Apicomplexa, the sporozoites of which infect intestinal epithelial cells (23).  General symptoms 
of Cryptosporidium infection include non-bloody, watery diarrhea which may be accompanied 
by cramping, nausea and vomiting, which is a result of abnormal absorption and altered secretion 
by intestinal epithelial cells (23, 91).  As is the case for Giardia, clinical presentation of 
Cryptosporidium in immunocompetent patients may be asymptomatic, acute, or persistent.  In 
general, symptoms last approximately two weeks (23).   
 The primers and probe for this assay were previously described for a real-time PCR 
platform and were designed to amplify and detect a 138 base-pair region that falls within a 450 
base-pair sequence described by Laxer et al. (44, 67).  No specific gene has been attributed to 
this region, and the cited Genbank accession identifies the sequence as ―Cryptosporidium 
parvum genomic sequence‖.  This region appears to have been chosen for organism specificity 
and not due to an associated virulence determinant target (44),(67).  
Cyclospora cayetanensis.   C. cayetanensis is a relatively recently-identified intracellular 
pathogen, also of the phylum Apicomplexa and is currently known to infect only humans (86, 87, 
91).  The pathogen infects the intestinal epithelium of the small intestine, causing inflammation 
and villous atrophy.  Typical symptoms of infection include diarrhea, nausea, flatulence, low-
grade fever, fatigue and weight loss, and may last from a few days to over a month (18, 86).  
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 The genetic target of this primer and probe set is the SSU rRNA gene region.   As is 
typical of rRNA, this region is present in multiple copies, with the total number of copies 
dependent on the sporulation state of the extracted organisms.  Assuming the Cyclospora 
population in stool represents all life cycle stages (sexual and asexual), it is estimated that the 
copy number is 2-20 per organism (112).  The expected amplicon size is 280 base pairs.  The 
primers were previously described for a conventional multiplex PCR assay for the differentiation 
of Cyclospora spp. and Eimeria spp. (85).  The probe was designed by Dr. Mami Taniuchi of the 
University of Virginia (M. Taniuchi, unpublished data). 
Entamoeba histolytica.  E. histolytica is characterized by an amoeboid trophozoite stage and an 
infectious cyst stage (104).  Infection may present as asymptomatic or amoebic colitis, and in 
some cases progress to amoebic liver abscess.  Infection in the human host takes place at the 
colonic epithelium, and is characterized by mucosal thickening and ulceration due to cytolytic 
activity.  The organism can also invade the mucosa, eventually traveling to the liver, causing 
amoebic liver abscesses (104).  Typical colitis cases present with bloody diarrhea and abdominal 
pain for several weeks, although symptoms may vary in severity between patients (104).   
 The primers and probe used to detect this pathogen target a 134 base-pair region of the 
SSU rRNA gene.  These were originally designed for use in a singleplex real-time molecular 
beacon PCR assay for the detection of E. histolytica, and were adapted directly to the Bio-Plex 
system (98, 107).  The rRNA genes have been shown to reside on an extrachromosomal circular 
episome, with an estimated 200 gene copies per organism (6). 
Results. 
Validation of LV-PVA and unpreserved specimens - precision studies.  Repeatability (within-
run precision) was determined for a panel of select specimens by testing amplicons from a single 
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specimen in ten separate wells of a Bio-Plex detection plate, as described in Materials and 
Methods.  To assess repeatability, precision for positive-target specimens was expressed as the 
CV, which ranged from 5.89% to 30.36% for the five specimens tested in the study (Table 4).  
Each specimen in the panel also yielded negative results for three additional assay targets.  
Within-run precision for negative targets was expressed as SD, and ranged from 3.35 – 15.53 
(Table 5).   
 Reproducibility (between-day) precision of the amplification and detection steps 
combined was determined by amplifying and detecting extracted nucleic acid from select 
specimens each day for five days, as described in Materials and Methods.  Precision was 
calculated in the same manner as repeatability, with positive-target specimens yielding a CV 
range of 12.50% to 59.54% (Table 6), and SD values for negative assay targets ranging from 
1.72 to 11.51 (Table 7).  Precision for the detection step alone was determined by amplifying 
extracted nucleic acid from each specimen once and detecting each day for four days, as 
described in Materials and Methods.  Evaluation of precision for the detection step alone resulted 
in a CV value range of 6.20% to 28.71% (Table 8) for positive-target specimens, while negative 
targets exhibited an SD value range of 3.09-8.96 (Table 9).   
Validation of LV-PVA and unpreserved specimens - analytical sensitivity (limits of detection).  
The analytical sensitivity or limits of detection of the described multiplex assay was evaluated 
using cultivated G. intestinalis cysts and C. parvum oocysts.  Because quantifiable C. 
cayetanensis and E. histolytica organisms were not available, cloned nucleic acid standards were 
evaluated as a measure of analytical sensitivity for these targets.  Table 10 summarizes the limit 
of detection ranges established for each assay target in both unpreserved and LV-PVA specimen 
types.  Analytical sensitivity of the assays ranged from 10
1
 – 102 cysts/200 mg stool for   
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Table 4.  Bio-Plex 200 detection repeatability results for positive targets in LV-PVA and 
unpreserved stool specimens.  Specimen type and positive assay target is indicated for each 
specimen.  Extracted nucleic acid from each specimen was amplified and then detected in ten 
replicate wells, as described in Materials and Methods.  Mean, SD and CV were calculated using 
result values for each well obtained by subtracting the mean fluorescence of ten background 
wells from the Bio-Plex FI output of individual sample wells. 
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Specimen/ 
Target Organism 
Mean  
(FI) 
(n = 10 wells) 
SD 
(FI) 
CV
a
 
(%) 
LV-PVA 
G. intestinalis 
46.30 14.06 30.36 
Unpreserved 
C. cayetanensis 
81.15 9.85 12.14 
Unpreserved 
G. intestinalis 
181.65 12.09 6.66 
Unpreserved 
C. hominis 
2619.90 154.39 5.89 
LV-PVA 
E. histolytica 
147.55 13.79 9.34 
a
 CV:  coefficient of variation; (SD / mean) x 100   
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Table 5.  Bio-Plex 200 detection repeatability results for negative targets in LV-PVA and 
unpreserved stool specimens.  Specimen type and positive assay target is indicated for each 
specimen used in the study.  Mean and SD were calculated using result values for each well 
obtained by subtracting the average of ten background wells from the Bio-Plex FI value.  Ranges 
provided for mean and SD reflect the range of statistics calculated for all specimens of the 
indicated type (LV-PVA or unpreserved) that were negative for the target listed to the left of the 
table.  The total number of specimens in the panel that were negative for the select target is 
indicated. 
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Specimen/Target Organism Total specimens 
negative for target 
Mean (FI) 
(n = 10 
wells/specimen) 
SD 
(FI) 
LV-PVA 
G. intestinalis  
C. cayetanensis  
C. parvum/hominis  
E. histolytica  
 
1 
2 
2 
1 
 
-3.25 
-2.75 - -2.70 
-5.70 – 6.10 
-5.90 
 
5.61 
4.05 - 4.84 
3.71 – 4.58 
3.35 
Unpreserved 
G. intestinalis 
C. cayetanensis 
C. parvum/hominis 
E. histolytica 
 
2 
2 
2 
2 
 
-2.10 – 4.80 
-2.05 – 16.30 
-1.70 – 9.95 
-3.95 – 15.30 
 
4.18 – 6.42 
5.38 – 15.53 
3.61 – 7.70 
5.94 – 14.77 
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Table 6.  Amplification and Bio-Plex 200 detection reproducibility results for positive 
targets in LV-PVA and unpreserved stool specimens.  Specimen type and positive assay 
target is indicated for each specimen used in the study.   Extracted nucleic acid from each 
specimen was amplified and detected each day for five days, as described in Materials and 
Methods.  Mean, SD and CV were calculated by using results representing the specimen FI 
minus the background well FI for each positive target.  
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Specimen/ 
Target Organism 
Mean (FI) 
(n = 5) 
SD 
(FI) 
CV
a
 
(%) 
LV-PVA 
G. intestinalis  
87.50 32.76 37.44 
Unpreserved 
C. cayetanensis 
99.00 58.94 59.54 
Unpreserved 
G. intestinalis 
245.60 30.71 12.50 
Unpreserved 
C. hominis 
2050.90 258.13 12.59 
LV-PVA 
E. histolytica 
255.80 50.00 19.55 
a
 CV:  coefficient of variation; (SD / mean) x 100   
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Table 7.  Amplification and Bio-Plex 200 detection reproducibility results for negative 
targets in LV-PVA and unpreserved stool specimens.  Specimen type and positive assay 
target is indicated for each specimen used in the study.  Nucleic acid extracted from each 
specimen was amplified and detected each day for five days, as described in Materials and 
Methods.  Mean and SD were calculated using result values for each well obtained by 
subtracting the mean of one background well from the Bio-Plex FI output of individual sample 
wells.   Ranges for mean and SD reflect the range of statistics calculated for all specimens of the 
indicated specimen type (LV-PVA or unpreserved) that were negative for the target listed to the 
left of the table.  The total number of specimens in the panel that were negative for the select 
target is indicated. 
  
 76 
 
Specimen/Target Organism Total specimens 
negative for target 
Mean (FI) 
(n = 5/specimen) 
SD 
(FI) 
LV-PVA 
G. intestinalis  
C. cayetanensis  
C. parvum/hominis  
E. histolytica  
 
1 
2 
2 
1 
 
13.90 
6.10 – 7.10 
-1.30 – 1.40 
-1.70 
 
8.00 
6.11 – 7.50 
9.51 – 11.51 
6.82 
Unpreserved 
G. intestinalis 
C. cayetanensis 
C. parvum/hominis 
E. histolytica 
 
2 
2 
2 
2 
 
-4.90 – 0.80 
0.20 – 6.80 
-4.10 – -1.40 
-6.20 – 4.00 
 
1.72 – 7.21 
5.89 – 10.04 
8.15 – 10.57 
2.58 – 6.28 
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Table 8.  Bio-Plex 200 detection reproducibility results for positive targets in LV-PVA and 
unpreserved stool specimens.  Specimen type and positive assay target is indicated for each 
specimen used in the study.  Extracted nucleic acid from each specimen was amplified once and 
detected each day for four days, as described in Materials and Methods.  Mean, SD and CV were 
calculated using result values for each replicate well obtained by subtracting the fluorescence of 
one background well from the Bio-Plex FI output of individual sample wells.   
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Specimen/ 
Target Organism 
Mean (FI) 
(n = 4) 
SD 
(FI) 
CV
a
 
(%) 
LV-PVA 
G. intestinalis  
64.00 18.38 28.71 
Unpreserved 
C. cayetanensis 
62.00 6.75 10.88 
Unpreserved 
G. intestinalis 
257.25 19.26 7.49 
Unpreserved 
C. hominis 
2358.88 148.98 6.32 
LV-PVA 
E. histolytica 
211.50 13.12 6.20 
a
 CV:  coefficient of variation; (SD / mean) x 100   
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Table 9.  Bio-Plex 200 detection reproducibility results for negative targets in LV-PVA and 
unpreserved stool specimens.  Specimen type and assay target is indicated.  Nucleic acid 
extracted from each specimen was amplified once and detected each day for four days, as 
described in Materials and Methods.  Mean and SD were calculated using result representing the 
specimen FI for minus the background well FI for each positive target.  Ranges values for each 
well obtained by subtracting the fluorescent of one background well from the Bio-Plex FI output 
of individual sample well.  Mean and SD ranges reflect the range of statistics calculated for all 
specimens of the indicated type (LV-PVA or unpreserved) that were negative for the target listed 
to the left of the table.  The total number of specimens in the panel that were negative for the 
select target is stated. 
. 
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Specimen/Target Organism Total specimens 
negative for target 
Mean (FI) 
(n = 4/specimen) 
SD 
(FI) 
LV-PVA 
G. intestinalis  
C. cayetanensis  
C. parvum/hominis  
E. histolytica  
 
1 
2 
2 
1 
 
15.38 
5.75 – 7.50 
-1.88 – 3.25 
3.38 
 
6.74 
6.33 - 7.99 
5.66 – 6.99 
3.09 
Unpreserved 
G. intestinalis 
C. cayetanensis 
C. parvum/hominis 
E. histolytica 
 
2 
2 
2 
2 
 
1.13 – 4.50 
-0.75 – -1.75 
-3.13 – 3.63 
-3.38 – 1.13 
 
8.04 – 8.96 
7.64 – 7.66 
4.53 – 4.77 
4.84 – 5.99 
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G. intestinalis in unpreserved stools to the maximum estimated range of 3.5x10
2
-3.5x10
4 
oocysts/200 mg stool for C. cayetanensis clone in LV-PVA stools.   
Validation of LV-PVA and unpreserved specimens - analytical specificity (cross-reactivity).  
Many of the LV-PVA specimens tested in this study contained organisms not targeted by the 
Bio-Plex protozoan assay, including Blastocystis hominis, Entamoeba coli, Entamoeba 
hartmanni, Dientamoeba fragilis, Chilomastix mesnili and/or Endolimax nana.  No cross-
reactivity was observed between these organisms and any of primer and probe sets in the 
multiplex assay (data not shown).  In addition, the specimens positive for G. intestinalis, 
Cryptopsoridium spp., C. cayetanensis, and E. histolytica tested in the study exhibited no cross-
reactivity to non-complementary primers and probes in the multiplex assay.   
Validation of LV-PVA and unpreserved specimens - comparison-of-methods.    Seventy (70) 
specimens were tested using the multiplex microsphere assay and results compared to those 
obtained with the reference methods of either microscopy or PCR.  Positive specimens, as 
characterized by reference methods, included: G. intestinalis (n=13), E. histolytica/dispar (n=4), 
G. intestinalis and E. histolytica/dispar (n=3), C. cayetanensis (n=6), C. parvum (n=2), and C. 
hominis (n=1).  The calculated sensitivity and specificity for each target and corresponding 
confidence intervals are shown in Table 11.   The sensitivity for G. intestinalis, C. cayetanensis, 
C. parvum/hominis, and E. histolytica was 81.25%, 83.33%, 100.00% and 42.86%, respectively.  
Specificity of all targets was at or near 100%.   
Discussion.  In this study, a multiplex PCR-based Bio-Plex assay targeting intestinal protozoan 
pathogens was evaluated for precision (repeatability and reproducibility), analytical sensitivity 
(limits of detection), analytical specificity (cross-reactivity), and performance as compared to 
reference methods.  Results were evaluated for acceptability as a screening method to provide   
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Table 10.  Analytical sensitivity (limits of detection) of the Bio-Plex 200 intestinal protozoan 
assay.    Quantified cysts, oocysts, or cloned amplicon were diluted and spiked into 200 mg 
stool, as described.  Spiked stools were extracted, template amplified, and detected as described.  
Dilutions were performed in triplicate.  Positivity was determined as described for detection of 
targets in Materials and Methods.  The limit of detection range represents the concentration of 
organism or cloned amplicon in the lowest dilutions yielding a minimum of 1 positive result.  
Analytical sensitivity was determined for each assay target using both unpreserved and LV-PVA 
specimens. 
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Organism 
Limit of Detection  
Unpreserved LV-PVA 
G. intestinalis  10
1
 – 102  
(cysts/200 mg stool) 
 
10
2
 – 104 
(cysts/200 mg stool) 
C. parvum 10
2
 - 10
4 
(cysts/200 mg stool) 
 
10
3
 - 10
4 
(cysts/200 mg stool) 
C. cayetanensis  
7x10
2
-7x10
3 
 (genome copies/200 mg stool) 
 
3.5x10
1
-3.5x10
3 
(oocysts/200 mg stool, estimated) 
 
 
7x10
3
-7x10
4
  
(genome copies/200 mg stool) 
 
3.5x10
2
-3.5x10
4 
(oocysts/200 mg stool, estimated.) 
E. histolytica  
4x10
3
  
(genome copies/200 mg stool) 
 
2x10
2 
(organisms/200 mg stool, 
estimated) 
 
4x10
2
-4x10
3 
(genome copies/200 mg stool) 
 
2x10
1
-2x10
2
   
(organisms/200 mg stool, 
estimated) 
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Table 11. Comparison of multiplex microsphere assay results to reference method results, 
by assay target.  Qualitative results of multiplex PCR testing using the Bio-Plex platform to 
detect protozoan pathogens in LV-PVA and unpreserved stool specimens were compared to 
those obtained with the reference methods of microscopy and/or PCR.  Sensitivity was calculated 
using the formula: [TP/(TP+FN)]x100.  Specificity was calculated using the formula:  
TP/(TP+FN)]x100.  Confidence intervals were calculated using Wilson’s score confidence 
interval method (28).  
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 TP 
(n) 
FN 
(n) 
Se 
(%) 
CISe, 95 TN 
(n) 
FP 
(n) 
Sp 
(%) 
CISp, 95 
G. intestinalis 13 3 81.25 L: 56.99 
U: 93.41 
54 0 100.00 L: 93.36 
U: 100.00 
C. cayetanensis  5 1 83.33 L: 43.5  
U: 97.00 
64 0 100.00 L: 94.34 
U: 100.00 
C. parvum/hominis 3 0 100.00 L: 43.85 
U: 100.00  
67 0 100.00 L: 94.58   
U: 100.00 
E. histolytica 3 4 42.86 L: 15.82 
U: 74.96 
62 1 98.00 L: 91.54 
U: 99.72 
Abbreviations:  
TP,  True positive; Bio-Plex 200 positive for an organism identified as positive by reference 
method;  
TN, True negative; Bio-Plex 200 negative for an organism identified as negative by reference 
method;  
FP, False positive; Bio-Plex 200 positive for an organism identified as negative by reference 
method;  
FN, False negative; Bio-Plex 200 negative for an organism identified as positive by reference 
method;  
Se, sensitivity; Sp, specificity; CI. confidence interval; L, lower limit; U, upper limit  
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preliminary outbreak etiologic agent information to epidemiologists and to focus confirmatory 
testing decisions in the laboratory.   
 Precision of the protozoan assay was evaluated by testing a panel of specimens 
representing stool specimens typically received by public health laboratories in the course of an 
outbreak investigation.  As previously discussed in Chapter 2, the literature contains limited data 
with respect to the precision of Bio-Plex 200 nucleic acid assays and there are no standards 
established to specifically determine the acceptability of precision data for molecular assays (8).  
Therefore, the repeatability and reproducibility data generated by this study were compared to 
data available in the commercial and scientific literature.  In order to assess the precision of 
organism-positive targets, the CV values calculated in both the repeatability and reproducibility 
studies were compared to CV values published for the only FDA-cleared infectious disease 
microsphere multiplex assay on the market, the xTAG® RVP (Respiratory Virus Panel).  
Coefficient of variation values for the RVP assay were established in a reproducibility study to 
range from 2.40% to 87.20% (75).  This wide range in precision represented testing conducted at 
multiple laboratories for a variety of targets using single-infection specimens containing a range 
of virus concentrations (75).  As shown in Table 4, the CV value range of 5.89% to 30.36% 
achieved with the protozoan assay in the repeatability study for all positive-target specimens 
were comparable to the precision ranges reported for the RVP assay.  Similarly, as shown in 
Tables 6 and 8, the reproducibility study CV values ranging from 12.50% to 59.54% for the 
amplification and detection steps combined, and 6.20% to 28.71% for the detection step alone, 
were comparable to those published for the RVP assay.  Of note is the marked reduction in the 
detection step CV values (Table 8) as compared to the CV values for the combined amplification 
and detection steps (Table 6), suggesting that the amplification step is an important source of 
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variability in this assay.  Although the RVP assay and intestinal protozoan assay precision 
studies differed in several respects, this comparison suggests that multiplex microsphere-based 
nucleic acid assays may exhibit a wide range of variability, particularly at the low end of the FI 
measuring range for positive specimens, and facilitates the conclusion that the Bio-Plex 
protozoan assay exhibits comparable repeatability and reproducibility for pathogen-positive LV-
PVA and unpreserved specimens. 
As discussed in Chapter 2, variation of fluorescent intensity values less than 50 are 
difficult to assess (J. Eveleigh, personal communication).  Therefore, standard deviation (SD) 
was used to assess the variation for target-negative specimens.  The SD was compared to similar 
calculated values described in the literature for a microsphere-based Plasmodium spp assay (77).  
For both Plasmodium-negative specimens and negative targets of the malaria assay, SD values 
ranged from 18.1 to 39.0 based on mean FI values of 81.3 to 121.2 (77).  These values were 
calculated using FI values detected on the Bio-Plex with a high RP1 target setting, which 
typically results in higher FI values as compared to using the low RP1 target setting.  Because 
the protozoan PCR assay is detected on the Bio-Plex using a low RP1 target setting, the mean FI 
and SD values for negative specimens in the study described here are lower than those described 
for the Plasmodium assay.  However, a relative comparison of the two assays remains 
informative.  As shown in Table 5, the SD range of 3.35-15.53 FI obtained for negative targets in 
the repeatability study similarly represent the range of variability described for the multiplex 
microsphere-based assay described by McNamara et al. (77).  In addition, the SD value ranges of 
2.58 – 11.51 FI and 3.09 – 8.96 FI achieved in the reproducibility study of negative targets for 
both the amplification/detection and detection-only steps, respectively, are comparable to 
published data (Tables 7 and 9).  This comparison therefore allows us to conclude that the Bio-
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Plex protozoan assay exhibits comparable precision for pathogen-negative LV-PVA and 
unpreserved specimens.  
 Analytical sensitivity data for microscopic techniques used for the detection and 
identification of intestinal protozoa is not readily available in the published literature; therefore, 
comparisons to limits of detection established in this study were not possible.  However, it is 
acknowledged that molecular amplification techniques for the detection of protozoa are typically 
more sensitive than microscopy (43, 70, 99, 105).  Comparing limits of detection for each primer 
and probe set with published data is informative in understanding how well established primers 
and probes can be adapted to the Bio-Plex platform.  Therefore, the analytical sensitivity (limits 
of detection) of the Bio-Plex assay primers and probes when used to detect pathogens in 
unpreserved stools were compared to the published data available for the original testing 
platforms from which most of the Bio-Plex primers and probes were adapted.  
 Analytical sensitivity of the Giardia primers and probe are previously described for a 
multiplex real-time PCR format and were estimated to be 10 trophozoites/200 mg stool (50).  In 
addition, Taniuchi et al. (107) recently published a limit of detection of 10
3
 Giardia cysts/200 
mg stool for the Bio-Plex platform.  Interestingly, Taniuchi et al. observed a greater limit of 
detection of 10
3
 cysts/200 mg stool when the primers and probe were evaluated using real-time 
PCR, as described by Haque et al. (107).  Therefore, the analytical sensitivity of the Giardia 
primers and probe achieved in this study for unpreserved stool specimens was comparable to that 
described for the real-time multiplex assay and more sensitive than described for the BioPlex by 
Taniuchi et al. (Table 10) (50, 107).  Differences in Bio-Plex platform analytical sensitivity in 
this study as compared to Taniuichi et al. may be due to the use of different extraction and/or 
amplification methods.  In contrast, the C. parvum target was not as sensitive as that described 
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by Fontain et al. (44), yielding detection limits 10-fold to 1000-fold higher than the 5 
oocysts/PCR reaction described for a singleplex real-time PCR assay (Table 10).  Sensitivity of 
the Bio-Plex assay could be reduced due to the fact that the assay is a multiplex detection assay 
or due to differences in method biochemistries.  The C. cayetanensis target limit of detection of 
3.5x10
1
-3.5x10
3 
oocysts/200 mg stool from this study was comparable only at the lower limit to 
the sensitivity of 10 oocysts described by Orlandi et al. when the primers were used for multiplex 
conventional PCR testing (85).  
 Finally, the E. histolytica target exhibited an estimated limit of detection 10 to 100-fold 
higher than the limit of 1 trophozoite/200 mg stool previously described for a multiplex real-time 
PCR assay (50).  These primers and probe were also tested on the Bio-Plex platform and in a 
real-time PCR assay developed by project collaborators, and determined to have a limit of 
detection of 10 trophozoites/200 mg stool in both cases (107).  The comparison of assays in this 
case is not a direct one, as cloned DNA was used to establish the limits of detection of the 
primers and probe utilized in this study and trophozoites were used in the other two studies (50, 
107).  Differences in Bio-Plex platform sensitivity may be due to the use of different extraction 
and/or amplification methods as well as the approach used to establish limit of detection. The 
limits of detection established using cloned DNA is an estimate, as mathematical formulas are 
used to calculate both the genome copy values and the organism equivalents.  It is also important 
to note that the limit of detection range for the E. histolytica target is a better estimate of 
trophozoite concentration in stool than that of cyst concentration.  This is due to the fact that the 
conversion factor used to estimate the number of genome copies (Materials and Methods) 
present in the cloned standards was originally established for trophozoites, and it has been 
postulated that copy numbers in cysts may be lower (82).   
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 Comparative data describing limits of detection for the protozoan assay targets in LV-
PVA specimens is not readily available.  When compared to the limits of detection obtained in 
this study for unpreserved specimens, the limits of detection for the G. intestinalis, C. 
parvum/hominis, and C. cayetanensis targets in PVA specimens were approximately 1-2 logs 
higher.  These increased limits of detection are possibly due to the addition of washing steps 
prior to extraction of Giardia and Cryptosporidium or due to variation in pipetting clone 
dilutions of Cyclospora.  Interestingly, the analytical sensitivity range of the E. histolytica target 
in LV-PVA was lower than that achieved for unpreserved specimens.  Again, a plausible source 
of this discrepancy is pipetting variation when spiking the cloned plasmid.  The difference in 
matrix consistency of the unpreserved and LV-PVA specimens may be considered an alternate 
source of variation, but is unlikely as the same clone plasmid was used for Cyclospora and a 
similar difference in limit of detection ranges was not observed. 
 Another practical analysis compares the limits of detection to excreted concentrations of 
organism available in the literature in order to determine if the assay is sensitive enough to detect 
organism in clinical specimens.  While excretion patterns of protozoa are highly variable, the 
data are useful in estimating actual performance of the assay on clinical specimens collected as 
part of an outbreak investigation.  For example, a study of asymptomatic pediatric patients 
infected with Giardia reported a variety of cyst excretion patterns, with titers ranging from 10-
2000 cysts per milligram of unpreserved stool (34).  Converting these titers to 2x10
3
 to 4x10
5
 
cysts/200 mg stool enables comparison with the Bio-Plex G. intestinalis limits of detection for 
both unpreserved and LV-PVA specimens.  Comparing the approximate G. intestinalis target 
sensitivity range of 10
1
 to 10
4 
cysts/200 mg stool established in this study for both specimen 
types suggests that the assay is sensitive enough to detect pathogen in clinical specimens if the 
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patient is excreting at the time of collection (Table 10).  A study in which three methods were 
used to recover oocysts from unpreserved patient specimens was evaluated and provides a 
similar means of comparison for the Cyclospora target (66).  Recovery from suspensions 
representing 5 mg of stool ranged from one to 7720 oocysts, which can be converted to the 
average estimate of 4.0x10
1
 to 3.1x10
5
 oocysts/200 mg stool.  Comparison of the Bio-Plex 
Cyclsopora limits of detection (Table 10) suggests that this multiplex assay is also capable of 
detecting physiological concentrations of organism in both unpreserved and LV-PVA stools.  
Similar comparisons cannot be conducted for the Bio-Plex protozoan assay C. parvum and E. 
histolytica targets, as no excretion data is available for either organism.   
 Specificity of the intestinal protozoa assay primers and probe was evaluated by challenge 
with non-targeted intestinal parasites in LV-PVA .  The assay was challenged with the following 
organisms:  Blastocystis hominis, Entamoeba coli, Entamoeba hartmanni, Endolimax nana, 
Dientamoeba fragilis, and Chilomastix mesnili.  No cross-reactivity was observed with these 
organisms, as exhibited by the lack of positive results for any assay targets.  In addition, the 
primers and probes were evaluated for cross-reactivity with other assay targets and similarly no 
non-specific amplification was observed.  Previously-published studies have also demonstrated 
that the primer and probe sequences do not cross-react with a variety of non-target sequences in 
other pathogens (44, 113).  However, unexpected cross-reactivity of the E. histolytica primers 
and probe to E. dispar was identified in one LV-PVA specimen (data not shown).  Additional 
testing using an alternate conventional PCR assay that discriminates between E. histolytica and 
E. dispar confirmed cross-reactivity to E. dispar.  Sequencing of the amplification product 
identified five mismatched base pairs when compared to the E. histolytica probe sequence.  The 
sequence analysis utilizing the nucleotide Basic Alignment Search Tool (BLAST; National 
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Center for Biotechnology Information, Bethesda, MD) ranked the top three alignments to E. 
histolytica 18S rRNA gene (Genbank AB426549) and two E. dispar 18S rRNA genes (Genbank 
AB282661 and Z49256), with the amplicon sequence aligning most closely to E. dispar.  
Additional testing with DNA extracted from cultures of E. dispar trophozoites followed by PCR 
and Bio-Plex detection also yielded positive results, further supporting the cross reactivity 
finding (data not shown).  It is postulated that despite the observed mismatches between the 
probe and specimen amplicon, the relatively low stringency of the hybridization conditions in the 
Bio-Plex assay enables binding of the E. histolytica-specific probe to E. dispar amplicon 
sequences.  These findings support those of Taniuchi et al. (107), indicating that the primers and 
probe lack species-specificity on the Bio-Plex platform and therefore may not differentiate 
between pathogenic and non-pathogenic Entamoeba in all specimens. 
 Finally, overall Bio-Plex assay performance was assessed by comparing the results 
obtained from testing previously characterized specimens representative of those typically 
submitted for outbreak investigations with results obtained by performing microscopy and/or 
PCR.  The analytical sensitivity for G. intestinalis, C. cayetanensis, C. parvum/hominis and E. 
histolytica was 81.25%, 83.33%, 100.00%, and 42.86%, respectively.  A screening assay with 
high sensitivity is typically desirable as it gives the operator confidence that negative results are 
true negatives and further testing is not required.  However, in most public health laboratories, 
multiple specimens are submitted in outbreak situations, allowing for increased sampling and 
increased overall sensitivity.  In addition, the proposed overall testing algorithm will require 
follow-up of testing results with confirmatory methods, particularly in situations in which all 
specimens submitted yield negative results.  Together these approaches allow for some tolerance 
of lower sensitivity values, as discussed in Chapter 2.  Therefore, for the intended use of the Bio-
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Plex protozoan as a screening assay, the sensitivity of the Giardia, Cyclospora, and 
Cryptosporidium targets is acceptable, as the values exceeded the minimum acceptable 
sensitivity of 80% (Chapter 2).  In contrast, the sensitivity of the E. histolytica target is markedly 
low as compared to microscopy, and discrepants could not be resolved upon further 
troubleshooting with microscopy and an alternate PCR method that discriminates between E. 
histolytica and E. dispar.   
In order to determine if the presence of inhibitors were the cause of eight false-negative 
results for the G. intestinalis, C. cayetanensis, and E. histolytica targets, discrepant specimens 
were tested using 1:10 and 1:50 dilution of template nucleic acids.  Negative results indicated 
inhibitors were not present (data not shown).  Assay limitations that may have contributed to 
decreased sensitivity include prolonged storage of template DNA used for the study, inability to 
re-confirm the original reference method results, the presence of amplification products below 
assay limits of detection and the small number of specimens available for testing.  It is 
acknowledged that the sensitivity of morphologic identification of E. histolytica may be as low 
as 60% target, resulting in false-positive results (105).  It is possible that misidentification of 
morphologic features on microscopy may have occurred for several specimens in this study, 
contributing to the decreased sensitivity of the E. histolytica target.  
Rather than ruling out disease, as with traditional diagnostic screening assays, this multiplex 
assay is intended to be used to screen outbreak specimens to rule in a possible etiologic agent in 
order to focus further confirmatory testing.  Based on this intended use, a high specificity is the 
priority, as this provides confidence in positive results due to a low incidence of false positive 
results.  The specificity of the four multiplex targets was 98-100%, exceeding the minimum 
acceptable specificity of 95% established in Chapter 2.   The excellent specificity of the assay 
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facilitates preliminary identification of the etiologic agent leading to the development of 
effective, data driven public health management practices by epidemiologists.  
 The evaluations described here have assessed the performance of a microsphere-based 
multiplex assay for the simultaneous detection of G. intestinalis, C. cayetanensis, C. 
parvum/hominis, and E. histolytica in a public health laboratory setting.  This assay exhibits 
acceptable precision for all targets, as compared to data available in the commercial and 
scientific literature for microsphere-based assays.  With the exception of G. intestinalis, all 
targets exhibited higher limits of detection in unpreserved specimens as compared to the real-
time and conventional PCR assays for which they were originally designed.  These data suggest 
that the chemistry of Bio-Plex reactions may not facilitate direct adaptation of primers and 
probes successfully used in other amplification based methods, and instead additional 
optimization may be required.   A practical comparison of the limits of detection with Giardia 
and Cyclospora concentrations described for clinical specimens suggests, however, that the 
protozoan screening assay is capable of detecting the intended targets in typical outbreak 
specimens.  The data also show that analytical sensitivity is somewhat reduced in LV-PVA 
specimens; therefore, it is recommended that unpreserved specimens be the preferred specimen 
type for testing. The protozoan assay showed acceptable sensitivity as compared to reference 
methods for G. intestinalis, C. cayetanensis, and Cryptosporidium spp. targets based on its 
intended use as an outbreak screening method.  The three targets also exhibited excellent 
specificity.  Because the sensitivity of the assay is less than 100% for several targets, it is 
recommend that an outbreak investigation algorithm include further testing using alternate 
protocols when all specimens submitted for an outbreak are negative for assay pathogen targets.  
In addition, confirmatory testing to verify screening results is recommended.  Finally, the 
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multiplex exhibited no cross-reactivity to a variety of non-target intestinal parasites, with the 
exception of E. dispar.   The capability of the E. histolytica primers and probe to cross-react with 
E. dispar sequences requires that the primers and probe be re-designed and optimized to achieve 
improved species specificity.  In summary, the data demonstrate that the Bio-Plex multiplex 
protozoan assay has potential as a screening assay in outbreak investigations, with one target 
modification, in order to provide preliminary pathogen information to epidemiologists and to 
better focus confirmatory laboratory testing.  In addition, the assay may serve as the backbone to 
which additional pathogen targets may be added, maximizing the flexibility of the Bio-Plex 200 
platform. 
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CHAPTER 5 EVALUATION OF A PCR-BASED BACTERIAL BIO-PLEX ASSAY 
 
 
 
Overview of Enteric Bacterial Pathogens and Assay Molecular Targets.  The six-plex 
bacterial assay developed for and evaluated in this aim of the project targets multiple 
diarrheagenic E. coli strains and Shigella spp.  The primers and probes include previously 
published sequences and new unpublished sequences, adapted to or designed for the Bio-Plex 
platform by collaborators at the University of Virginia and at DCLS.  Genetic targets included in 
the Bio-Plex bacterial assay enable the detection of shiga toxin-producing E. coli (STEC), 
enterotoxigenic E. coli (ETEC), and enteroinvasive E. coli (EIEC), and Shigella spp.  
STEC.   Shiga toxin producing E. coli comprise a group of E. coli strains that include multiple 
serotypes, including the most well-characterized foodborne pathogen, E. coli O157:H7.  Initial 
symptoms of infection by STEC include watery diarrhea and abdominal pain for 1-2 days, 
followed by an increase in symptom severity that may include bloody diarrhea for several days 
(57).    Fever is not a prominent symptom.  Perhaps of most concern with these strains is the 
potential for the infection to move beyond hemorrhagic colitis to hemolytic uremic syndrome or 
thromocytopenic purpura, both of which are life-threatening (57).  
STEC strains are characterized by their ability to produce one or both of two shiga-like 
toxins, the genes of which are designated stx1 and stx2.  These toxins were first described in 
Shigella dysenteriae and are composed of one active (A) subunit that interrupts ribosomal RNA 
to ultimately halt protein synthesis in the infected cell and five binding (B) subunits (61).  There 
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is approximately 55% identity between the stx1 and stx2 genes, with the stx1 sequences’ being 
well-conserved, while the stx2 sequence exhibits multiple variants.  Both stx1 and stx2 are 
encoded on lambdoid lysogenic bacteriophages, while the stx2e variant is chromosomally-
encoded (79, 109).  Bacteria may have single or multiple phage copies (109). 
The primers and probe to detect stx1 were adapted directly from a multiplex real-time 
PCR assay described by Hidaka et al. (53).  The targeted genome sequence is a 132-base-pair 
region of the gene encoding the A subunit of the stx1 toxin.  The primers for stx2 detection were 
adapted from a multiplex conventional PCR assay and yield a 255 base-pair amplification 
product representing the gene encoding the A subunit of the stx2 toxin gene (90).  The primers 
are designed to detect all stx2 variants.  The stx2-specific probe was designed by Dr. Taniuchi at 
the University of Virginia (M. Taniuchi, unpublished data). 
E. coli O157.  Because infections caused by E. coli O157:H7 may result in a more severe clinical 
presentation than those caused by other STEC strains and the fact that E. coli O157:H7 strains 
are more frequently associated with significant foodborne outbreaks, it is desirable to be able to 
specifically detect O157 serotypes that may be associated with an outbreak (57).  Specific 
detection of O157 strains is possible due to the description of a single base pair mutation in the 
β-glucuronidase gene (uidA) that is conserved in O157 strains versus other STEC serotypes (10, 
42).  The current assay incorporates primers and a probe described by Yoshitomi et al. that were 
originally designed for use in a singleplex real-time PCR assay and exhibited optimal Bio-Plex 
fluorescent data for positive specimens as compared to other primer and probe designs (data not 
shown) (119).  The probe sequence is specific for the O157 base pair mutation.   
ETEC.  This group of organisms is the primary cause of ―traveler’s diarrhea‖ (1).  In addition, 
ETEC strains have been implicated in a variety of outbreaks on cruise ships and within the U.S., 
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many cases of which were due to consumption of contaminated food or water (4, 33).  The 
primary symptom of ETEC infection is diarrhea, with varying reports of abdominal cramps, 
fever, nausea and vomiting.  When vomiting is present, diarrhea has generally been reported to 
occur at least 2.5 times the incidence of vomiting.  Duration of symptoms is widely variable 
among reported patients, with a median duration of >72 hours described for multiple U.S. 
outbreaks caused by ETEC strains (4, 33). 
 ETEC strains cause the symptoms of disease through the production of one or both of 
two toxins that lead to excess intestinal secretion (61).  One toxin is termed ―heat labile toxin‖ 
(LT), and its structure and function are closely related to the cholera toxin of Vibrio cholerae 
(79).  There are two serogroups described for LT:  LT-I and LT-II.  LT-I is produced by ETEC 
strains that are pathogenic for both humans and animals.  In contrast, strains expressing LT-II are 
found primarily in animals, and have not been associated with human disease (79).  The gene for 
the LT-I toxin is identified as elt, and resides extrachromosomally on a plasmid (79).  The 
second toxin that may be produced is a ―heat stable toxin‖ (ST).  As is the case for LT, there are 
several variants of the ST. The toxin variants are small single-peptide toxins of which the STa 
(ST-1) variant is primarily associated with human disease (61).  The estA gene that encodes this 
toxin is located primarily on a plasmid, although the genes have also been found on transposons 
(79).   
 The primer and probe set employed in the multiplex for the LT gene was described for 
use in a multiplex real-time PCR assay, targeting a 62 base-pair region of the A subunit gene 
(eltA) (53).  The primer and probe set to detect the estA gene (ST) was designed by Dr. Mami 
Taniuchi of the UVA and produces a 172 base-pair amplification product (M. Taniuchi, 
unpublished data). 
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EIEC/Shigella.  Enteroinvasive E. coli  (EIEC) and Shigella spp. are highly similar in terms of 
biochemical identification, genetics and pathogenesis.  Separate taxonomies are maintained, 
however, due to the clinical symptoms of Shigella (61). Clinical presentation of Shigella 
infection is that of dysentery: diarrhea with blood and/or mucus, fever, and abdominal cramps 
(61).  In contrast, infection with EIEC manifests similarly to other E. coli infections, including 
watery diarrhea, abdominal cramps, fever and malaise.  Progression to dysentery can occur, but 
is not common (57).  Pathogenesis of both organisms is characterized by invasion of intestinal 
epithelial cells, intracellular replication, invasive movement into adjacent cells, and induction of 
apoptosis (61). 
 The genetic region targeted by the Bio-Plex assay for both of these strains is the ipaH 
gene, a multi-copy gene on the large invasion plasmid and chromosomes of both Shigella and 
EIEC strains (9, 52, 89).  Investigation of primarily S. flexneri strains has shown that ipaH gene 
products are secreted via the organism’s invasion plasmid-encoded Type III secretion apparatus 
(36). Recently the structure and activity of ipaH gene products in Shigella were elucidated, 
identifying this family of proteins as a new class of E3 ubiquitin ligases that may be involved in 
dampening host innate immune responses (103, 121).  The primers and probe set employed in 
this assay was designed by Dr. Mami Taniuchi of UVA, and target a 64-base pair sequence of 
the ipaH gene (M. Taniuchi, unpublished data). 
Results. 
Preliminary assessment of the multiplex bacterial assay using stool broth specimens.  A 
preliminary evaluation of the bacterial assay 6-plex was performed by testing 50 characterized 
stool broth specimens using the multiplex Bio-Plex bacterial assay and the qualitative results 
were compared to those obtained using molecular and shiga toxin enzyme immunoassay 
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reference methods.  The calculated sensitivity and specificity for each target and corresponding 
intervals are shown in Table 12.  The sensitivities for stx1, stx2, and uidA were 100%, 95% and 
100%, respectively.  Specificity of all targets was 100%, with the exception of 95% specificity of 
the stx1 target.   
Validation of Cary-Blair specimens - precision studies.  Repeatability (within-run precision) 
was performed by amplifying nucleic acid from a select panel of specimens using the bacterial 
assay and detecting in ten replicate wells on the Bio-Plex, as described in the Materials and 
Methods.  The statistics of mean, standard deviation (SD) and coefficient of variation (CV) were 
calculated, as described. To assess repeatability, the precision for positive-target specimens was 
expressed as the CV, which ranged from 6.50% to 26.83% for the three specimens tested in the 
study (Table 13).  Each specimen in this panel also yielded negative results for additional assay 
targets (e.g., O157:H7-positive specimen had negative results for eltA, estA and ipaH).  In 
addition, the panel included one Cary-Blair specimen known to be negative for enteric bacteria, 
and therefore yielded negative results for all assay targets.  Within-run precision for negative 
targets was expressed as SD, and ranged from 4.32 – 9.30 (Table 14).   
 In order to evaluate between-day variation (reproducibility) of the amplification and Bio-
Plex steps together, nucleic acid template from the specimen panel used in the repeatability study 
was amplified and detected for five days using the Bio-Plex bacterial assay, as described in 
Materials and Methods.  The mean, SD and CV were calculated as described.  The between-day 
CV values of the amplification and detection steps combined for positive assay targets ranged 
from 13.54% to 41.26% (Table15), and SD values (FI) for negative assay targets ranged from 
3.14 – 12.76 (Table 16).  Evaluation of the precision of the detection step alone resulted in  
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Table 12.  Preliminary assessment of a multiplex Bio-Plex 200 bacterial assay using stool 
broth specimens.  Qualitative results of multiplex testing using the Bio-Plex platform to detect 
enteric bacterial pathogens in 50 characterized stool broth specimens were compared to those 
obtained with reference methods.  Sensitivity was calculated using the formula: 
[TP/(TP+FN)]x100.  Specificity was calculated using the formula:  TP/(TP+FN)]x100.  
Confidence intervals were calculated using Wilson’s score confidence interval method (28).  
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Target TP 
(n) 
FN 
(n) 
Se 
(%) 
CISe, 95 TN 
(n) 
FP 
(n) 
Sp 
(%) 
CISp, 95 
stx1 31 0 100.00 L: 88.98 
U: 100.00 
18 1 95.00 L: 75.36 
U: 99.07 
stx2 20 1 95.00 L: 77.33 
U: 99.16 
29 0 100.00 L: 88.31 
U: 100.00 
uidA 4 0 100.00 L: 51.02 
U: 100.01 
46 0 100.00 L: 92.29 
U: 100.00 
eltA (LT)  0 0 N/A N/A 50 0 100.00 L: 92.87 
U: 100.00 
estA (ST) 0 0 N/A N/A 50 0 100.00 L: 92.87 
U: 100.00 
ipaH 0 0 N/A N/A 50 0 100.00 L: 92.87 
U: 100.00 
Abbreviations:  
TP,  True positive, Bio-Plex 200 positive for an organism identified as positive by reference 
method;  
TN, True negative, Bio-Plex 200 negative for an organism identified as negative by reference 
method;  
FP, False positive, Bio-Plex 200 positive for an organism identified as negative by reference 
method;  
FN, False negative, Bio-Plex 200 negative for an organism identified as positive by reference 
method;  
Se, sensitivity; Sp, specificity; CI. confidence interval; L, lower limit; U, upper limit 
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Table 13.  Bio-Plex 200 detection repeatability results for positive targets in Cary-Blair 
stool specimens.  The known pathogen and bacterial assay positive gene target(s) are indicated 
for each specimen used in the study.  Extracted nucleic acid from each specimen was amplified 
and then detected in ten replicate wells, as described in Materials and Methods.  Mean, SD and 
CV were calculated using result values for each well obtained by subtracting the mean 
fluorescence of ten background wells from the Bio-Plex FI output of individual sample wells.  
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Pathogen/ 
Gene Target(s) 
Mean  
(FI) 
(n = 10) 
SD 
(FI) 
CV
a
 
(%) 
O157:H7 
stx1 
stx2 
uidA 
 
605.50 
67.00 
74.75 
 
39.33 
9.78 
20.06 
 
6.50 
14.60 
26.83 
 
ETEC (ATCC 35401) 
eltA (LT) 
estA (ST) 
 
1140.20 
333.30 
 
 
112.76 
44.63 
 
9.89 
13.39 
S. flexneri 
ipaH 
 
786.25 
 
81.51 
 
10.37 
a
 CV:  coefficient of variation; (SD / mean) x 100   
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Table 14.  Bio-Plex 200 detection repeatability results for negative targets in Cary-Blair 
stool specimens. The bacterial assay gene target and total number of specimens negative for the 
target are indicated.  Extracted nucleic acid from each specimen was amplified and then detected 
in ten replicate wells, as described in Materials and Methods.  Mean and SD were calculated 
using result values for each well obtained by subtracting the mean fluorescence of ten 
background wells from the Bio-Plex FI output of individual sample wells.  Mean and SD ranges 
reflect the range of statistics calculated for all panel specimens negative for the respective assay 
target.  The total number of specimens in the panel that were negative for the select target is 
provided. 
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Gene Target Number of specimens Mean (FI) 
(n = 10 wells/specimen) 
SD 
(FI) 
stx1  
stx2  
uidA 
eltA (LT) 
estA (ST) 
ipaH 
3 
3 
3 
3 
3 
3 
-1.00 – 3.05 
0.15 – 2.85 
-10.00 – -0.40 
-3.50 – 2.45 
-3.40 – 0.35 
-2.70 – 1.70 
5.47 – 5.84 
5.14 – 5.27 
4.76 – 5.52 
5.33 – 6.51 
4.32 – 9.30 
4.45 – 6.35 
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Table 15.  Amplification and Bio-Plex 200 detection reproducibility results for positive 
targets in Cary-Blair stool specimens.  The known pathogen and bacterial assay-positive gene 
target(s) are indicated for each specimen used in the study.   Extracted nucleic acid from each 
specimen was amplified and detected each day for five days, as described in Materials and 
Methods.  Mean, SD and CV were calculated by using results representing the specimen FI 
minus the background well FI for each positive target.    
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Pathogen/ 
Gene Target(s) 
Mean (FI) 
(n = 5) 
SD 
(FI) 
CV
a
 
(%) 
E. coli O157:H7 
stx1 
stx2 
uidA 
 
965.80 
104.10 
87.50 
 
309.26 
31.91 
34.20 
 
32.02 
30.66 
39.09 
ETEC (ATCC 35401) 
eltA (LT) 
estA (ST) 
 
993.63 
163.00 
 
134.56 
67.25 
 
13.54 
41.26 
Shigella flexneri 
ipaH 
 
454.10 
 
142.09 
 
31.29 
a
 CV:  coefficient of variation; (SD / mean) x 100   
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Table 16.  Amplification and Bio-Plex 200 detection reproducibility results for negative 
targets in Cary-Blair stool specimens.  The bacterial assay gene target and total number of 
specimens negative for the target are indicated.  Nucleic acid extracted from each specimen was 
amplified and detected each day for five days, as described in Materials and Methods.  Mean and 
SD were calculated using result values for each well obtained by subtracting the mean of one 
background well from the Bio-Plex FI output of individual sample wells.  Mean and SD ranges 
reflect the range of statistics calculated for all panel specimens negative for the respective assay 
target.  The total number of specimens in the panel that were negative for the select target is 
indicated. 
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Gene Target Number of 
specimens 
Mean (FI) 
(n = 5/specimen) 
SD 
(FI) 
stx1  
stx2  
uidA 
eltA (LT) 
estA (ST) 
ipaH 
3 
3 
3 
3 
3 
3 
2.90 – 9.00 
-6.25 – -3.70 
-6.30 – 3.13 
-3.60 – -1.00 
-3.20 – 1.50 
-7.63 – -4.00 
9.97 – 12.76 
4.70 – 10.29 
5.23 – 9.56 
3.54 – 6.87 
3.14 – 7.01 
3.67 – 7.87 
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a CV value range of 7.28% to 28.23% (Table 17) for positive-target specimens, while negative 
targets exhibited an SD value range of 1.65 – 14.26 (Table 18). 
Validation of Cary-Blair specimens – analytical sensitivity (limits of detection).  The analytical 
sensitivity, or limits of detection (LoD), of each target in the bacterial assay was evaluated using 
E. coli O157:H7, ETEC (ATCC 35401) and S. flexneri (ATCC 12022) isolates spiked into Cary-
Blair stool aliquots characterized to be negative for pathogenic enteric bacteria, as described.  
Dilution series were extracted and tested in triplicate and colony counts on blood agar plates 
were conducted to determine organism concentrations.  Table 19 summarizes the limits of 
detection established for each assay target in Cary-Blair stool specimens.  Analytical sensitivity 
of the assay ranged from approximately 2.7x10
1
 CFU/200 mg stool to 2.4x10
6
 CFU/200 mg 
stool.  Based on a spiking volume of 10 µL, the LoDs can be converted to a range of 2.7x10
3
 to 
2.4x10
8
 CFU/mL (Table 19).  
Validation of Cary-Blair specimens – analytical specificity.  The organisms present in the Cary-
Blair specimens tested in this study exhibited no cross-reactivity to non-complementary primers 
and probes in the multiplex assay (data not shown).  Organisms tested included E. coli O157:H7 
(n = 2), E. coli non-O157 (stx1-positive; n = 1), E. coli of unknown serotype (stx1-positive, n = 
3), Shigella spp. (n = 4) and Salmonella spp. (n = 5).  In addition, the assay was challenged with 
bacterial isolates including ETEC (n = 5; serotypes O153:H45, Ound:H16, Ound:NM, O6:H16, 
and O148:NM), EPEC (n = 10; serotypes O119:H6, O55:NM, Ound:NM, O115:NM, 
Orough:H8, O111:NM, O55:H6, O111:H2, O128:H1, and O86:H34), and EIEC (n = 2; serotypes 
O124:NM and O29:NM) strains.  No cross-reactivity was observed with non-complementary  
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Table 17.  Bio-Plex 200 detection reproducibility results for positive targets in Cary-Blair 
stool specimens. The known pathogen and bacterial assay positive gene target(s) are indicated 
for each specimen used in the study.   Extracted nucleic acid from each specimen was amplified 
once and detected each day for four days, as described in Materials and Methods.  Mean, SD and 
CV were calculated using result values for each replicate well obtained by subtracting the 
fluorescence of one background well from the Bio-Plex FI output of individual sample wells.   
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Pathogen/ 
Gene Target(s) 
Mean (FI) 
(n = 4) 
SD 
(FI) 
CV
a
 
(%) 
E. coli O157:H7 
stx1 
stx2 
uidA 
 
818.25 
91.50 
53.13 
 
105.02 
25.83 
4.17 
 
12.83 
28.23 
7.85 
ETEC (ATCC 35401) 
eltA (LT) 
estA (ST) 
 
1084.38 
63.13 
 
78.98 
11.51 
 
7.28 
18.23 
Shigella flexneri 
ipaH 
 
635.13 
 
74.33 
 
11.70 
a
 CV:  coefficient of variation; (SD / mean) x 100   
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Table 18.  Bio-Plex 200 detection reproducibility results for negative targets in Cary-Blair 
stool specimens.  The bacterial assay gene target and total number of specimens negative for the 
target are indicated.  Nucleic acid extracted from each specimen was amplified once and detected 
each day for four days, as described in Materials and Methods.  Mean and SD were calculated 
using result values for each well obtained by subtracting the fluorescence of one background 
well from the Bio-Plex FI output of individual sample wells.  Mean and SD ranges reflect the 
range of statistics calculated for all panel specimens negative for the respective assay target.   
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Gene Target Number of 
specimens 
Mean (FI) 
(n =4/specimen) 
SD 
(FI) 
stx1  
stx2  
uidA 
eltA (LT) 
estA (ST) 
ipaH 
3 
3 
3 
3 
3 
3 
-2.75 – 2.38 
-2.13 - 5.75 
-5.88 – 2.38 
-1.38 – 4.75 
-4.63 - -1.88 
-2.25 – 8.38 
2.87 – 5.85 
10.05 - 14.26 
4.17 – 10.78 
2.78 – 5.19 
1.65 – 5.11 
2.87 – 11.14 
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Table 19.  Analytical sensitivity (limits of detection) of the Bio-Plex 200 enteric bacterial 
assay.  Quantified bacterial isolates were diluted and spiked into 200 mg Cary-Blair stool 
aliquots, as described.  Spiked stools were extracted, template amplified, and detected as 
described.  Dilutions were performed in triplicate.  Positivity was determined as described for 
detection of targets in the Materials and Methods section.  The limit of detection range represents 
the lowest concentrations yielding a minimum of 1 positive result.  Limit of detection ranges are 
also converted to CFU/g stool and CFU/mL for analytical comparison..
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stx1 stx2 uidA eltA (LT) estA (ST) ipaH 
LoD, Cary-
Blair stool 
 (CFU/ 
200 mg stool) 
1.0x10
3
-2.4x10
4
 3.5x10
1
-3.5x10
3
 1.0x10
5
-2.4x10
6
 1.5x10
2
-2.5x10
3
 1.5x10
4
-2.5x10
4
 2.7x10
1
-2.7x10
2
 
LoD, Cary-
Blair stool 
 (CFU/g stool) 
5.0x10
3
-1.2x10
5
 1.7x10
2
-1.7x10
4
 5.0x10
5
-1.2x10
7
 7.5x10
2
-1.2x10
4
 7.5x10
4
-1.2x10
5
 1.3x10
2
-1.3x10
3
 
LoD, Cary-
Blair stool 
(CFU/mL) 
1.0x10
5
-2.4x10
6
 3.5x10
3
-3.5x10
5
 1.0x10
7
-2.4x10
8
 1.5x10
4
-2.5x10
5
 1.5x10
6
-2.5x10
6
 2.7x10
3
-2.7x10
4
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assay targets, with the exception of a repeated positive result exhibited by one EPEC strain of 
serotype O86:H34 when detected with the uidA target. 
Validation of Cary-Blair specimens – comparison-of-methods study.  Sixteen (16) previously-
characterized Cary-Blair stool specimens were tested using the multiplex microsphere assay and 
results compared to those obtained with molecular and biochemical reference methods.  Positive 
specimens included: E. coli O157:H7 (n = 2), E. coli non-O157:H7 (n = 1), E. coli of unknown 
serotype (n = 3), Shigella spp. (n =4), and Salmonella spp. (n = 5).  One specimen was negative 
for pathogenic enteric bacteria.  The calculated sensitivity and specificity for each target and 
corresponding confidence intervals are shown in Table 20.  The sensitivity for the stx1, stx2, 
uidA and ipaH targets as compared to reference methods was calculated to be 100.00% for all 
four targets.  No positive specimen data was available to estimate sensitivity of the eltA and estA 
targets.  Specificity of all targets as compared to reference methods was calculated to be 100%.   
Discussion.  A comparison-of-methods study was conducted to assess the potential utility of the 
six-plex enteric bacterial Bio-Plex assay on DCLS platforms.  This initial study was completed 
by testing stool broth specimens typically submitted to state public health laboratories for 
confirmation of the presence of shiga toxin-producing organisms and characterized to be positive 
for stx1, stx2, and/or uidA targets.  Studies initially focused on these specimen types because a 
large number of specimens were readily available and the original intent was to validate broth 
stool matrices for use in outbreak investigations.  Results achieved on the Bio-Plex were 
compared to those obtained with biochemical and molecular reference methods used to 
characterize the specimens upon submission to DCLS, and sensitivity and specificity were 
calculated as described.  As shown in Table 12, sensitivity for the stx1, stx2, and uidA targets 
was excellent, exceeding the minimum acceptable sensitivity of 80% established for this assay.    
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Table 20.  Comparison of Bio-Plex 200 bacterial assay results to reference method results, 
by assay target.  Qualitative results of multiplex testing using the Bio-Plex platform to detect 
bacterial pathogens in Cary-Blair stool specimens were compared to those obtained with 
molecular and/or biochemical reference methods.   Sensitivity was calculated using the formula: 
[TP/(TP+FN)]x100.  Specificity was calculated using the formula: [TN/(TN+FP)]x100.  
Corresponding 95% confidence intervals were calculated using Wilson’s score confidence 
interval method. (28)  
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Target TP 
(n) 
FN 
(n) 
Se 
(%) 
CISe, 95 TN 
(n) 
FP 
(n) 
Sp 
(%) 
CISp, 95 
stx1 6 0 100.00 L: 60.97 
U: 100.00 
10 0 100.00 L: 72.25 
U: 100.00 
stx2 2 0 100.00 L: 34.24 
U: 100.01 
14 0 100.00 L: 78.47 
U: 100.00 
uidA 2 0 100.00 L: 34.24 
U: 100.01 
14 0 100.00 L: 78.47 
U: 100.00 
eltA (LT)  0 0 N/A N/A 16 0 100.00 L: 80.64 
U: 100.00 
estA (ST) 0 0 N/A N/A 16 0 100.00 L: 80.64 
U: 100.00 
ipaH 4 0 100.00 L: 51.02 
U: 100.01 
12 0 100.00 L: 75.76 
U: 100.00 
Abbreviations:  
TP,  True positive; Bio-Plex 200 positive for an organism identified as positive by reference 
method;  
TN, True negative; Bio-Plex 200 negative for an organism identified as negative by reference 
method;  
FP, False positive; Bio-Plex 200 positive for an organism identified as negative by reference 
method;  
FN, False negative; Bio-Plex 200 negative for an organism identified as positive by reference 
method;  
Se, sensitivity; Sp, specificity; CI. confidence interval; L, lower limit; U, upper limit  
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Specificity for all targets was also excellent, meeting or exceeding the minimum acceptable 
specificity of 95% established for this assay.  
 Several limitations exist for this comparison-of-methods study.  First, no stool broth 
specimens were available containing either ETEC or EIEC/Shigella spp., resulting in no 
sensitivity data for the eltA, estA and ipaH targets.  Second, only four uidA-positive specimens 
were available, thus lowering the statistical confidence of the sensitivity data for this target.  A 
limitation in assay performance was also identified, particularly for the stx2 target.  One 
specimen was negative for the stx2 target when tested on the Bio-Plex, though it was previously 
determined to be positive by both the LightCycler reference method and the Bio-Plex a year 
before (data not shown).  This broth specimen was highly pigmented and the boiled preparation 
yielded equally pigmented supernatant containing template nucleic acid.  Testing on both the 
Bio-Plex and LightCycler as described using 1:10 and 1:50 nucleic acid template dilutions 
revealed that amplification of the specimen was being inhibited, most likely by the substance 
causing the pigmentation (data not shown).  Such pigmentation is rare in stool broth specimens; 
therefore, it is recommended that a simple procedure for diluting pigmented stool broth 
specimens be added to future testing protocols, rather than pursuing a more complicated solution 
of incorporating an inhibition control.   
 Following completion of the comparison-of-methods study, further validation was not 
pursued with stool broth specimens.  As mentioned previously, this specimen type is submitted 
to state reference laboratories in order to enable the isolation and confirmation of shiga toxin-
producing E. coli bacteria.  Since stool-containing broth specimens are not a primary specimen 
type collected for testing in outbreak investigations, the need for validation of this specimen type 
with the bacterial assay was not pursued.  Instead, validation studies were conducted on the 
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primary outbreak specimen type submitted during outbreak investigations, which are stools 
diluted in Cary-Blair medium (referred to here as ―Cary-Blair stools‖ or ―Cary-Blair 
specimens‖).   
 Following initial testing of stool broth specimens, the multiplex assay was evaluated 
using Cary-Blair specimens for the characteristics of precision (repeatability and 
reproducibility), analytical sensitivity (limits of detection), analytical specificity (cross-
reactivity), and performance as compared to reference methods.  Validation study results were 
then evaluated for assay acceptability as a screening method to provide preliminary outbreak 
etiologic agent information to epidemiologists and to focus confirmatory testing in the 
laboratory.   
 As described, precision studies were conducted with a panel of four Cary-Blair 
specimens representing the type of specimen typically received in the course of an outbreak 
investigation.  As was done in the enteric protozoan study, the CV data generated in the 
repeatability and reproducibility studies for positive assay targets were compared to positive 
target CVs published for the xTAG® RVP commercial assay.  Coefficient of variation values for 
the RVP assay were established in a multi-laboratory reproducibility study to range from 2.40% 
to 87.20% for a range of virus single-infection virus concentrations (75).  As shown in Table 13, 
the within-run (repeatability) CV value range of 6.50% to 26.83% achieved for positive targets 
with the bacterial assay was comparable to the values reported for the RVP assay.  Of some 
concern was the larger CV exhibited for the uidA target as compared to the other two targets near 
the assay cutoff value (stx2, estA).  The higher variance suggests that low-concentration 
specimens positive for uidA may exhibit a higher incidence of false negative results due to lack 
of sensitivity.  Interestingly, singleplex real-time detection of uidA using other established assays 
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at DCLS have also historically exhibited notable variation in uidA detection, suggesting that 
optimizing the chemistry of detecting the single base pair mutation in O157 strains is inherently 
difficult and the source of variability.  
 Similarly, as shown in Tables 15 and 17, the reproducibility study CV value range of 
13.54% to 41.26% for the amplification and detection steps combined, and 7.28% to 28.23% for 
the detection step alone, were comparable to the values published for the RVP assay.  It is worth 
mentioning that on several days of the reproducibility studies the uidA-positive specimen yielded 
negative qualitative results for that target.  Based on this performance in both the repeatability 
and reproducibility studies, it should be noted that low-concentration uidA targets may not be 
detected consistently.  As was the case for the protozoan assay, the enteric bacterial assay 
exhibited a notable reduction in the detection-only CV values as compared to those seen for the 
combined amplification and detection steps, suggesting that amplification is an important source 
of variability.  Therefore, the comparison of Bio-Plex bacterial assay precision values for 
positive targets with those of the RVP assay suggests that multiplex microsphere-based nucleic 
acid assays may exhibit a wide range of variability, particularly at the low end of the FI 
measuring range for positive specimens, and facilitates the conclusion that the Bio-Plex bacterial 
assay exhibits comparable precision for Cary-Blair stool specimens.  
 As performed with the protozoan assay, SD values were used in this study to describe the 
variation for target-negative specimens and were compared to those described for a microsphere-
based assay to detect Plasmodium spp. (77).  In the malaria assay, SD values ranged from 18.1 to 
39.0 for both negative specimens and negative targets, based on mean FI values ranging from 
81.3 to 121.2.  These values were calculated using FI values detected on the Bio-Plex with a high 
RP1 target setting, which typically results in higher FI values as compared to using the low RP1 
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target setting.  Because the bacterial assay is detected on the Bio-Plex using a low RP1 target 
setting, the mean FI and SD values for negative specimens in the study described here are lower 
than those described for the Plasmodium assay.  However, a relative comparison of the two 
assays remains informative.  Although not a direct comparison, the SD range of 4.32-9.30 FI 
achieved in the repeatability study appears to similarly represent the range of variability 
described for this type of assay (Table 14).  In addition, the between-day SD ranges of 3.14 – 
12.76 for the combined amplification and detection steps (Table 16) and 1.65 – 14.26 (Table 18) 
for the detection step only are comparable to published data.  Based on these evaluations, the 
Bio-Plex bacterial assay exhibits comparable precision for pathogen-negative Cary-Blair 
specimens. 
 Several primers and probes used in the bacterial multiplex assay were adapted from 
previously-published real-time or conventional PCR protocols.  Therefore, a limited comparison 
of Bio-Plex assay’s analytical sensitivity (limits of detection) to that of previously-described 
assays was conducted to evaluate how well the described primers and probes were adapted to the 
Bio-Plex platform.  The stx1 and eltA (LT) primers and probes were adapted from a multiplex 
real-time PCR assay for which the limits of detection were established by diluting organism 
spiked into enrichment broths, as opposed to the stool aliquots used in this Bio-Plex study (53).  
The Bio-Plex limits of detection are comparable to or lower than the published values of 2.0-
2.7x10
6 
CFU/mL for stx1 and 1.3-1.6x10
6 
CFU/mL for eltA (Table 19).  Reasons for the lower 
limit of detection of the bacterial assay may be affinity of the probe for the Bio-Plex chemistry, 
differences in experimental design, or different gene copy numbers in the isolates used.    
 The stx2 primers were also adapted, in this case from a published conventional assay 
(90).  The probe was designed in this study for the Bio-Plex assay.  Again, comparison of 
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detection limits is not exact, as the published sensitivity for the primers was established using 
spiked fecal cultures, not stool, and the probe is a new design.  The Bio-Plex limit of detection as 
determined for a 200 mg stool reaction was slightly lower than the 1x10
3 
CFU/reaction achieved 
for the conventional assay and may be due to the Bio-Plex chemistry and probe design.  In the 
case of the uidA target, both primers and probe from the literature were used in the Bio-Plex 
assay (119).  Comparison of sensitivity data is difficult, however, as the published limit of 
detection of 1-1000 CFU/g was estimated by spiking food supplemented by enrichment, not a 
stool matrix.  However, the analytical sensitivity of this target as compared to others in the Bio-
Plex multiplex indicates that adaptation to the Bio-Plex format reduced the sensitivity of the 
primer and probe set (Table 19).  No comparative data is available for the estA (ST) and ipaH 
targets, as they were designed for this study. 
 A practical comparison of the Bio-Plex assay limits of detection to known excreted 
concentrations of organism is also useful in determining if the Bio-Plex bacterial assay is 
sensitive enough to detect organism concentrations typically seen in clinical specimens.  As was 
the case for enteric protozoa, examples of bacterial shedding concentrations are available in the 
literature.  It is important to note that data discussed below for ETEC and S. flexneri are from 
volunteer challenge studies, so the organism concentrations determined to be excreted may not 
be an exact representation of natural infection.  In a study of pediatric patients infected with E. 
coli O157, long-term shedders excreted over 10
6
 CFU/g stool, while convalescent shedders were 
determined to excrete 10
5
-10
6
 CFU/g stool (63).  It was noted, however, that convalescent 
shedders may excrete lower levels of organism that may not have been detected due to the LoD 
of the assay used in the Karch et al. study (63).  A comparison of the detection limits, as 
converted to CFU/g stool, for the Bio-Plex stx1 and stx2 targets to the study data suggests that 
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the bacterial assay is capable of detecting physiologic concentrations of organism in clinical 
specimens (Table 19).  Detection of uidA may be limited as suggested by the estimated limit of 
detection and precision data described previously.   
 An example of ETEC excretion levels is provided in a heat-labile toxin vaccine study, 
during which volunteers were challenged with 6x10
8
 CFU of organism (76).  The median peak 
excretion was quantified to be 1x10
8
 CFU/g stool, with the implication that excretion levels may 
be lower.  Comparison of the estimated limit of detection ranges for Bio-Plex eltA and estA 
targets with these data suggests that the bacterial assay is capable of detecting clinically relevant 
concentrations of organism (Table 19).  In an antibiotic efficacy study, volunteers were 
challenged with 1500 CFU of S. flexneri, and peak shedding in those taking placebo was 
quantified to be 1x10
3
-3x10
6
 CFU/g stool (108).  Comparison of the estimated Bio-Plex ipaH 
limit of detection with these data indicates the bacterial assay is capable of detecting 
concentrations of organism that may be expected in clinical specimens (Table 19). 
 A potential limitation in estA (ST) target detection was identified when testing several 
ETEC isolates previously characterized by the Minnesota Department of Health to contain the 
estA1 allele.  Confirmation testing upon receiving isolates of serotype Ound:H16 and O148:NM 
with the Bio-Plex bacterial assay yielded negative results for ST.  Subsequent testing using an 
alternate DCLS ETEC real-time protocol, as described in Materials and Methods, yielded 
positive ST results (data not shown).  Bio-Plex primers and probe sequences were compared with 
those published for the complete coding sequence for the estA1 allele of the heat-stable toxin I 
gene from E. coli strain 18D (Genbank accession M58746) (data not shown).  Multiple base pair 
mismatches were identified between the Bio-Plex primers and probe and the published gene 
sequences, suggesting that detection of this ST allele is hindered in the Bio-Plex assay.  Re-
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design of the primers and probe or addition of an allele-specific primers and/or probe may be 
desired.  
 The Bio-Plex bacterial assay exhibited no cross-reactivity between microsphere targets.  
In addition, when challenged with ETEC, EIEC, and most EPEC strains, none of the multiplex 
microspheres yielded positive results.  These data complement previously-published studies 
demonstrating that the primers and/or probe sequences for stx1, six2 and eltA (LT) do not cross-
react with non-target sequences in other pathogens (53, 90).  Of note is repeated cross-reactivity 
of the uidA probe with one EPEC strain (serotype O86:H34) tested in the study.  Similar cross-
reactivity with several EPEC strains was also seen with experimental uidA probes designed at 
DCLS (data not shown).  As discussed previously, detection of the O157-specific uidA sequence 
is based on a one base-pair mutation as compared to non-O157 strains in the β-glucuronidase 
gene.  Designing reaction conditions to ensure specific hybridization can be a challenge.  As 
described by Yoshitomi et al. (119), even under real-time singleplex conditions very stringent 
cycling temperature and probe and magnesium concentrations must be established to reduce 
cross-reactivity to non-O157 strains.  Due to the possibility of cross-reactivity with EPEC 
strains, it is recommended that result interpretation of the uidA target be accomplished only when 
stx1 and/or stx2 targets are positive. 
 Finally, overall performance of the bacterial Bio-Plex assay was assessed by comparing 
results obtained from testing well-characterized Cary-Blair specimens representative of those 
typically submitted during outbreak investigations with results obtained by performing the 
reference methods of biochemical, enzyme immunoassay and/or molecular testing.  Based on 
Bio-Plex and reference method result comparisons, Bio-Plex results were designated as either 
true positive (TP), true negative (TN), false positive (FP), or false negative (FN), and the 
 128 
 
analytical sensitivity and specificity for each assay target were calculated (Table 20).  Bio-Plex 
results that did not correlate with the reference method upon initial testing (FP, FN) were 
investigated using re-extraction and re-testing with both the Bio-Plex and molecular reference 
methods, as available.  As shown in Table 20, sensitivity for the stx1, stx2, uidA, and ipaH 
targets is excellent, exceeding the minimum acceptable sensitivity of 80% established for this 
assay (Chapter 2).  Specificity for all targets is also excellent, exceeding the minimum acceptable 
specificity of 95% established for this assay (Chapter 2).  
 Several limitations exist for the comparison-of-methods study.  First, no Cary-Blair stool 
specimens containing ETEC organisms were available, resulting in no comparative data for the 
eltA and estA targets.  However, successful detection of ETEC strains in Cary-Blair specimens 
can be anticipated based on the ability to detect low concentrations of organism in the course of 
the analytical sensitivity (LoD) study (Table 19).  Second, the comparison-of-methods study 
sample size was limited by availability and was thus very small (n = 16).  Therefore, the 
sensitivity confidence limit ranges for stx1, stx2, uidA and ipaH are fairly wide, illustrating the 
low statistical confidence provided by the sensitivity calculations.  Additional data can be 
gathered in the course of future outbreak investigations to bolster the statistical confidence.  
Confidence limit ranges for the calculated specificity of all targets are smaller than those for the 
sensitivity calculations, providing a higher level of confidence in these data.   
 An evaluation has been conducted to assess the performance of a microsphere-based 
multiplex assay for the simultaneous detection of six STEC, ETEC, and EIEC/Shigella spp. 
molecular targets in Cary-Blair stool specimens in a public health laboratory setting.  This assay 
exhibits acceptable precision for all targets, as compared to data available in the commercial and 
scientific literature (75, 77).  A potential limitation is that variability of the uidA target in 
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specimens with organism concentrations near the assay cutoff may lead to inconsistent target 
detection.  The stx1, stx2, and eltA (LT) targets exhibited similar or lower limits of detection 
when compared to the previously-published assays from which the primers and/or probes were 
adapted.  In addition, a comparison of the Bio-Plex analytical sensitivity results (CFU/g stool) 
with those described for clinical and challenge studies suggests that the Bio-Plex assay targets of 
stx1, stx2, eltA, estA, and ipaH are capable of detecting physiologic concentrations of organism 
in clinical specimens.  Performance of the uidA target in limit of detection studies was not 
optimal, again suggesting that detection of the uidA gene target in Cary-Blair specimens may be 
problematic.  Optimization of the uidA primers and probe reaction conditions has been described 
to be critical to successful O157 strain detection (119).  However, conditions for the other primer 
and probe sets in the multiplex must also be considered, therefore limiting optimization.  As 
discussed earlier in this chapter, testing of alternate primer and probe designs yielded less 
successful performance, suggesting that the current primers and probe are at this time the best 
option as long as the operator is aware of the performance limitations.   In the case of the estA 
(ST) target, however, re-design of the primers and probe or addition of an allele-specific primer 
and probe set may be desired in the future. 
 The assay targets exhibited no cross-reactivity when challenged with a variety of E. coli, 
Shigella spp. and Salmonella spp.  One notable exception was repeated cross-reactivity of the 
uidA target to a select EPEC strain.  Because cross-reactivity to EPEC strains may occur, it is 
recommended that uidA results be considered for interpretation only when stx1 and/or stx2 
targets are also positive.  Finally, comparison of Bio-Plex qualitative results for Cary-Blair 
specimens with those of reference methods yielded sensitivity and specificity values that 
exceeded expectations, although confidence of sensitivity data is lowered due to the small 
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sample size.  Despite the small study sample sizes and potential limitations, the Bio-Plex 
bacterial assay exhibits performance characteristics sufficient for use as a screening assay to 
provide preliminary etiologic agent information and focus laboratory confirmatory testing in 
outbreak investigations. 
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CHAPTER 6 EVALUATION OF A MANUAL METHOD FOR THE EXTRACTION OF 
VIRAL NUCLEIC ACIDS 
 
 
 
Overview of Norovirus and Rotavirus Pathogens and Molecular Assays for Detection of 
Gene Targets.  Noroviruses are the leading cause of acute gastroenteritis in the U.S., and are the 
leading non-bacterial cause of foodborne illness (22, 100).  Rotaviruses are more typically 
associated with gastroenteritis in pediatric patients, although they have also been implicated in 
foodborne illnesses (11).  An overview of the viruses, their clinical signs and symptoms and 
testing methods utilized by public health laboratories to detect these viruses is provided below. 
Norovirus genogroups I and II.  Noroviruses (NoVs) are small round-structured non-enveloped 
RNA viruses belonging to the family Caliciviridae (51).  They are currently classified into five 
genogroups, with GI and GII primarily associated with human infection (3).  Genogroups are 
further subdivided into genotypes based on sequence variations in the capsid genes of the viruses 
(3, 120).  Definitive characterization of NoVs is conducted under the auspices of the CDC’s 
CaliciNet Network, a national NoV electronic surveillance network intended to track NoV 
strains and outbreak trends through the use of a comprehensive genome sequence database (22).  
Based on data analyzed through CaliciNet, variants of NoV genotype GII.4 have been the 
predominant cause of NoV infections in the U.S. since 2001 (22). 
Infection with NoV causes acute gastroenteritis, typically after a 12-48 hour incubation 
period.  Symptoms include diarrhea, vomiting, nausea, and/or abdominal cramps.  Infrequently 
patients may experience low-grade fever and/or body aches (22).  Infections are usually self-
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limiting in immunocompetent people.  Prolonged symptoms, including dehydration, can occur in 
the young, elderly, and hospitalized (22). 
 Detection and characterization of NoVs are primarily performed using molecular 
methods, as no culture techniques are available.  Only one FDA-approved immunoassay recently 
became available in the U.S., but is not recommended as a replacement for molecular methods in 
public health outbreak investigations because negative samples must still be confirmed by a 
second technique (22).  The NoV genome is a single-stranded, positive sense RNA of 
approximately 7.7kb in length (51).  The genome contains three open reading frames (ORFs), of 
which ORF1 encodes non-structural proteins, ORF2 encodes the major capsid protein VP1, and 
ORF3 encodes the minor structural protein VP2 (51).  Detection of NoV GI and GII is currently 
performed at state laboratories in collaboration with the CDC using a real-time RT-PCR assay 
targeting the relatively conserved junction between the ORF1 and ORF2 (60).  In addition, 
conventional RT-PCR methods are performed to target the capsid regions encoded on ORF2 and 
amplification products sequenced to identify the genotype of the viruses detected in clinical 
specimens (114).  
Group A rotaviruses.  Rotaviruses (RVs) are non-enveloped RNA viruses that belong to the 
family Reoviridae, named for their wheel-like shape when visualized using electron microscopy 
(2).  Like NoVs, these viruses are classified based on the characterization of serotypes and/or 
genotypes of specific viral proteins.  Major RV groupings are designated A to G, and are based 
on antigenicity of epitopes in the most abundant virus structural protein, VP6 (47).  Group A 
rotaviruses are the primary rotavirus type that causes disease in the U.S., and are further 
characterized based on the serological reactivity of two outer capsid proteins, VP7 and VP4.  The 
VP4 protein determines the P type, and VP7 the G type of the virus (37).  Fourteen G types are 
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known, with G1-G4 being the most common, and it has been shown that serotype directly 
correlates with genotype.  Twenty P types have been identified, with ten known to occur in 
human RV infections.  For the P types, serotype does not correlate directly with genotype (37). 
 The incubation period for RV infection is usually 24-48 hours.  Typical symptoms in 
both adults and children are fever and vomiting for several days, followed by often profuse 
diarrhea.  However, time to onset of illness and symptoms in adults may be widely variable (2).  
As is the case for norovirus, dehydration is a concern, particularly in children and the elderly. 
 The rotavirus genome is made up of 11 segments that are double-stranded.  Segments 
range in size from 660 to 3,300 base pairs (37).  Historically at DCLS, as well as other state 
public health laboratories, a conventional RT-PCR assay targeting the VP6 gene has been used 
for viral detection (49, 92).  Recently, a real-time RT-PCR assay was implemented targeting a 
structural protein, NSP3, that exhibits a more conserved sequence than that of VP6 (59).  
Integration of Enteric Virus Detection into a Foodborne Outbreak Screening Algorithm.  
The original intent during the initial stages of this project was to design a multiplex Bio-Plex 
enteric viral assay, similar to those designed for protozoa and bacteria.  Bio-Plex assay design 
was to complement the other two assays and create a multiple pathogen approach in which three 
Bio-Plex assays could be utilized to concurrently screen clinical specimens for protozoa, bacteria 
and viruses of public health significance in foodborne outbreaks.  In support of this goal, Bio-
Plex primers and probes targeting NoV GI, NoV GII and RV were designed based on sequences 
previously described for real-time and conventional RT-PCR methods [J. Vinjé, unpublished 
data; (49, 60, 64)].  While the NoV GII and RV designs adapted readily to the Bio-Plex platform, 
issues such as lack of sensitivity and cross-reactivity with the NoV GII target were encountered 
with the NoV GI designs (data not shown).  Exhaustive efforts to modify primers, probes and 
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reaction conditions finally resulted in a set of NoV GI-specific probes that showed promise in 
multiplex, but still required extensive testing to confirm acceptable performance (data not 
shown). 
As assay development and evaluation progressed, the vision of the integrated screening 
algorithm was reassessed and it was concluded that continuing to develop a Bio-Plex the virus 
assay provided no benefit to the overall testing algorithm.  In fact, multiple real-time RT-PCR 
assays for the detection of NoV and RV are readily available at most state public health 
laboratories and these methods yield confirmatory results faster than the Bio-Plex screening 
assay.  As previously discussed in Chapter 2, additional practical reasons for not pursuing the 
assay further included the fact that the Bio-Plex norovirus gene targets were the same as those 
detected using current standardized real-time assays and the Bio-Plex rotavirus gene targets, 
though different than standardized protocols, provided no additional information than that gained 
from the current method.  Therefore, unlike the parasite and bacterial assays that would be filling 
a testing void and reducing turnaround time for screening results, a Bio-Plex virus assay would 
only provide a redundant testing system that would be more costly in terms of supplies and 
manpower than current confirmatory testing methods.  
However, integrating the real-time RT-PCR virus testing procedure into an outbreak 
screening algorithm which also includes the Bio-Plex protozoan and bacterial assays was 
required.  Harmonization called for the ability to test a single stool specimen with all the assays.  
Therefore, it was determined that the extraction step needed to be changed to enable an efficient 
testing algorithm, since the extraction method for the real-time protocols was different than that 
used for the Bio-Plex assays and a common extraction method was required.  The current 
extraction method utilized for the real-time RT-PCR norovirus and rotavirus methods is the 
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Ambion® MagMAX™-96 Viral RNA Isolation Kit combined with the automated KingFisher® 
Magnetic Particle Processor, whereas the manual QIAamp DNA Stool Mini Kit method is used 
in conjunction with the Bio-Plex assays.  Successful extraction of norovirus nucleic acids has 
been previously described using the Qiagen QIAamp DNA Stool Mini Kit (97).  Establishing the 
Bio-Plex extraction method as the common protocol would allow nucleic acids to be used for 
testing with not only the Bio-Plex assays, but also the real-time RT-PCR viral assays.  Therefore, 
a parallel study was conducted to compare the results obtained for specimens extracted with both 
methods and then tested using the NoV and RV real-time RT-PCR assays. 
Results. 
Comparison of extraction methods.  Unpreserved stool specimens and stools in Cary-Blair 
transport medium known to be positive for NoV or RV were extracted as described using both 
the Ambion® MagMAX™-96 Viral RNA Isolation Kit combined with the automated 
KingFisher® Magnetic Particle Processor and the manual QIAamp DNA Stool Mini Kit 
extraction method, as described (Table 21).  Extracted nucleic acids were tested using the 
standardized real-time RT-PCR assays currently employed at DCLS for NoV or RV, as 
appropriate.  The real-time RT-PCR crossing point values (Ct) obtained upon testing are 
summarized in Table 22.  Pooled study results representing Ct values for Kingfisher-extracted 
and Qiagen-extracted specimens were tested separately for a normal distribution using the 
Shapiro-Wilk test (78).  Because the p-values for both the Kingfisher and Qiagen data sets were 
less than 0.05 (α), it can be concluded that the data are not from a normally distributed 
population (Kingfisher: W = 0.938, p = 0.015, n = 47; Qiagen: W = 0.922, p = 0.004, n = 47).  
Therefore, correlation between pooled Kingfisher and Qiagen results was performed using the 
Spearman’s rho (rank) correlation, which is appropriate for data that is not normally   
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Table 21.  Summary of the NoV and RV specimens tested in a nucleic acid extraction 
comparison study.  Pathogen, specimen type and total number are summarized for the 
specimens utilized to compare the automated Kingfisher and manual Qiagen extraction methods.   
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Virus Specimen Type Number (n) 
NoV GI Unpreserved 
Cary-Blair 
6 
6 
NoV GII Unpreserved 
Cary-Blair 
14 
7 
RV Unpreserved 
Cary-Blair 
7 
7 
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Table 22.  Real-time RT-PCR crossing point (Ct) values obtained for specimens positive for 
NoV GI, NoV GII and RV, using Kingfisher and Qiagen extraction methods.  Select 
specimens positive for NoV and RV were extracted with both the Kingfisher automated 
extraction method and the manual Qiagen extraction method and tested using real-time RT-PCR 
assays.  (A) The Ct values obtained are for unpreserved and Cary-Blair specimens positive for 
NoV GI are summarized.  (B) The Ct values obtained are for unpreserved and Cary-Blair 
specimens positive for NoV GI are summarized. (C)  The Ct values obtained are for unpreserved 
and Cary-Blair specimens positive for NoV GI are summarized.  Abbreviations:  KF, Kingfisher; 
Q, Qiagen 
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(A) 
 
Specimen 
Identification 
Unpreserved Specimens 
Specimen 
Identification 
Cary-Blair Specimens 
KF 
(Ct) 
Q 
(Ct) 
KF 
(Ct) 
Q 
(Ct) 
V-S-001 28.19 27.72 V-CB-145 28.70 28.68 
V-S-009 36.92 32.90 V-CB-146 37.31 35.74 
V-S-118 25.31 23.90 V-CB-147 25.59 22.24 
V-S-120 23.76 21.88 V-CB-148 35.87 33.60 
V-S-143 34.60 31.46 V-CB-149 36.49 34.57 
V-S-144 36.68 23.22 V-CB-150 35.42 33.86 
 
(B) 
 
Specimen 
Identification 
Unpreserved Specimens 
Specimen 
Identification 
Cary-Blair Specimens 
KF 
(Ct) 
Q 
(Ct) 
KF 
(Ct) 
Q 
(Ct) 
V-S-011 22.61 25.71 V-CB-151 29.49 27.79 
V-S-013 19.85 17.81 V-CB-152 19.93 17.89 
V-S-015 25.13 28.47 V-CB-153 20.91 21.39 
V-S-017 28.82 27.73 V-CB-154 16.51 16.58 
V-S-021 27.45 26.86 V-CB-157 35.59 33.28 
V-S-033 16.73 16.42 V-CB-158 33.9 32.76 
V-S-037 20.71 17.52 V-CB-159 28.25 28.05 
V-S-038 17.15 16.04    
V-S-047 17.87 17.14    
V-S-055 23.07 22.065    
V-S-056 33.39 37.15    
V-S-059 31.65 28.8    
V-S-063 23.07 18.74    
V-S-066 36.37 32.76    
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(C) 
 
Specimen 
Identification 
Unpreserved Specimens 
Specimen 
Identification 
Cary-Blair Specimens 
KF 
(Ct) 
Q 
(Ct) 
KF 
(Ct) 
Q 
(Ct) 
V-S-537 26.14 34.25 V-CB-568 16.46 21.16 
V-S-558 14.05 17.01 V-CB-569 16.73 21.08 
V-S-559 16.29 23.44 V-CB-570 28.66 32.63 
V-S-562 14.27 16.20 V-CB-571 32.28 32.05 
V-S-564 17.12 20.13 V-CB-572 31.30 35.39 
V-S-565 17.35 18.43 V-CB-574 14.92 19.32 
V-S-566 27.05 31.53 V-CB-575 19.17 20.36 
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distributed (35).  The correlation coefficient was calculated to be 0.886, indicating a statistically 
significant correlation between the Kingfisher and Qiagen results (p = 0.000, α=0.01).  
Correlation analysis data output and the corresponding scatterplot are illustrated in Figure 5.  
Confidence intervals for the correlation coefficient were calculated at the 95% level to be 0.80 – 
0.93 using the Fisher z transformation as described by Dawson and Trapp (35, 72).  The standard 
deviation of the differences between the Kingfisher and Qiagen Ct values for each specimen was 
also calculated (S.D. = 3.05), and the 1 S.D. and 2 S.D. ranges are illustrated in Figure 5. 
In addition to the statistical analyses, the difference in Ct values of Kingfisher-extracted 
versus Qiagen-extracted stool specimens (ΔCt) amplified by RT-PCR were calculated and 
graphed (Figure 6).  Delta Ct values greater than 0 (bar above the x-axis) indicate that the Ct 
value of the Qiagen-extracted specimen is lower.  Conversely, delta Ct values less than 0 (bar 
below the x-axis) indicate that the Ct value of the Kingfisher-extracted specimen is lower.  
Twenty-seven (27) of 33 norovirus specimens exhibited lower Ct values when extracted with the 
Qiagen method, and 14 of 14 rotavirus specimens exhibited lower Ct values when extracted with 
the Kingfisher method. 
Discussion.  A three-plex viral assay targeting NoV GI, NoV GII and group A RV genome 
targets was initially designed and evaluated at DCLS.  However, when considering the most 
efficient testing algorithm for screening of outbreak specimens, it was determined that 
development of a viral Bio-Plex assay was not optimal.  Due to the time required to perform the 
newly developed BioPlex viral assay, it was determined that its use did not improve the timeline 
for detection of viral agents in association with viral outbreaks.  Instead, the focus of integrating 
an enteric virus testing assay into a multi-agent screening algorithm moved toward establishing a 
common extraction method.  As discussed previously, the Kingfisher extraction method   
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Figure 5.  Spearman rho correlation data output and corresponding scatterplot, comparing 
Kingfisher and Qiagen extraction methods.  Real-time RT-PCR crossing points (Ct) obtained 
by testing unpreserved and Cary-Blair specimens positive for NoV or RV and extracted with 
both Kingfisher and Qiagen methods were pooled and assessed for normal distribution.  
Correlation of Kingfisher and Qiagen results was calculated using the Spearman rho correlation, 
and 95% confidence intervals determined using the Fisher z transformation.  Descriptive 
statistics as determined by analysis using PASW 18.0 are presented in addition to the scatterplot 
illustrating comparative results.  Maroon lines at Ct = 40 indicate positive cutoff value for real-
time RT-PCR assays.  Dashed blue line:  One standard deviation of the difference between 
Kingfisher and Qiagen Ct values (ΔCt; Kingfisher minus Qiagen).  Solid blue line:  Two 
standard deviations of the difference between Kingfisher and Qiagen Ct values (ΔCt; Kingfisher 
minus Qiagen).   
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Descriptive Statistic Output 
n 47 
Mean, Kingfisher 25.4289 
Mean, Qiagen 25.6106 
Standard deviation, Kingfisher 7.26226 
Standard deviation, Qiagen 6.63405 
Spearman’s rho  0.886 
Significance (2-tailed, α = 0.01) 0.000 
CI95 0.80 – 0.93 
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Figure 6.  Comparison of real-time RT-PCR crossing points (Ct) for NoV and RV 
specimens extracted with Kingfisher and Qiagen methods.  Crossing points achieved by 
testing Kingfisher- and Qiagen-extracted NoV and RV positive specimens followed by real-time 
RT-PCR assays were subtracted to yield a delta Ct (ΔCt; Kingfisher minus Qiagen).  Bars above 
the x-axis indicate a lower Ct achieved for a Qiagen-extracted specimen as compared to 
Kingfisher; bars below the x-axis indicate a lower Ct achieved for a Kingfisher-extracted 
specimen as compared to Qiagen.  A)  Unpreserved specimens positive for NoV GI and GII.  B)  
Cary-Blair specimens positive for NoV GI and GII.  C)  Unpreserved and Cary-Blair specimens 
positive for RV. 
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currently used at DCLS for virus molecular assay testing is different from the Qiagen extraction 
method used with the protozoan and bacterial Bio-Plex screening assay.  Therefore, in order to 
perform virus testing in conjunction with the Bio-Plex parasite and enteric bacterial screening 
assays, two extraction methods would be required.  The capability of using only one extraction 
method for both the virus real-time assays and the parasite and bacterial Bio-Plex screening 
assays was desired.  Thus, a comparison was conducted using the current DCLS real-time RT-
PCR NoV and RV assays to test positive stool specimens extracted with both the Kingfisher 
automated method and the Qiagen manual method, as described.  The Kingfisher extraction 
method is currently used to obtain RNA from virus containing stool specimens followed by real-
time RT-PCR assay detection.  If the Qiagen method yielded comparable results, nucleic acids 
extracted for Bio-Plex testing could also be used for real-time RT-PCR virus testing, thus 
reducing the need for a second extraction. 
A total of 47 unpreserved and Cary-Blair specimens known to be positive for NoV or RV 
were extracted with both the Kingfisher and Qiagen methods, tested using real-time RT-PCR 
protocols, and crossing point (Ct) data pooled and analyzed for statistical correlation (r) (35).  
Correlation between the Kingfisher and Qiagen Ct results were found to be statistically 
significant and the 95% confidence interval was small (Figure 5).  An important practical note is 
the fact that no specimen Ct values exceeded the positive cutoff values of either assay with either 
extraction method, providing anecdotal confidence that both extraction methods would yield 
comparable results.  Evaluation of the delta Ct data presented in Figure 6 suggests that the 
Qiagen extraction method is more efficient for NoV nucleic acid extraction, while the Kingfisher 
method appears more efficient for RV nucleic acid extraction.  However, as noted previously, all 
specimens yielded positive results in this study as expected regardless of the extraction method. 
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Preliminary design and testing have led to the development and adaptation of primers and 
probes targeting NoV GI, NoV GII and RV genome sequences for detection on the Bio-Plex 
platform.  Initial studies suggest that the NoV GII and RV assays may work well in multiplex 
without the specificity issues encountered during development.  Upon conducting a benefit 
analysis of the three Bio-Plex assays under development, the viral assays were determined to 
provide redundant qualitative results when compared to current testing capabilities and did not 
provide any turn-around time advantage at this time.   
Although a complete validation of the viral BioPlex assay was not conducted, the primers 
and probes described are available for future assay development, if desired.  The RV primer and 
probe set has been updated to detect VP6 sequences of recent strains, as recommended by Kerin 
et al., and could be used on the Bio-Plex or adapted to other detection platforms (64).  Sequence-
specific probes have been designed to specifically detect predominantly circulating NoV GI 
genotypes and thus could serve as a model for genotype screening.   
A comparison study has been conducted in order to assess the performance of the Qiagen 
manual extraction method to the Kingfisher automated extraction method.  Comparison of real-
time RT-PCR assay results for unpreserved and Cary-Blair specimens positive for NoV GI, NoV 
GII or RV following RNA extraction with both methods indicates that the positive correlation is 
statistically significant.  Based on this study, it is recommended that specimens to be tested with 
both Bio-Plex and real-time RT-PCR viral assays be extracted with the Qiagen manual method, 
eliminating the need for two extractions.  
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CHAPTER 7 CONCLUSIONS AND OVERALL OBSERVATIONS 
 
Implementation of a Bio-Plex Assay Outbreak Screening Algorithm.  Development and 
implementation of rapid and easy-to-use testing methods to concurrently screen clinical 
specimens for a variety of foodborne pathogens enables public health laboratories to provide 
timely preliminary etiologic agent information to epidemiologists or outbreak investigators and 
to focus subsequent confirmatory testing.  Toward this aim, two multiplex assays targeting 
enteric protozoa and enteric bacteria were developed for the Bio-Plex 200 platform and 
performance characteristics were established.  In addition, detection of viral nucleic acids 
extracted with two different extraction protocols was compared using a real-time RT-PCR assay 
currently in use for the detection of viral pathogens.  With several limitations, the Bio-Plex 
assays and manual extraction of viral nucleic acids are suitable for integration into a screening 
algorithm for use in foodborne outbreak investigations in a public health laboratory setting.   
Proposed outbreak screening algorithm.  The typical outbreak investigation protocol employed 
by DCLS is illustrated in Figure 1 (Chapter 1), which summarizes a sometimes lengthy process 
that incorporates biochemical, enzyme immunoassay and molecular methods, as well as a 
reliance on reference laboratory testing for detection of intestinal protozoa.  Based on the overall 
vision of this project, and the results of our subsequent studies, we propose the algorithm shown 
in Figure 7 for screening clinical specimens submitted during foodborne outbreak investigations.  
The proposed algorithm integrates the enteric protozoan and bacterial multiplex Bio-Plex 
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Figure 7.  Proposed foodborne outbreak investigation testing algorithm with Bio-Plex 
screening.  The proposed algorithm integrates the enteric protozoan and bacterial multiplex Bio-
Plex screening assays and real-time RT-PCR viral assays with one nucleic acid extraction 
method.  Examples of possible symptoms and other epidemiologic data that may be provided for 
use in directing the decision as to whether to use each assay are provided.  Confirmatory testing 
following initial screening with the Bio-Plex assays is recommended below the algorithm, as 
well as estimated time to achieve preliminary and confirmatory results. 
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screening assays and real-time RT-PCR viral assays with one extraction method.  These assays, 
by design, can be used alone or in combination as the situation dictates.  Examples of symptoms 
and other epidemiologic data that may be used to decide which assays to use are illustrated in 
Figure 7.  Because the assays are separate, yet linked with a common extraction method, 
laboratories can decide to utilize one assay in outbreaks which have detailed epidemiologic data, 
or all assays in outbreaks for which no case history is provided or symptoms are confusing.  
Confirmatory testing that is required following initial screening with the Bio-Plex assays is 
included in the algorithm.  The estimated times to achieve preliminary and confirmatory results 
are also provided. 
Patient and/or outbreak history provided by epidemiologists may be useful in identifying which 
screening (protozoan, bacterial) and/or confirmatory (viral) assay(s) to be performed.  In some 
outbreaks, as in a recent Giardia outbreak in Virginia, the identification of the etiologic agent 
may already be reported for some patients that were diagnosed at local physician offices and/or 
by laboratory testing conducted at private or commercial laboratories.  A decision flow chart is 
provided in Figure 8 that illustrates how the screening algorithm may be specifically employed in 
outbreak situations in which information is already known about the etiologic agent.  In other 
outbreaks, public health officials may only provide limited reported symptoms and/or incubation 
times to help guide testing decision.  However, as illustrated in Table 1 (Chapter 2), symptoms 
for infections may overlap greatly.  Figure 9 provides a decision flow chart that may be used to 
assist in determining assay(s) to perform when information regarding symptoms of outbreak 
cases is available.  In these situations, active involvement of the laboratory’s management or 
scientific team in making testing decisions will be required.  However, the proposed decision   
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Figure 8.  Proposed decision chart for outbreaks in which the etiologic agent is known.  The 
proposed decision chart is provided to guide testing decisions for foodborne outbreaks in which 
an etiologic agent has been previously identified by another laboratory.  In these outbreaks, a 
laboratory may choose to perform only a single assay targeting the previously identified 
pathogen.  The pathogen targets of each of the assays are listed at the top of the decision chart to 
easily identify the correct assay.  If the pathogen information provided by public health officials 
is not detected by the protozoan, bacterial or viral assays, alternative testing may be required.  
For the protozoan and bacterial assays, preliminary positive screening results should be 
communicated to public health officials, prior to obtaining final confirmatory test results.  All 
negative Bio-Plex assay results will require confirmation using standard methodologies 
employed by the laboratory except for the viral real-time RT-PCR assay results, which are 
confirmatory.   
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Figure 9.  Proposed decision chart for outbreaks in which symptoms are known.  The 
proposed decision chart is provided to assist in guiding testing decisions for foodborne outbreaks 
in which detailed or sufficient information concerning symptoms and/or incubation periods are 
provided by public health officials.  The chart is based on the symptoms of diarrhea and/or 
vomiting, and incorporates key incubation periods.  Additional symptoms may be experienced by 
patients, including fever, cramps and/or nausea, depending on the infection, and these data may 
be further considered in triage decisions at the discretion of laboratory management or scientific 
staff.  For the protozoan and bacterial assays, preliminary positive results should be 
communicated to public health officials, followed by confirmatory testing.  All negative Bio-
Plex assay results will require confirmation using standard methodologies employed by the 
laboratory except for the viral real-time RT-PCR assay results, which are confirmatory.   
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flow chart facilitates screening for the widest variety of pathogens with the least number of 
screening assays to conserve resources.  Finally, in some cases, clinical specimens may be 
submitted to a public health laboratory for outbreak investigation with sparse or no 
epidemiologic data available at that time.  In these situations, laboratorians have the flexibility to 
test with all three assays using a single eluted nucleic acid sample from each specimen, as 
illustrated by the decision chart provided in Figure 10.  Examples of non-symptom 
epidemiologic data, such as travel or location, may be available and may be used to decide which 
screening assays to perform.    
 Assuming that all three assays are to be performed concurrently to test specimens 
submitted in support of an outbreak investigation, it is recommended that conventional 
amplification (Bio-Plex) and real-time RT-PCR (virus) reactions be set up in a specific order so 
as to minimize the time to results.  The bacterial assay requires the longest amplification period 
at 2.5 hours, and therefore should be set up first.  The protozoan assay should follow, with an 
amplification of 1.5 hours.  Finally, the viral assay may be set up as both amplification and real-
time detection only require 1.5 hours.  While amplification of the Bio-Plex reactions is 
occurring, preparations may be performed for the detection steps on the Bio-Plex platform.  Once 
amplification is complete, wells can be prepared on the Bio-Plex detection plate for both the 
protozoan and bacterial assays.  The laboratorian could opt to set up separate detection runs for 
each assay; however, this would delay preliminary results if only one heated shaker is available 
as plate setup cannot be accomplished concurrently.  Starting with the extraction, estimated time 
to preliminary Bio-Plex results is 4-6 hours (Figure 7).  Time to confirmatory virus results is 
approximately 3 hours for NV or NV plus RV, and 48 hours if the RV assay is tested as a reflex 
assay.    
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Figure 10.  Proposed decision chart for outbreaks in which epidemiologic information is 
limited or unknown.  The proposed decision chart is provided to assist in guiding testing 
decisions for foodborne outbreaks in which the epidemiologic data provided public health 
officials is limited or unknown.  Non-symptom information such as travel, suspected sources, 
and/or location, if available, may be used in determining which of the assays to perform.  In 
situations in which no epidemiologic data is available, laboratories may choose to perform all 
three assays following preparation of nucleic acids with the common extraction method.  Based 
on the time required for nucleic acid amplification and detection for each assay, the most 
efficient set-up order is noted.  For the protozoan and bacterial assays, preliminary positive 
results should be communicated to public health officials, followed by confirmatory testing.  All 
negative Bio-Plex assay results will require confirmation using standard methodologies 
employed by the laboratory except for the viral real-time RT-PCR assay results, which are 
confirmatory.   
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 Because the Bio-Plex assays are to be used for screening and providing preliminary 
results to public health officials, follow-up confirmatory testing is recommended (Figure 7).  
Should some or all of the specimens submitted in support of an outbreak yield positive results for 
a protozoan target, specimens would be confirmed using microscopy, EIA, and/or molecular 
methods, if available, or sent to a reference laboratory for confirmation.  Additional testing may 
then be suspended.  Positive bacterial assay results may be confirmed with biochemical and/or 
alternate molecular techniques in order to focus testing on the final identification of the detected 
organism, as appropriate.  Should all specimens be negative for all Bio-Plex assay targets, testing 
with confirmatory techniques and/or by a reference laboratory would still be required.  The time 
to obtain confirmatory results for protozoan and bacterial testing varies from 2-6 days.   
Advantages of the screening algorithm.  The recommended foodborne outbreak screening 
algorithm illustrated in Figure 7 provides several advantages.  First, addition of the protozoan 
and bacterial assays, albeit in a screening capacity, may fill a testing void for a public health 
laboratory.  In the case of DCLS no testing is currently available for the identification of 
parasites or EIEC.  In addition, a real-time PCR assay has been validated for the detection of 
ETEC, but it is rarely employed.  Therefore, the algorithm provides new testing capabilities, and 
testing with the bacterial multiplex will enable more routine screening for both ETEC and EIEC 
strains, perhaps revealing a higher prevalence of these strains than is currently understood.  
Recent reports of at least three outbreaks in the state of New York associated with a restaurant 
and catered events and affecting over 28 people suggests that the routine addition of ETEC 
testing in outbreak investigations should be considered (H. Hanson, personal communication).  
Second, the algorithm reduces the time required to inform public health officials of the possible 
outbreak etiologic agent, which is a high priority.  Third, detection of positive screening targets 
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allows laboratorians to quickly and efficiently focus confirmatory testing, potentially reducing 
the unnecessary wasting of resources expended on pathogen identification.  A fourth advantage 
is that of flexibility.  The two validated Bio-Plex assays were designed separately, allowing 
laboratorians to screen with only the assay(s) if desired based on outbreak information.  
Additional flexibility is provided by the ability of these screening assays to utilize the same 
extracted nucleic acids for both the Bio-Plex and virus real-time RT-PCR portions, thus 
eliminating the need to conduct multiple different extractions.  Long-term flexibility is afforded 
by the potential to add primer and probe sets to each multiplex assay to expand the number of 
pathogens targeted for screening.  Finally, since the unpreserved, LV-PVA and Cary-Blair stool 
specimens tested in the described studies were representative of those specimens typically 
submitted in an outbreak investigation, and were of the types validated for other confirmatory 
molecular assays, new specimen preservation methods need not be added to collection protocols.   
Disadvantages of the screening algorithm.  The recommended screening algorithm and the 
assays that are incorporated into that algorithm have several disadvantages.  The first 
disadvantage is that of time; the Bio-Plex assays may take up to six hours to complete.  
Therefore, it is important that specimen processing and testing begin immediately upon specimen 
arrival in order to gain the maximum benefit of obtaining first-day preliminary results.  A second 
disadvantage is that of programming limitations in the current Bio-Plex software.  The version 
currently in use does not allow for concurrent detection of multiple microsphere mixes (i.e., 
assays) within the same run on the same plate.  Therefore, when a detection plate is set up to 
include more than one assay, the operator must program the Bio-Plex to detect one multiplex 
microsphere mix, then quickly re-program to detect a second.  A new BioPlex software version 
eliminates this limitation, and should be considered for future implementation.  A third 
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disadvantage is the low sensitivity of the E. histolytica primers, indicating the potential to miss 
pathogen detection.  Despite high specificity for this target, positive results are not readily 
available for epidemiological use due to potential cross-reactivity with E. dispar, thus requiring 
confirmation with a discriminatory assay.  However, the target will remain as part of the 
validated format at this time.  Another disadvantage is that of the potential inability of the 
bacterial assay to detect estA1 alleles of the heat stable toxin in ETEC strains.  This lack of 
specificity may result in missed preliminary detection of an outbreak etiologic agent.   
Other Considerations for Bio-Plex Protocol Implementation.  Although establishing the 
performance characteristics described in previous chapters is a major element in employing new 
molecular assays, other practical considerations for deciding to implement Bio-Plex assays 
include ease of use, personnel qualifications and training, equipment and supply requirements, 
and cost.   
Ease of use of the Bio-Plex assays and system.  For a laboratorian trained in molecular 
techniques, using the Bio-Plex assays to test outbreak specimens is relatively easy.  At a 
minimum, the Bio-Plex assay is no more difficult than performing real-time PCR molecular tests 
that are routinely performed in a public health molecular laboratory.  Chemical solutions 
required for microsphere-probe coupling and Bio-Plex detection plate setup are easily mixed 
using readily-available standard protocols and coupling of the target-specific probes to the Bio-
Plex microspheres is a straightforward series of adding solutions, centrifuging, and removing 
supernatant.  The manual extraction employs a commercial spin column method that is easy to 
follow, though it is a bit time-consuming.  Setup of the multiplex PCR amplification reactions is 
equivalent in technique to those used for real-time and conventional molecular PCR methods, 
and is made easier with the use of commercial master mix kits.  Working with the Bio-Plex 
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microspheres and setting up the detection plate may be initially challenging, as the operator must 
become comfortable with working swiftly and efficiently so the microspheres do not settle or 
clump.  The most difficult portion of the setup is removing the adhesive film plate cover, which 
is done twice.  Peeling the film off the plate requires firm handling in order to not tear the film 
and to not cross-contaminate wells. The Bio-Plex system facilitates flexible batch sizes, ranging 
from 1 well to 96 wells, and use of multi-channel pipettes eases setting up larger batch sizes.  
Programming of the Bio-Plex is well-described in the software manual, allowing assay 
parameters to be saved for repeated use and providing flexibility in programming the output 
order of results without regard for how the wells are set up on the plate.  Results may be exported 
as a spreadsheet for analysis; graph functions are also available, but were not utilized in this 
project. 
Personnel qualifications and training.  The Bio-Plex assay and detection plate setup require the 
same qualifications and training needed to perform other molecular-based assays.  Training for 
an experienced molecular scientist would be minimal, and could realistically be completed 
following one or two learning and familiarization runs, an observed run, an unobserved run, and 
a final certification run.  Training for an operator with little-to-no experience in molecular testing 
would, by necessity, be more extensive.   
Equipment and supply requirements.  In addition to the Bio-Plex system, very little extra 
equipment is needed to support testing.  A heated 96-well plate shaker, sonicator, centrifuges and 
vortexers are typically standard equipment in a molecular laboratory or can readily be purchased.  
Facilities for sample extractions, amplification setups and storage are also required.  Facility and 
engineering controls are required for the detection solutions, as they contain chemicals that are 
respiratory, skin and eye irritants.  Solutions should be handled in a fume hood or dead air 
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cabinet (<1mL only), and although not designated to be carcinogenic, caution should be 
exercised in allowing pregnant personnel to handle the solutions.  There is a significant up-front 
supply requirement to begin Bio-Plex testing, particularly if microspheres will be coupled in-
house.  Items to purchase include microspheres, primers, probes, chemicals for coupling and 
detection solutions, detection plates and covers, Bio-Plex validation and calibration kits and 
system sheath fluid.  Once purchased, the supplies can last several months to a year, particularly 
if testing is not done daily or in high volume.  Other support items such as microcentrifuge tubes, 
pipettes, pipette tips, deionized water, isopropyl alcohol, plate racks, personal protective 
equipment, etc. are standard in a molecular laboratory. 
Sustainment costs of Bio-Plex assays.  Costs for long-term sustainment of the extraction and 
amplification steps of Bio-Plex assays are similar to those for real-time molecular assays.  The 
pricing for the QIAamp DNA Stool Mini Kit extraction method validated in the described studies 
lies within the typical range of costs for commercial extraction kits.  The costs per test of both 
master mix kits used for the protozoan and bacterial assays are a bit higher than for other PCR 
master mix kits, but are less expensive than RT-PCR kits.  Pricing for Bio-Plex primers has 
proven to be less expensive than that for real-time primers and probes, mainly because the Bio-
Plex oligonucleotides do not require as high a level of purification following synthesis.   
 Added costs include the probes, which are inexpensive compared to real-time probes, and 
the coupling reagents.  Most reagents can be purchased relatively inexpensively in bulk.  The 
additional costs of Bio-Plex detection are overcome by the platform’s ability to accommodate 
large multiplex reactions, which is a limitation for real-time platforms.  However, if only a two- 
or three-plex is desired and high throughput is not a goal, the Bio-Plex platform may not be a 
cost-effective option. 
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Future Considerations.  This paper describes two Bio-Plex assays that have been validated for 
use as screening tools in foodborne outbreak investigations and a proposed testing algorithm that 
also maximizes use of extracted nucleic acids for other testing platforms.  However, some 
improvements may be considered to address assay limitations, expand testing capability, and 
take advantage of instrumentation system upgrades.  Due to the low sensitivity of the E. 
histolytica target as compared to reference methods and the potential to cross-react with E. 
dispar gene sequences, it is recommended that a re-designed primer and probe set be 
incorporated.  An alternative approach would be to remove the E. histolytica target from the 
multiplex completely, due to low prevalence of the pathogen in foodborne outbreaks in the U.S.  
In either case, re-validation would be required.  A similar re-design recommendation is made for 
the estA target of the bacterial assay.  It is also recommended that performance characteristics of 
the bacterial assay be established using unpreserved stool specimens, as this specimen type may 
also be submitted during outbreak investigations in lieu of Cary-Blair specimens.  Validating the 
assay for unpreserved stool specimens provides an additional flexible testing option.  As 
mentioned previously, a new software upgrade is available for the Bio-Plex platform that 
incorporates concurrent detection of up to twelve multiplex assays on one detection plate.  
Implementing this software will make the detection step more efficient and require less operator 
intervention.  Finally, additional pathogen targets may be considered for addition to the existing 
assays or additional multiplex assays implemented for concurrent detection with the protozoan 
and bacterial assays on the Bio-Plex platform in order to build a more comprehensive screening 
protocol for foodborne outbreak investigations.  
Conclusions.  In the studies described here, two multiplex nucleic acid assays for the detection 
of enteric protozoa and bacteria were designed for the Bio-Plex 200 platform and performance 
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characteristics evaluated.  Both the Bio-Plex protozoan and bacterial assays exhibited precision 
similar to that described for other microsphere-based nucleic acid methods.  Analytical 
sensitivity of the assay targets was established and comparison to the previously published 
assays from which most primers and probes were adapted showed that some targets exhibited 
improved limits of detection on the Bio-Plex platform while others did not.  A comparison to 
organism excretion concentrations in the literature suggests, however, that most assay targets are 
capable of detecting organism concentrations typically encountered in clinical specimens.  
Sensitivity and specificity of most targets as compared to reference methods ranged from 81.25% 
to 100%, which is acceptable for the screening assays.  Sensitivity for the E. histolytica target in 
the enteric protozoan assay was 42.86%, another indicator that re-design of this target should be 
considered.  Both the protozoan and bacterial assays exhibited no cross-reactivity to a variety of 
non-target parasites and bacteria, with the exception of E. dispar (E. histolytica target in the 
protozoan assay) and EPEC strains (uidA target in the bacterial assay).  Additionally, no cross-
reactivity between assay targets was noted.  Interpretation of results for the uidA target only 
when shiga toxin targets are positive overcomes the cross-reactivity of the uidA target with 
certain EPEC strains.  The development of a Bio-Plex multiplex assay to detect viral targets, 
while promising, was not required due to redundancy with other rapid testing protocols.  Real-
time detection of NV and RV nucleic acids extracted from clinical specimens with the QIAamp 
DNA Stool Mini Kit was found to be statistically comparable to detection of nucleic acids 
extracted with the current viral RNA extraction method on the Kingfisher platform.  Therefore, 
should Bio-Plex testing be desired in addition to viral testing, only one extraction method would 
be required.  In summary, integration of the Bio-Plex and real-time assays with a common 
extraction method provides a simple, rapid and flexible foodborne outbreak screening algorithm 
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that can be optimized and tailored based on epidemiological history and preliminary etiologic 
agent data provided on the day of specimen submission, and may be used to focus subsequent 
confirmatory laboratory testing.   
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